Aberg-Wistedt A, Comparison between zimelidine and desipramine in endogenous depression: A cross-over study. Acta Psychiatr Scan. 1982;66:129-138
Aberg-Wistedt A, The antidepressant effects of 5-HT uptake inhibitors. Br J Psychiatry. 1989;155(suppl 8):32-40
Abernethy DR, Greenblatt DJ, Morse DS, et al, Interaction of propoxyphene with diazepam, alprazolam and lorazepam. Br J Clin Pharmacol 1985;19:51-7
Adler LA, Angrist BM, Paroxetine and akathisia. Biol Psychiatry. 1995;37:336-337
Agundez JA, Gallardo L, Ledesma MC, et al, Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology 2001;61:59-63
Agundez JAG, Martinez C, Ladero JM, et al, Pharmacokinetics and drug disposition: Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther. 1994;55:10-14
Albengres E, Le LH, Tillement JP, Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18: 83-97
Albers LJ, Reist C, Helmeste D, Vu R, Jang SW, Paroxetine shifts imipramine metabolism. Psychiatry Research. 1996; 59:189-196
Alderman CP, Seshadri P, Ben-Tovim DI, Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996;30:1232-1234
Alderman J, Greenblatt D, Allison J, Preskorn S, Harrison W, Chung M, Desipramine pharmacokinetics with the selective serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline. Poster presented at the American Psychiatric Association Sesquicentennial Celebration, 1844-1994; May 21-26, 1994; Philadelphia, Pa
Alderman J, Preskorn S, Greenblatt D, et al, Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91
Alexanderson B, Sjoqvist F, Individual differences in the pharmacokinetics of monomethylated tricyclic antidepressants: Role of genetic and environmental factors and clinical importance. Ann NY Acad Sci 1971;179:739-51
Alfaro CL, Lam YWF, Simpson J, et al, CYP2D6 Inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000;40:58-66
Alfaro CL, Lam YWF, Simpson J, et al, CYP2D6 Status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine or sertraline. J Clin Pharmacol 1999;19: 155-63
Altamura AC, Montgomery SA, Wernicke JF, The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry. 1988;153 (suppl 3):109-112
Altamura AC, Moro AR, Percudani M, Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994;26: 201-214
Amchin J, Ereshefsky L, Zarycranski W, et al, Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol 2001;41:443-51
American Academy of Child and Adolescent Psychiatry, Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(suppl 10):275-455
American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 3rd edition, revised. Washington, DC: American Psychiatric Association; 1987
American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 3rd edition. Washington, DC: American Psychiatric Association; 1980
American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994
American Psychiatric Association, Diagnostic and statistical manual of mental disorders, tad edition. Washington, DC: American Psychiatric Association; 1968
American Psychiatric Association, Diagnostic and statistical manual: Mental disorders. Washington, DC: American Psychiatric Association; 1952
American Psychiatric Association, Practice guidelines for major depressive disorder in adults. Am J Psychiatry. 1993;150(suppl 4):1-26
Amsterdam JD, Garcia-Espana F, Goodman D, Hooper M, Hornig-Rohan M, Breast enlargement during chronic antidepressant therapy. J Affect Disord. 1997;46:151-156
Andersen BB, Mikkelsen M, Vesterager A, et al, No influence of the antidepressant paroxetine on carbamazepine valproate and phenytoin. Epilepsy Res. 1991:201-204
Andersson T, Omeprazole drug interaction studies. Clin Pharmacokinet. 1991;21:195-212
Andersson T, Miners JO, Veronese ME, Birkett DJ, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol. 1994;38:131-137
Andreasen NC, Rice J, Endicott J, Coryell W, Grove WM, Reich T, Familial rates of affective disorder. A report from the National Institute of Mental Health Collaborative Study [published erratum appears in Arch Gen Psychiatry. 1988;45:776]. Arch Gen Psychiatry. 1987;44:461-469
Anonymous, Drugs for psychiatric disorders. Med Lett Drugs Ther. 1994;36:89-96
Arana GW, Baldessarini RJ, Ornsteen M, The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry. 1985;42: 1193-1204
Armitage R, Rush AJ, Trivedi M, Cain J, Roffwarg HP, The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology. 1994;10:123-127
Armitage R, Trivedi M, Rush AJ, Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology. 1995;12:159-165
Armstrong SC, Schweitzer SM, Delirium associated with paroxetine and benztropine combination. Am J Psychiatry. 1997;154:581-582. Letter
Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L, Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984;36:138-144
Aronson TA, Shukla S, Hoff A, Cook B, Proposed delusional depression subtypes: Preliminary evidence from a retrospective study of phenomenology and treatment course. J Affect Disord. 1988;14:69-74
Artigas F, Perez V, Alvarez E, Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51
Asberg M, Individualization of treatment with tricyclic compounds. Med Clin North Am 1974;58:1083-91
Ascher JA, Cole JO, Colin J-N, et al, Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401
Asghari V, Schoots O, Van Katz S, et al, Dopamine D4 receptor repeat: Analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 1994;46:363-73
Ayd FJ, Paroxetine, a new selective serotonin reuptake inhibitor. Int Drug Ther Newsletter. 1993;28:5-12
Azmitia EC, Segal M, An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978;179:641-68
Baker GB, Coutts RT, Holt A, Metabolism and chirality in psychopharmaoclogy. Biol Psychiatry. 1994:36:211-213. Editorial
Bakish D, Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry. 36(10):749-50;1991
Balant LP, Pharmacokinetics in special populations. Presented at European Psychopharmacology Consensus Meeting as a satelilite meeting to the First International Congress on Hormones, Brain and Neuropscyhopharmacology; September 13-17, 1993; Rhodes, Greece
Balant-Gorgia AE, Balant LP, Genet C, Dayer P, Aeschlimann JM, Garrone G, Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol. 1986;31:449-455
Balant-Gorgia AE, Schulz P, Dayer P, et al, Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenki. 1982;232:215-222
Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS, Akathisia: A review and case report following paroxetine treatment. Compr Psychiatry. 1996;37:122-124
Baldessarini R, Frankenburg FR, Clozapine: A novel antipsychotic agent. N Engl J Med 1991;324:746-54
Baldwin D, Fineberg N, Montgomery S, Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol. 1991;6:51-58
Ballesteroa JA, Shi L, Javitch JA, Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 2001;60:1-19
Balon R, Antidepressants in the treatment of premature ejaculation. J Sex Marital Ther. 1996;22:85-96
Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JGC, Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80(suppl 350):102-106
Barbeau A, Roy M, Paris S, Cloutier T, Plasse L, Poirier J, Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet. 1985;2:1213-1216
Barbhaiya RH, Buch AB, Greene DS, A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996;16:19-25
Barbhaiya RH, Buch AB, Greene DS, Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996;42:573-81
Barbhaiya RH, Shukla U, Natarajan C, Behr D, Greene DS, Sainati S, Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 1995;58:390-8
Barbhaiya RH, Shukla UA, Kroboth- PD, Greene DS, Coadministration of nefazodone and benzodiazepines:.Il. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995;15:320-6
Barker EL, Blakely RD, Norepinephrine and serotonin transporters: Molecular targets of antidepressant drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994;321-334
Barr LC, Goodman WK, Price LH, Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994;151:289. Letter
Batty KT, Davis TM, Illett KF, Dusci LJ, Langton SR, The effect of ciprofloxacin on theophyline pharmacokinetics in healthy subjects. Br J Clin Pharm 1995;39(3):305-11
Baumann P, Bertschy G, Pharmacodynamic and pharmacokinetic interactions of selective serotonin reuptake inhibiting antidepressants (SSRIs) with other psychotropic drugs. Nord J Psychiatry. 1993;47(suppl 30):13-19
Baumann P, Jonzier-Perey M, Koeb L, Kupfer A, Tinguely D, Schopf J, Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Intl Clin Psychopharmacol. 1986;1:102-112
Baumann P, Rochat B, Comparative pharmacokinetics of selective serotonin reuptake inhibitors: A look behind the mirror. Intl Clin Psychopharmacol. 1995;10(suppl 1):15-21
Baunwald E, Fauci A, Kasper DL, et al, Harrison’s principles of internal medicine, 15th edition. New York: McGraw-Hill; 2001
Bayer AJ, Roberts NA, Allen EA, et al, The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scan. 1989;80(suppl 350):85-86
Beasley CM, Masica DN, Heiligenstein JH, et al, Possible monoamine oxidate inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol. 1993;13:312-320
Beck AT, Brown G, Berchick RJ, Stewart BL, Steer RA, Relationship between hopelessness and ultimate suicide: A replication with psychiatric outpatients. Am J Psychiatry. 1990;147:190-195
Beedle D, Krasuski J, Janicak PG, Advances in somatic therapies: Electroconvulsive therapy, repetitive transcranial magnetic stimulation and bright light therapy. In: Janicak PG, Davis JM, Preskorn SH, Ayd FJ, eds. Principles and Practice of Psychopharmacotherapy. 2nd ed. Baltimore, Md: L
Belpaire FM, Wignant P, Temmerman A, et al, The oxidative metabolism of metoprolol in human liver microsomes: Inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998;54: 261-4
Benfield P, Ward A, Fluvoxamine: A review of its pharmacodyamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986; 32:313-334
Bergendal L, Friberg A, Schaffrath AM, et al, The clinical relevance of the interaction between carbamazepine and dextropropoxyphene in elderly patients in Gothenburg, Sweden. Eur J Clin Pharmacol 1997;53:203-6
Bergeron R, Blier P, Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry. 1994;151:1084-1086
Bergstrom RF, Lemberger L, Farid NA, Wolen RL, Clinical pharmacology and pharmacokinetics of fluoxetine: A review. Br J Psychiatry. 1988;153(suppl 3):47-50
Bergstrom RF, Peyton AL, Lemberger L, Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51:239-248
Bertilsson L, Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics 1995;29:192-209
Bertilsson L, Aberg-Wistedt A, The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol. 1983;15:388-390
Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T, Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45:348-355
Bertschy G, Baumann P, Eap CB, Baettig D, Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit. 1994;16:42-45
Bertschy G, Vandel S, Francois T, et al, Metabolic interaction between tricyclic antidepressant and fluvoxamine and fluoxetine, a pharmacogenetic approach. Clin Neuropharm. 1992;15(suppl 1):78A-79A
Bhatara VS, Bandettini FC, Possible interaction between sertraline and tranylcypromine. Clin Pharmacol. 1993;12: 222-225
Bierrum OJ, New safe medicines faster: A proposal for a key action within the European Union’s 6th Framework Programme. Pharmacol Toxicol 2000;86(suppl 1):23-6
Bigger JT Jr, Methodology for clinical trials with antiarrhythmic drugs to prevent cardiac death: US experience. Cardiology 1987;74(Suppl 2):40-56
Biglin KE, Faraon MS, Constance TD, Lieh-Lai M, Drug-induced torsades de pointes: A possible interaction of terfenadine and erythromycin. Ann Pharmacother. 1994; 28:282
Birgersson C, Morgan ET, Jornvall H, von Bahr C, Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P450 from human liver. Biochem Pharmacol. 1986;35:3165-3166
Bjerkenstedt L, Flyckt L, Overo KF, Lingjaerde O, Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol. 1985;28:553-557
Blattner FR, Plunkett G III, Bloch CA, et al, The complete genome sequence of Escherichia coli K-12. Science 1997;277:1453-74
Blayac JP, Hillaire-Buys D, Peyriére H, Pharmacovigilance of new antidepressants: Evaluation of neuropsychobehavioral disorders [in French]. Therapie. 1997;52:117-122
Blier P, Bergeron R, The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry. 1998;59(suppl 5):16-23, 24-25
Blier P., Curet O., Chaput Y., de-Montigny C, Tandospirone and its metabolite, 1-(2-pyrimidinyl) piperazine-II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology. 39(7):691-701;1991
Bloch M, Stager SV, Braun AR, Rubinow DR, Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet. 1995;346:57. Letter
Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT, The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol. 1992;33:521-523
Blume CD, Dear doctor letter regarding use of eldepryl. Tampa, Fla: Somerset Pharmaceuticals; 1994, Nov 14
Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ, Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58:137-145
Boehnert MT, Lovejoy FH, Value of the QRS duration versus serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med. 1985;313:474-479
Bolden-Watson C, Richelson E, Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52:1023-1029
Bonnet P, Vandel S, Nezelog S, Sechter D, Bizouard P, Carbamazepine, fluvoxamine: Is there a pharmacokinetic interaction?. Therapie. 1992;47:165
Borys DJ, Setzer SC, Ling LJ, et al, Acute fluoxetine overdose: A report of 234 cases. Am J Emerg Med. 1992;10: 115-120
Bouquet S, Vandel S, Bertschy G, et al, Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal results. Clin Neuropharmacol. 1992;15(suppl 1): 82A-83A
Brøsen K, Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions. Nord J Psychiatry. 1993;47(suppl 30):21-26
Brøsen K, Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics. Clin Pharmacokinet. 1990;18:220-239
Brøsen K, Gram LF, Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol. 1989;37:155-160
Brøsen K, Gram LF, Kragh-Sorensen P, Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipiramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit. 1991;13:177-182
Brøsen K, Gram LF, Sindrup S, Skjelbo E, Nielson KK, Pharmacogenetics of tricyclic and novel antidepressants: recent developments. Clin Neuropharm. 1992;15(suppl 1): 80A-81A
Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF, Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993;44:349-355
Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L, Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol. 1986;30:679-684
Brøsen K, Otton SV, Gram LF, Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther. 1986;40:543-549
Brøsen K, Skjelbo E, Rasmussen BB, Puolsen HE, Loft S, Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45:1211-1214
Brøsen K, Zeugin T, Meyer UA, Role of P4502D6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther. 1991;49:609-617
Brannan SK, Talley BJ, Bowden CL, Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol. 1994;14:144-145. Letter
Brauner-Osborne H, Jensen AA, Sheppard PO, et al, Cloning and characterization of a human orphan family C G-protein coupled receptor GPACSD. Biachim Biophys Acts 2001;1518:237-48
Bremner JD, Wingard P, Walshe TA, Safety of mirtazapine in overdose. J Clin Psychiatry. 1998;59:233-235
Breyer-Pfaff U, Pfandl B, Nill K, et al, Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isoenzymes. Clin Pharmacol Ther. 1992; 52:350-358
Broadhead WE, Blazer DG, George LK, Tse CK, Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264:2524-2528
Brown GW, Harris TO, Social Origins of Depression:A Study of Psychiatric Disorder in Women. London, UK: Tamstock Publications; 1978
Brown WA, Dornseif BE, Wernicke JF, Placebo response in depression: A search for predictors. Psychiatry Res. 1988;26: 259-264
Brown WA, Harrison W, Are patients who are intolerant to one SSRI intolerant to another?. Psychopharmcol Bull. 1992;28:253-256
Bryois C, Rubin C, Zbinden JD, Baumann P, Withdrawal syndrome caused by selective serotonin reuptake inhibitors: apropos of a case [in French]. Schweiz Rundsch Med Prax. 1998;87:345-348
Bu HZ, Knuth K, Magis L, Teitelbaum P, High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. Rapid Commun Mass Spectrom 2000;14:1943-8
Bunney WE Jr, Goodwin FK, Murphy DL, House KM, Gordon EK, The "switch process" in manic-depressive illness. II. Relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry. 1972;27:304-309
Burke MJ, Preskorn SH, Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice. Clinical Pharmacokinetics 1999;37:147-65
Burke MJ, Silkey B, Preskorn SH, Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry. 1994;55 (suppl A): 42-52
Burke MJ, Silkey B, Preskorn SH, Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry. 1994;55(suppl A):42-52, 53-54, 98-100
Burrows GD, Maguire KP, Norman TR, Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry. 1998;59 (suppl 14):4-7
Burrows GD, Norman TR, Tricyclic antidepressants: Plasma levels and clinical response. In: Burrows GD, Norman TR, eds. Psychotropic drugs; Plasma concentration and clinical response. New York: Marcel Dekker; 1981: 69-204
Butler M, Lang N, Young J, et al, Determination of CYP 1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116-127
Caccia S, Ballabio M, Samanin R, Zanini MG, Garattini S, (--)-m-Chlorophenylpiperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol. 1981;33:477-478
Cade JFJ, Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2:349-352
Callaham M, Kassel D, Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emer Med. 1985;14:1-9
Callahan AM, Fava M, Rosenbaum JF, Drug interactions in psychopharmacology. Psychiatr Clin North Am 1993;16:647-71
Cao BJ., Li,WP, Antagonism of clonidine antinociception by buspirone and 1-(2-pyrimidinyl) piperazine. Eur J Pharmacol. 259(1):75-8;1994
Caporaso N, Hayes RB, Dosemeci M, et al, Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 1989;49:3675-3679
Caporaso N, Landi MT, Vineis P, Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics. 1991;1:4-19
Caporaso NE, Tucker MA, Hoover RN, et al, Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst. 1990;82:1264-1272
Caraco Y, Tateishi T, Wood AJJ, Ethnic effects on inhibition of drug metabolism. Clin Pharmacol Ther. 1994;55: 169. Abstract
Cardiac Arrhythmia Pilot Study (CAPS) Investigators, Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol. 1988;61: 501-509
Carlson A, Morris L, Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm: Pharmacists can be key in changing prescribing behavior to avoid drug-drug interactions. Science & Practice 1996;NS36:263-9
Carpenter LL, McDougle CJ, Epperson CN, Price LH, A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf. 1996;15:116-134
Carrillo JA, Ramos SI, Herraiz AG, et al, Pharmacokinetic interaction of fluvoxamine and thiroidazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19:494-9
Catterson M, Preskorn SH, Bremner JD, Dessain EC, Double-blind crossover study of mirtazapine, amitriptyline and placebo in patients with major depression. Poster presentation at the 36th annual meeting of the American Psychiatric Association. New York, May 7, 1996
Centurrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG, Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol. 1994;14:119-125
Chaput Y, de Montigny C, Blier P, Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991;5:219-29
Charney DS, Mihic SJ, Harris RA, Hypnotics and sedatives. In: Hardman JG, Limbird LE. Goodman & Gilman?s the pharmacological basis of therapeutics, 10th edition. New York: McGraw-Hill; 2001:399-428
Chen ZR, Irvine RJ, Bochner F, et al, Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci 1990;46: 1067-74
Chiba K, Kobayashi K, Antidepressants. In: Levy R, Thummel K, Trager R; et al. (eds) Metabolic drug interactions. Philadelphia: Lippincott William & Wilkins 2000:233-243
Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T, The role of S-mephenytoin 4’-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol. 1994;37:237-242
Choo V, Paroxetine and extrapyramidal reactions. Lancet. 1993;341:624. Letter
Chouinard G, Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 1992;7(suppl 2):37-41
Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL, Drug interactions in psychiatry. Baltimore: Williams & Wilkins; 1995
Civelli O, Nothacker HP, Reinscheid R, Reverse physiology: Discovery of the novel neuropeptide, orphanin FQ/nocieceptin. Critical Reviews in Neurobiology 1998;12:163-76
Civelli O, Reinscheid RK, Nothacker HP, Orphan receptors, novel neuropeptides and reverse pharmaceutical research. Brain Res 1999;848:63-5
Claghorn JL, Feighner JP, A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol. 1993;13(suppl 2):23S-27S
Clerc GE, Ruimy P, Verdeau-Pallés J, A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9:139-143
Committee on Safety of Drugs, Curr Prob Pharmacovigilance. 1993;19:1
Cooper RG, Evans DAP, Whibley EJ, Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet. 1984;21:27-33
Cooper TA, Valcour VG, Gibbons RB, O’Brien-Falls K, Spontaneous ecchymoses due to paroxetine administration. Am J Med. 1998;104:197-198
Cooper TB, Perumal AS, Suchow RF, Glassman A, Bupropion: Possible role of major metabolites in mode of action (Abstract). Clin Pharmacol Ther 1984;37:187
Coplan JD, Gorman JM, Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry. 1993;150:837
Costa e Silva J, Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1998;59:352-357
Coulehan JL, Schulberg HC, Block MR, et al, Depressive symptomatology and medical co-morbidity in a primary care clinic. Intl J Psychiatry Med. 1990;20:335-347
Crane GE, Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatry Res Rep. 1957;8:142-152
Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE, The effect of paroxetine and other specific serotonin reuptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br J Clin Pharmacol. 1991;32: 658P-659P
Cupp-Vickery JR, Garcia C, Hofacre A, et al, Ketoconazole-induced conformational changes in the active site cytochrome P450eryF. J Mol Biol 2001;311:101-10
Curzon G, Kennett GA, mCPP: a tool for studying behavioral responses associated with 5-HT1c receptors. Trends Pharmacol Sci 1990;11:181-2
Cusack B, Nelson A, Richelson E, Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 1994;114:559-565
Dahl M, Nordin C, Bertilsson L, Enantioelective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit. 1991;13:189-194
Dahl-Puustinen ML, Liden A, Alm C, Nordin C, Bertilsson L, Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78-81
Dalhoff K, Almdal TP, Bjerrum K, et al, Paroxetine in patients with cirrhosis. Psychopharmacol. 1991;103:B13
Danish University Antidepressant Group, Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1986;90:131-138
Danish University Antidepressant Group, Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disorder. 1990;18:289-299
Darley J, Interaction between phenytoin and fluoxetine. Seizure. 1994;3:151-152
Davidson J, Seizures and bupropion: a review. J Clin Psychiatry. 1989;50:256-261
Davis JM, Janicak PG, Lindon R, et al, Neuroleptics and psychotic disorders. In: Coyle JT, Enna SJ, eds. Neuroleptics: Neurochemical, behavioral and clinical perspectives. New York: Raven Press; 1983
Davis R, Appleby J, Patient safety being left behind. USA Today . Oct 11, 2000
Dayer P, Leemann T, Striberni R, Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther 1989;45:34-40
de Boer T, Ruigt G, Berendsen H, The alpha2-selective adrenoceptor antagonist Org 3770 (mirtazapine remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol. 1995;10:107S-118S
de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM, Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988;27:399-408
De Ponti F, Poluzzi E, Montanaro N, QT-interval prolongation by noncardiac drugs: Lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56:1-18
de Vries MH, Raghoebar M, Mathlener IS, van Harten J, Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit. 1992;14: 493-498
DeBoer TH, Ruigt GSF, Berendsen HHG, The alpha 2 - selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology 1995;10:S107-S118
Dechant KL, Clissold SP, Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41:225-253
Delay J, Deniker Pl, Le traitement des psychoses par une m?thode neurolytique d?riv?e de I’hibermotherapie. Congr?s des m?decins alienistes et neurologistes de France. Luxembourg: July 1952: 497-502
Delbressine L, Vos R, The clinical relevance of preclinical data: Mirtazapine, a model compound. J Clin Psychopharmacol 1997;17:29S-33S
Delpon E, Valenzuela C, Tamargo J, Blockade of cardiac potassium and other channels by antihistamines. Drug Saf 1999;21:11-8
Depression Guideline Panel, Clinical Practice Guideline. Number 5. Depression in Primary Care, Vol. 1: Detection and Diagnosis; and Vol 2: Treatment of Major Depression. Rockville, Md: US Dept. of Health and Human Services, Public Health Service, AHCPR Publication No. 93-0551; April
DeVane CL, Dr. DeVane replies. J Clin Psychiatry 1996;57(5):225-7
DeVane CL, Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med. 1994;97(suppl 6A): 13S-23S
Devane CL, Markowitz JS, Antipsychotics. In: Levy R, Thummel K, Trager W et al. (eds) Metabolic drug interactions. Philadelphia: Lippincott William & Wilkins 2000:245-59
Done CJ., Sharp T, Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 33(3-4):411-21;1994
Doogan DP, Caillard V, Sertraline in the prevention of depression. Br J Psychiatry. 1992;160:217-222
Dorian P, Sellers EM, Reed KL, et al, Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. Eur J Clin Pharmacol. 1983;25:325-331
Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF, Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 1989;25:71-79
Doyle GD, Laher M, Kelly JG, et al, The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand. 1989;80(suppl 350):89-90
Drolet B, Vincent F, Rail J, et al, Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 1999;288:1261
DuBuske LM, Second-generation antihistamines: The risk of ventricular arrhythmias. Clin Ther 1999;21:281-95
Dufour H, Bouchacourt M, Thermoz P, et al, Citalopram -- a highly selective 5-HT reuptake inhibitor in the treatment of depressed patients. Intl Clin Psychopharmacol. 1987;2:225-237
Dunner DL, Gershon ES, Goodwin FK, Heritable factors in the severity of affective illness. Biol Psychiatry. 1976;11:31-42
Dworkin SF, VonKorff M, LeResche L, Multiple pains and psychiatric disturbance: an epidemiologic investigation. Arch Gen Psychiatry 1990;47:239-44
Edwards P, HIV 1 protease inhibitors. Drug Discov Today 2001;6: 437-9
Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD, Nefazodone: Preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-15
Elonen E, Mattila M, Saarnivaara L, Cardiovascular effects of amitriptyline, nortriptyline, protriptyline, and doxepine in conscious rabbits. Eur J Pharmacol 1974;28:178-88
Emrich HM, Berger M, Riemann D, von Zerssen D, Serotonin reuptake inhibition versus norepinephrine reuptake inhibition: a double-blind differential therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatrica. 1987;20:60-63
Eric LT, A prospective double-blind comparative multicentre study of paroxetine and placebo in preventing recurrent major depression episodes. Biol Psychiatry. 1991; 29(suppl 11):2545
Esposito S, Prange AJ Jr, Golden RN, The thyroid axis and mood disorders: overview and future prospects. Psychopharmacol Bull. 1997;33:205-217
Evans D, Antidepressant adverse effects and antidepressants in the medically ill. Am Soc Clin Psychopharm Progress Notes. 1995;6:22-25
Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17:102-105
Evans ME, Kortas KJ, Potential interaction between isoniazid and selective serotonin-reuptake inhibitors. Am J Health Syst Pharm. 1995;52:2135-2136. Letter
Fabre LF, Abuzzahab FS, Amin M, et al, Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995;38:592-602
Fawcett J, Marcus RN, Anton SF, O’Brien K, Schwiderski U, Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry. 1995;56(suppl 6):37-42
Fawcett J, Scheftner W, Clark D, Hedeker D, Gibbons R, Coryell W, Clinical predictors of suicide in patients with major affective disorders: a controlled prospective study. Am J Psychiatry. 1987;144:35-40
Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS, Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57:53-62
Feighner JP, Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry. 1995;56:574-579
Feighner JP, Cohn JB, Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985;46:20-25
Feighner JP, Robins E, Guze SB, et al, Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972;26: 573
Fleishaker JC, Hulst LK, A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994; 46:35-39
Fleming CM, Kaisary A, Wilkinson GR, Smith P, Branch RA, The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics. 1992; 2:128-134
Flockhart DA, Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?. J Clin Psychopharmacol. 1996;16:101-103
Folgia JP, Perel JM, Nathan RS, Pollock BG, Therapeutic drug monitoring (TDM) of fluvoxamine, a selective antidepressant. Clin Chem. 1990;36:1043. Abstract
Fonne-Pfister R, Bargetzi MJ, Meyer UA, MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450 buf-I, P450 dbl) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Comm. 1987;148: 1144-1150
Fontaine B, Klarsfeld A, Changeux J-P, Calcitonin gene-related peptide and muscle activity regulate acetycholine receptor alpha-subunit mRNA levels by distinct intracellular pathways. J Cell Biol 1987;105:1337-42
Food and Drug Administration, List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness [Docket No. 98N-0655]. March 8, 1999. Accessed January 9, 2002,
Frank E, Kupfer DJ, Perel JM, et al, Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47:1093-1099
Frazer A, Antidepressants. J Clin Psychiatry. 1997;58(suppl 6):9-25
Fredericson OK, Toft B, Christophersen L, Gylding-Sabroe JP, Kinetics of citalopram in elderly patients. Psychopharmacol. 1985;86:253-257
Fredricson OK, Kinetics of citalopram in man: plasma levels in patients. Prog NeuroPsychopharmacol Biol Psychiatry. 1982;6:311-318
Fritze J, Unsorg B, Lanczik M, Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991;84:583-584
Frommer DA, Kulig DA, Marx JA, Rumack B, Tricyclic antidepressant overdose: a review. JAMA. 1987;257:521-526
Frost L, Lal S, Shock-like sensations after discontinuance of selective serotonin reuptake inhibitors. Am J Psychiatry. 1995;152:810. Letter
Frye MA, Ketter TA, Leverich GS, et al, The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15
Fuller RW, Snoddy HD, Krushinski JH, Robertson DW, Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropsychopharmacol. 1992; 31:997-1000
Gardner MJ, Ronfeld RA, Wilner KD, et al, Absence of a clinically meaningful effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Journal of Clinical Pharmacokinetics 32(suppl 1):43-49, 1997
Gelernter J, Kranzler H, Cubells JF, Serotonin transporter protein (SLC6A4) allele and haptotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 1997;101:243-6
Gernaat HBPE, Van De Woude J, Touw DJ, Fluoxetine and parkinsonism in patients taking carbamazepine. Am J Psychiatry. 1991;148:1604-1605. Fluoxetine and parkinsonism in patients taking
Gerner RH, Treatment of acute mania. Psychiatr Clin North Am 1993;16:443-60
Gershon ES, Berrettini W, Numberger J Jr, Goldin LR, Genetics of affective illness. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:481-491
Giammusso B, Morgia G, Spampinato A, Motta M, Paroxetine in the treatment of premature ejaculation [in Italian]. Arch Ital Urol Androl. 1997;69:11-13
Gidal BE, Anderson GD, Seaton TL, Miyoshi HR, Wilenksy AJ, Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit. 1993;15:405-409. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide
Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ, A comparison of nefazodone and fluoxetine on mood and on objective, subjective, clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. [published erratum appears in J Clin Psychiatry. 1997;58:275]. J Clin Psychiatry
Gilman AG, ed, Goodman and Gilman’s pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill; 1996
Glassman AH, Johnson LL, Giardina EG, et al, The use of imipramine in depressed patients with congestive heart failure. JAMA 1983;250:1997-2001
Glassman AH, Roose SP, Giardina EGV, Bigger JT Jr, Cardiovascular effects of tricyclic antidepressants. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987: 1437-1442
Glennon RA, Dukat M, Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994: 415-430
Golden, RN, DeVane CL, Laizure SC, Rudorfer MD, Sherer MA, Potter WZ, Bupropion in depression: The role of metabolites in clinical outcome. Arch Gen Psychiatry 1985;45:145-49
Goldstein JA, de Morais SM, Biochemistry and molecular biology of the human CYP 2C subfamily. Pharmacogenetics. 1994;4:285-299
Gonzalez FJ, Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 1992;13:346-352
Gonzalez FJ, Gelboin HV, Human cytochromes P450: evolution and cDNA-directed expression. Environmental Health Perspectives. 1992;98:81-85
Gonzalez FJ, Nebert DW, Evolution of the P450 gene superfamily: Animal-plant "warfare," molecular drive and human genetic differences in drug oxidation. Trends Genetics. 1990;6:182-186
Gonzalez FJ, Skoda RC, Kimura S, et al, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331:442-446
Gonzalez FJ, Vilbois F, Hardwick JP, et al, Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 1988;2:174-9
Goodnick PJ, Pharmacokinetics of second generation of antidepressants: fluoxetine. Psychopharm Bull. 1991;27: 503-512
Goodwin DW, Guze SB, Psychiatric Diagnosis. 4th ed. New York, NY: Oxford University Press; 1989:22
Goodwin DW, Preskorn SH, DSM-III and pharmacotherapy. In: Turner S, Hersen M, eds. Adult Psychopathology: A Behavioral Perspective. New York, NY: John Wiley & Sons; 1982:453-465
Graber MA, Hoehns TB, Perry PJ, Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother. 1994;28:732-735
Grace JM, Kinter MT, McDonald TL, Atypical metabolism of deprenyl and its enantiomer. (S)-(+)-N, alpha-dimethyl-N-propynylphenethylamine, by cytocrime P450 2D6. Chem Res Toxicol 1994;7:286-290
Grady TA, Pigott TA, L’Heureux F, Murphy DL, Seizure associated with fluoxetine and adjuvant buspirone therapy. J Clin Psychopharmacol. 12(1):70-1;1992
Gram L, Brøsen K, Kragh-Sorensen P, Christensen P, Steady-state plasma levels of E- and Z-10-OH-nortripty-line in nortriptyline-treated patients: significance of concurrent mediation and the sparteine oxidation phenotype. Ther Drug Monit. 1989;11:508-514. Gram L, Brøsen K, Kragh-Sorensen P, Christe
Gram LF, Debruyne D, Caillard V, et al, Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol. 1989;27:272-275
Gram LF, Hansen MGJ, Sindrup SH, et al, Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit. 1993;15:18-24
Grasby P., Sharp T., Moorman J., Grahame-Smith D, Comparison of the effect of buspirone and 1-(2-pyrimidinyl)piperazine on cerebral glucose utilization in the rat. Eur J Pharmacol. 230(1):41-6;1993
Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G, The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatr Scand. 1989;80(suppl 350):95-98
Green PC, et al, A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biological Chemistry 1993;268:23116-21
Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS, Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 1992;52:479-486
Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC, Efficacy and tolerability of serotonin transport inhibitors in obessive-compulsive disorder. A metaanalysis. Arch Gen Psychiatry. 1995;52:53-60
Gressens P, Hill JM, Gosez I, et al, Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 1993;362:155-8
Grimsley SR, Jann MW, Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm. 1992;11:930-957
Guengerich FP, Bioactivation and detoxication of toxic and carginogenic chemicals. Drug Metab Dispos. 1993; 21:1-6
Guengerich FP, Cytochrome P450 enzymes. Am Scientist. 1993;81:440-447
Guengerich FP, Human cytochrome P450 enzymes. Life Sci. 1992;50:1471-1478
Guengerich FP, Shimada T, Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol. 1991;4:391-407
Guyton AC, Hall JE, Textbook of medical physiology, 10th edition. Philadelphia: WB Saunders; 2000
Hamilton M, A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
Hamilton M, Development of a rating scale far primary depressive illness. Brit J Soc Clin Psychol 1967;6:278-96
Hardman JG, Limbird LE, Goodman & Gilman’s the pharmacological basis of therapeutics, 10th edition. New York: McGraw-Hill; 2001
Harris MG, Benfield P. Fluoxetine, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging. 1995;6:64-84
Hartig PR, Hoffman BJ, Kaufman MJ, et al, The 5-HT1C receptor. Ann NY Acad Sci 1990;600:149-66
Hartter S, Wetzel H, Hammes E, Hiemke C, Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacol. 1993; 110:302-308
Harvey AT, Preskorn SH, Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol. 1996;16:273-285
Harvey AT, Preskorn SH, Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol. 1996;16:345-355
Harvey AT, Preskorn SH, Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 2001;21:161-6
Harvey AT, Preskorn SH, Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry. 1995;52:783-784
Harvey AT, Preskorn SH, Mechanism of action of venlafaxine in normal male volunteers (Abstract). Clin Pharmacol Ther 1997;61:175
Harvey AT, Rudolph R, Preskorn SH, Evidence of the dual mechanism of action of venlafaxine in healthy male volunteers. Arch Gen Psychiatry, 2000;57:503-9
Hayashi S, Watanabe J, Nakachi K, Kawajiri K, Genetic linkage of lung cancer-associated Mspl polymorphisms with amino acid replacement in hemo binding region of the human cytochrome P4501A1 gene. J Biochem. 1991;110:407-411
Hebenstreit, GF, Fellerer K, Zochling R, Zentz A, Dunbar GC, A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand. 1989;80(suppl 350)81-84
Helzer JE, Burnam A, McEvoy LT, Alcohol abuse and dependence. In: Robins LN, Regier DA, Freedman DX, eds. Psychiatric Disorders in America: The Epidemiological Catchment Area Study. New York, NY: Free Press; 1991:81-115
Hemeryck A, Lefebvre RA, De Vriendt C, et al, Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 2000;67:283-91
Hendrickse W, Roffwarg H, Grannemann B, et al, The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. Neuropsychopharmacology 1994;10:85-91
Heninger GR, Charney DS, Sternberg DE, Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refactory depression. Arch Gen Psychiatry. 1983;40:1335-1342
Hersh EV, Adverse drug interactions in dental practice: Interactions involving antibiotics. Part II. J Am Dent Assoc 1999;130:236-51
Hershey AD, Krause JE, Molecular characterization of a functional cDNA encoding the rat substance P receptor. Science 1990;247:958-62
Hinmarch I, Subhan Z, Stoker MJ, The effects of zimelidine and amitriptyline on car driving and psychomotor performance. Acta Psychiatr Scand. 1983;68(suppl 308):141-146
Hinton JC, The Escherichia coli genome sequence: The end of an era or the start of the FUN?. Mol Microbiol 1997;26:417-22
Hiramatsu KT, Takahashi R, Mori A, et al, A multicentre, double-blind comparative trial of zimelidine and imipramine in primary major depressive disorders. Acta Psychiatr Scand. 1983;68(suppl 308):41-54
Hirschfeld RM, Keller MB, Panico S, et al, The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277: 333-340
Hokfelt T, Neuropeptides in perspective: The last ten years. Neuron 1991;7:867-9
Holliday SM, Plosker GL, Paroxetine: a review of its pharmacology, therapeutic use in depression, and therapeutic potential in diabetic neuropathy. Drugs Aging. 1993;3:278-299
Holm M, Olesen F, Psykofarmakordination i almen praksis (Prescribing of psychotropic drugs in general practice). Ugskr Laeger. 1989;151:2122-2126
Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr, Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8
Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518
Horst V;D, Preskorn SH, The role of benzodiazepines in the treatment of psychotic disorders. Psychiatric Ann 1993;23:317-24
Hoyer D, Clark DE, Fozard JR, et al, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46:157-203
Hoyer D, Clark DE, Fozard JR, et al, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46:157-203
Huff JR, Kahn J, Discovery and clinical development of HIV 1 protease inhibitors. Adv Protein Chem 2001;56:213-51
Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A, Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol. 1992;6(suppl 4):43-51
Hyttel J, Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry. 1993;47 (suppl 30):5-12
Hyttel J, Bogeso KP, Perregaard J, Sanchez C, The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm. 1992;88:157-160. Hyttel J, Bogeso KP, Perregaard J, Sanchez C
Inaba T, Jurima M, Mahon WA, Kalow W, In vitro inhibition studies of two isozymes of human liver cytochrome P450: mephenytoin P-hydroxylase and sparteine monooxygenase. Drug Metab Dispos.1985;13:443-448
Ingelman-Sundberg M, Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab Dispos 2001;29(4 Pt 2):570-3
Isaksen PM, The effect of an antidepressant agent on premature ejaculation [in Norwegian]. Tidsskr Nor Laegeforen. 1995;115:1616-1617
Ishigooka J, Kasahara T, Nagata E, Murasaki M, Miura S, Effects of washing procedure on platelets pretreated with serotonin uptake inhibitors in vitro: Low Ki values predict long-lasting inhibition of serotonin uptake in vivo. Nihon Shinkei Seishin Yakurigaku Zasshi 1998;1:19-21
Ishizaki T, Chiba K, Manabe K, et al, Comparison of the effects of E3810 and omeprazole on diazepam pharmacokinetics in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1994;55:141. Abstract
Jacobsen FM, Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 52(5):217-20;1991
Jacobsen FM, SSRI-induced sexual dysfunction. American Society of Clinical Psychopharmacology Progress Notes. 1994;5:1-4
Jalil P, Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry. 1992;55:412-413. Toxic reaction following the combined administration of fluoxetine and phenytoin
Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr, Principles and Practice of Psychopharmacotherapy. 2nd ed. Baltimore, Md: Lippincott, Williams & Wilkins; 1997
Janicak PG, Davis JM, Preskorn SH, Syd FJ Jr, Principles and Practices of Psychopharmacotherapy. Baltimore, Md: Williams and Wilkins; 1993
Jann MW, Carson SW, Grimsley SR, Erikson SM, Kumar A, Carter JG, Lack of effect of sertraline on the pharmacokinetics and pharmacodynamics of imipramine and its metabolites. Clin Pharm Therap. 1995;57:207. Abstract
Jerling M, Lindstrom L, Bondesson U, Bertilsson L, Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368-374
Jermain DM, Hughes PL, Follender AB, Potential fluoxetine-selegiline interaction. Ann Pharmacother. 1992;26:1300. Letter
Jody DM, Vice President Medical Marketing, Bristol-Myers Squibb, Letter to healthcare practitioners: Important drug warning including black box information. Received by author December 21, 2001
Joffe RT, Levitt AJ, Sokolov ST, Young LT, Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57:114-115
Joffe RT, Schuller DR, An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 54(7):269-71;1993
Joffe RT, Singer W, Levitt AJ, et al, A placebo-controlled comparison of lithium and triidothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387-393
Johnson DE, Wolfgang GH, Predicting human safety: Screening and computational approaches. Drug Discov Today 2000;5:445-54
Johnson JA, Racial differences in lymphocyte beta-receptor sensitivity to propranolol. Life Sciences 1993;53:297-304
Jozefowicz RF, Berg M, Dimitsopulos T, et al, Current therapy. In: Joynt RJ. Clinical neurology. Vol 1. Philadelphia: JB Lippincott; 1993
Julius D, MacDermott AB, Axel R, et al, Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. Science 1988; 241:558-64
Kahn RS, Asnis GM, Wetzler S, van Praag HM, Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology. 1988;96:360-364
Kaisary A, Smith P, Jaczq E, et al, Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 1987;47:5488-5493
Kalow W, Tyndale RF, Debrisoquine/sparteine monooxygenase and other P450s in brain. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York, NY: Pergammon Press, Inc; 1992:649-656
Kantor SJ, Bigger JT, Glassman AH, et al, Imipramine-induced heart block: A longitudinal case study. JAMA 1975;231:1364-6
Karp PD, Riley M, Paley SM, et al, EcoCyc: Encyclopedia of Escherichia coli genes and metabolism. Nucleic Acids Res 1997;25:43-51
Kasper S, Dotsch M, Vieira A, Kick H, Moller HJ, Plasma concentration of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharm. 1993;3:13-21
Katon W, Schulberg H, Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992;14:237-47
Katona CL, Hunter BN, Bray J, A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13:100-108
Kaul S, Shukla UA, Barbhaiya RH, Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol. 1995;35:830-839
Kay SR, Fiszbein A, Opler LA, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
Kaye CM, Haddock RE, Langley PF, et al, A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989;80(supp 350):60-75
Kelland MD, Freeman AS, Chiodo LA, Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther. 1990;253:803-811
Keller MB, Klerman GL, Lavori PW, et al, Treatment received by depressed patients. JAMA 1982;248:1848-55
Keller MB, Kocsis JH, Thase ME, et al, Maintenance phase efficacy of sertraline for chronic depression. A randomized controlled trial. JAMA. 1998;280:1665-1672
Kelly HO, Fay JE, Lavery FG, Thioridazine hydrochloride (Mellaril): Its effect on the electrocardiogram and a report on two fatalities with electrographic abnormalities. Can Med Assoc J 1963;89:546-54
Kelly MW, Perry PJ, Holstad SG, Garvey MJ, Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit. 1989;11:165-170
Kennedy JL, Petronis A, Gao J, et al, Genetic studies of DRD4 and clinical response to neuroleptic medications. Am J Hum Genet 1994;55:suppl:A190
Kennett GA, Wood MD, Glen A, et al, In vivo properties of SB 2000646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 1994;111:797-802
Kerr BM, Thummel KE, Wurden CJ, et al, Human liver carbamazepine metabolism. Role of CYP3A4 and CYP- 2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994;47:1969-1979
Kerr JS, Fairweather DB, Mahendran R, Hindmarch I, The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol. 1992;7:101-108
Kessler LG, Cleary PD, Burke JD Jr, Psychiatric disorders in primary care. Results of a followup study. Arch Gen Psychiatry. 1985;42:583-587
Ketter TA, Flockhart DA, Post RM, et al, The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995;15:387-398
Ketter TA, Post RM, Worthington K, Principles of clinically important drug interactions with carbamazepine. Part I and Part II. J Clin Psychopharmacol. 1991;11:198-203, 306-313
Kety SS, Genetic factors in suicide. In: Roy A, ed. Suicide. Baltimore, Md: Williams & Wilkins; 1986:41-45
Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA, Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol. 1994;14: 206-207. Letter
Kharasch ED, Opioid analgesics. In: Levy R, Thummel K, Trager W, et al. (eds) Metabolic drug interactions. Philadelphia: Lippincott William & Wilkins 2000:297-319
Kilicarslan T, Li N-Y, Busto U, et al, Flunitrazepam: Polymorphic metabolism by CYP2C19 (abstract). Clin Pharmacol Ther 1998;63:218
Kiloh LG, Andrews G, Neilson M, The longterm outcome of depressive illness. Br J Psychiatry. 1988;153:752-757
Kimura S, Umeno M, Skoda RC, et al, The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989;45:889-904
Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST, Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 1992;32:716-724
Klebe G, Recent developments in structure-based drug design. J Mol Med 2000;78;269-81
Kline SS, Mauro LS, Scala-Barnett DM, Zick D, Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm. 1989;8:510-514
Knesper DJ, Riba MB, Schwenk TL, Primary Care Psychiatry. Philadelphia, Pa: WB Saunders Co; 1997
Kraepelin E, Dementia praecox and paraphrenia. Translated by Barclay RM. Robertson GM, ed. Huntington. NY Krieger; 1971
Kraepelin E, Manic depressive insanity and paranoia. New York: Arno Press; 1976 (reprint of 1921 edition)
Kragh-Sorensen P, Overo KF, Peterson OL, Jensen K, Parnas W, The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol et Toxicol. 1981;48: 53-60
Krishna D, Klotz U, Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 1994;26:144-160
Kroger M, Wahl R, Compilation of DNA sequences of Escherichia coli K12: Description of the interactive databases ECD and ECDC. Nucleic Acids Res 1998;26:46-9
Kuhlmann J, Alternative strategies in drug development: Clinical pharmacological aspects. Int J Clin Pharmacol Ther 1999;37:575-83
Kuhn R, The treatment of depressive states with G-22355 (imipramine hydrochloride). Am J Psychiatry. 1958;115: 459-464
Kunze K, Eddy AC, Gibaldi M, Trager W, Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality. 1991;3:24-29
Kupfer A, Preisig R, Pharmacogenetics of p-mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26:753-759
Kupfer DJ, Frank E, Perel JM, The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry.1989;46:771-775
Kupfer DJ, Frank E, Perel JM, et al, Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49:769-773
Kurtz D, Bergstrom RF, Goldberg MJ, et al, The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997;62:145-56
Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimale BJ, Drug interation between sertraline and desipramine or imipramine. J Clin Pharmacol. 1994;34:1009-1033. Abstract
Laborit H, Huguenard P, Alluaume R, Un nouveau stabilisateur vegetatif, le 4560 RP. Presse Med. 1952; 60:206-208
Lader M, Melhuish A, Freka G, Fredericson, OK, Christensen V, The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol. 1986;31:183-190
Lamb D, Kelly D, Kelly S, Molecular aspects of azole antifungal action and resistance. Drug Resist Updat 1999;2:390-402
Landro JA, Taylor IC, Stirtan WG, et al, HTS in the new millennium: The role of pharmacology and flexibility. J Pharmacol Toxicol Methods 2000;44:273-89
Landry P, Roy L, Withdrawal hypomania associated with paroxetine. J Clin Psychopharmacol. 1997;17:60-61
Lane R, Baldwin D, Preskorn S, The SSRIs: advantages, disadvantages and differences. J Psychopharmacol. 1995; 9(suppl):163-178
Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ, Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacol. 1991;104:323-327
Laursen AL, Mikkelsen PL, Rasmussen S, le Fevre Honore P, Paroxetine in the treatment of depression -- a randomized comparison with amitriptyline. Acta Psychiatr Scand. 1985;71:249-255
Lawler CP, Prioleau C, Lewis MM, et al, Interactions of the novel antipsychotic aripiprazole (OPC-24597) with dopamine-receptor subtypes. Neuropsychopharmacology 1999;20:612-27
Lazowick AL, Levin GM, Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother. 1995;29:1284-1285
Lebegue B, Mania precipitated by fluoxetine. Am J Psychiatry. 1987;144:1620. Letter
Lebert F., Pasquier F., Goudemand M., Petit H, Euphoria with buspirone after fluoxetine treatment. Am J Psychiatry. 150(1):167;1993
Lefkowitz RJ, G-protein-coupled receptors: Turned on to ill effect. Nature 1993;365: 603-4
Lehmann HE, Ban TA, The history of the psychopharmacology of schiz ophrenia. Can J Psychiatry 1997;42:152-63
Lejoyeux M, Ades J, Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58(suppl 7):11-16
Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF, The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther. 1988;43:412-419
Lemberger L, Rowe H, Carmichael R, et al, Fluoxetine, a selective serotonin uptake inhibitor. Clin Pharmacol Ther 1978;23:421-9
Lembo PM, Grazzini E, Cao J, et al, The receptor for the orexigenic peptide melanin-concentrating hormone is a G-protein-coupled receptor. Nat Cell Biol 1999;1:267-71
Lemoine A, Gautier JC, Azoulay D, et al, Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993;43:827-832
Leonard BE, The comparative pharmacology of new antidepressants. [published erratum appears in J Clin Psychiatry. 1993;54:491]. J Clin Psychiatry. 1993;54(suppl):3-15
Leonard BE, Richelson E, Synaptic effects of antidepressants: Relation to their therapeutic and adverse effects. In: Buckley PF, Waddington JL, eds. Schizophrenia and mood disorders: The new drug therapies in clinical practice. Oxford: Butterworth Heinemann; 1999: [AU: PAGE NUMBE
Lesch K-P, Mossner R, Genetically driven variation in serotonin uptake: Is there a link to affective spectrum neurodevelopmental and neurodegenerative disorders?. Biol Psychiatry 1998;44:179-92
Lesch K-P, Wolozin BL, Murphy DL, Riederer P, Primary structure of the human platelet serotonin uptake site: Identity with the brain serotonin transporter. J Neurochem 1993;60:2319-22
Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, eds, Metabolic drug interactions. Philadelphia: Uppincott, Williams & Wilkins, 2000
Lewis J, Braganza J, Williams T, Psychomotor retardation and semistuporous state with paroxetine. Br Med J. 1993;306: 1169
Lewis R, Trager W, Chan K, et al, Warfarin: stereo-chemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974;53:1607-1617
Lin KM, Poland RE, Ethnicity, culture and psychopharmacology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994:1907-1918
Lin L, Yang F, Ye Z, et al, Case-control study of cigarette smoking and primary hepatoma in an aflatoxin-endemic region of China: a protective effect. Pharmacogenetics. 1991;1:79-85
Lingjaerde O, Bratfos O, Bratlid T, Havg JO, A double-blind comparison of zimelidine and desipramine in endogenous depression. Acta Psychiatr Scand. 1983;68:22-30
Litovitz TL, Holm KC, Clancy C, Schmitz BF, Clark LR, Oderda GM, 1992 annual report of the American Association of Poison Control Centers Toxic Exposures Surveillance System. Am J Emerg Med. 1993;11:494-555
Little KY, McLaughlin DP, Zhang L, et al, Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 1998;155:207-13
Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N, Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303-1307
Louie AK, Lannon RA, Ajari LJ, Withdrawal reaction after sertraline discontinuation. Am J Psychiatry. 1994;151:450-451. Letter
Ludovico GM, Corvasce A, Pagliarulo G, Cirillo-Marucco E, Marano A, Pagliarulo A, Paroxetine in the treatment of premature ejaculation. Br J Urol. 1996;77:881-882
Lund J, Lomholt B, Fabricius J, Christensen JA, Bechgaard E, Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man. Acta Pharmacol et Toxicol. 1979; 44:289-295
Lundmark J, Scheel K, Thomsen I, Fjord-Larsen T, et al, Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand. 1989;80(suppl 350):76-80
Luurila H, Olkkola KT, Neuvonen PJ, Interaction between erythromycin and nitrazepam in healthy volunteers. Pharmacol Toxicol 1995;76:255-8
Madsen H, Nielsen KK, Brøsen K, Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms -- a population study. Br J Clin Pharmacol. 1995;39:433-439
Maes M, Westenberg H, Vandoolaeghe E, et al, Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 1997;17:358-64
Malek-Ahmadi P, Allen SA, Paroxetine-molindone interaction. J Clin Psychiatry. 1995;56:82-83. Letter
Manahan-Vaughan D., Anwyl R., Rowan MJ, The azapirone metabolite 1-(2-pyrimidinyl) piperazine depresses excitatory synaptic transmission in the hippocampus of the alert rat via 5-HT1A receptors. Eur J Pharmacol. 294(2-3):617-24;1995
Marder SR, Meibach RC, Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835
Marez D, Legrand M, Sabbagh N, et al, Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202
Marsden CA, Tyrer P, Casey P, Seivewright N, Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. J Psychopharmacol. 1987;1:244-250
Marshall RD, Schneier FR, Fallon BA, et al, An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol. 1998;18:10-18
Martin P, 1-(2-pyrimidinyl) piperazine may alter the effects of the 5-HT1a agonist in the learned helplessness paradigm in rats. Psychopharmacology-Berl. 104(2):275-8;1991
Martin P, Massol J, Colin JN, Lacomblez L, Puech AJ, Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 1990;23:187-94
Masu Y, Nakayama K, Tamaki H, et al, cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature 1987;329:836-8
Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH, Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos. 1994;22:304-311
McCarthy JJ, Hilfiker R, The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 2000;18:505-8
McClelland GR, Raptopoulos P, Psychomotor effects of paroxetine and amitriptyline, alone and in combination with alcohol. Br J Clin Pharmacol. 1985;19:578P. Abstract
McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM Jr, Gross LS, The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry. 1990;51(suppl):60-69
McDowell F, Cedarbaum JM, The extrapyramidal system and disorder of movement. In: Joynt RJ. Clinical neurology. Vol 3. Philadelphia: JB Lippincott; 1993
McInnes GT, Brodie MJ, Drug interactions that matter: a critical reappraisal. Drugs 1988;36:83-110
McLellan RA, Oscarson M, Seidegard J, et al, Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7:187-91
Mellstrom B, Bertilsson L, Sawe J, Schulz H, Sjoqvist F, E- and Z-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther. 1981;30:189-193
Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, Clinical pharmacology: Basic principles in therapeutics, 3rd ed. New York: McGraw-Hill; 1992
Meltzer HY, Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review. Br J Psychiatry 1996;168:23-31
Meltzer HY, Matsubara S, Lee LC, Classification of typical and atypical antipsychotic drugs on the basis of dopamine D 1,D2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;25:238-46
Merikangas KR, Weissman MM, Pauls DL, Genetic factors in the sex ratio of major depression. Psychol Med. 1985;15: 63-69
Meyerhof W, Darlison MG, Richter D, The elucidation of neuropeptide receptors and their subtypes through the application of molecular biology. In: Hucho F, ed. Neurotransmitter receptors. Amsterdam:Elsevier, 1993; 335-53
Miles MV, Tennison MB, Erythromycin effects on multiple-dose carbamazepine kinetics. Ther Drug Monit. 1989;11:47-52
Miller F, Friedman R, Tanenbaum J, Griffin A, Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome. J Clin Psychopharmacol. 1991;11:277-279. Letter
Miller HL, Delgado PL, Salomon RM, Licinio J, Barr LC, Charney DS, Acute tryptophan depletion: A method of studying antidepressant action. J Clin Psychiatry 1992;53(suppl 10):28-35
Mills KC, Serotonin syndrome. Am Fam Physician. 1995;52:1475-1482
Milne RJ, Goa KL, Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41:450-477
Modell JG, Katholi CR, Modell JD, DePalma RL, Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther. 1997;61:476-487
Montejo AI, Llorca G, Izquierdo JA, et al, Sexual dysfunction secondary to SSRIs. A comparative analysis in 308 patients [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1996;24:311-321
Montejo-Gonzales AL, Llorca G, Izquierdo JA, et al, SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997; 23:176-194
Montgomery SA, Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. Intl Clin Psychopharmacol. 1995;10(suppl 1):23-27
Montgomery SA, Dufour H, Brion S, et al, The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 1988;153(suppl 3):69-76
Montgomery SA, Evans R, Relapse prevention with antidepressants. Nord J Psychiatry. 1993;47(suppl 30):83-88
Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P, The optimal dosing regimen for citalopram-a metaanalysis of nine placebo-controlled studies. Intl Clin Psychopharmacol. 1994;9(suppl 1):35-40
Montgomery SA, Rasmussen JG, Lyby K, Connor P, Tanghoj P, Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Intl Clin Psychopharmacol. 1992;6(suppl 5):65-70
Montgomery SA, Rasmussen JG, Tanghoj P, A 24-week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Intl Clin Psychopharmacol. 1993;8:181-188
Mori S, Matsuura T, Takino T, Sano Y, Light and electron microscopic immunohistochemical studies of serotonin nerve fibres in the substantia nigra of the rat, cat and monkey. Anat Embryol 1987;176:13-8
Mormon K, Hoffman B, Nierenberg D, Introduction to clinical pharmacology. In: Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Clinical pharmacology: Basic principles in therapeutics. New York: McGraw-Hill; 1992:7-19
Morowitz HJ, The completeness of molecular biology. Isr J Med Sci 1984;20:750-3
Moxon ER, Higgins CF, E coli genome sequence: A blueprint for life. Nature 1997; 389:120-1
Murray M, Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. Drug Metabolism Reviews. 1987;18:55-81
Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K, Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 1991;51:5177-5180
Nankai M, Yamada S, Yoshimoto S, et al, Platelet 3H-paroxetine binding in control subjects and depressed patients: Relationship to serotonin uptake and age. Psychiatry Res 1994;51:147-55
Naranjo CA, Sproule BA, Knoke DM, Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1999;14(suppl 2):S35-47
Narayan M, Anderson G, Cellar J, Mallison RT, Price LH, Nelson JC, Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol. 1998;18:67-71
Nathan RS, Perel JM, Pollock BG, Kupfer DJ, The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry. 1990; 51:367-372
Nebert DW, Proposed role of drug-metabolizing enzymes: regulation of steady-state levels of the ligands that effect growth, homeostatis, differentiation, and neuroendocrine functions. Mol Endocrinol. 1991;5:1203-1214
Nebert DW, Adesnik M, Coon MJ, et al, The P450 gene superfamily: recommended nomenclature. DNA. 1987;6:1-11
Nebert DW, Gonzalez FJ, P450 genes: structure, evolution and regulation. Ann Rev Biochem. 1987;56:945-993
Nebert DW, Nelson DR, Feyereisen R, Evolution of the cytochrome P450 genes. Xenobiotica. 1989;19:1149-1160
Nelson DR, Kamataki T, Waxman DJ, et al, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol. 1993;12:1-51
Nelson JC, Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58(suppl 6):26-31
Nelson JC, Mazure CM, Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry. 1986;143:363-366
Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI, A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-307
Nemeroff CB, DeVane CL, Pollock BG, Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320
Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E, Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993;342;1419. Letter
Nierenberg AA, Cole JO, Antidepressant adverse drug reactions. J Clin Psychiatry. 1991;52(suppl):40-47
Nierenberg AA, Cole JO, Glass L, Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry. 1992;53:83-85
Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J, Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:19-23
Nierenberg AA, White K, What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull. 1990;26:429-460
Nierenberg DW, Semprebon M, The central nervous system serotonin syndrome. Clin Pharmacol Ther. 1993;53:84-88
Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK, Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Intl Clin Psychopharmacol. 1993;8:25-29
Nystrom C, Hallstrom T, Double-blind comparison between serotonin and adrenaline reuptake blocker in the treatment of depressed outpatients: clinical aspects. Acta Psychiatr Scand. 1985;72:6-15
Nystrom C, Hallstrom T, et al, Comparison between serotonin and adrenaline reuptake blocker in the treatment of depressed outpatients: a crossover study. Acta Psychiatr Scand. 1987;75:377-382
Ohmori S, Takeda S, Rikihisa T, Kiuchi M, Kanakubo Y, Kitada M, Studies on cytochrome P450 resonsible for oxidative metabolism of imipramine in human liver microsomes. Biol Pharm Bull. 1993;16:571-575
Olkkola KT, Aranko K, Luurila H, et al, A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53:298-305
Orzechowska-Juzwenko K, Wiela A, Cieslinska A, Roszkowska E, Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. Cancer. 1987;59:1607-1610
Oshiro Y, Sato S, Kurahashi N, et al, Novel antipsychotic agents with dopamine autoreceptor agonist properties: Pharmacology of 7-[4-(4phenyl-1-piperazinyl)butoxy]. J Med Chem 1998;41:658-67
Oswald I, Adam K, Effects of paroxetine on human sleep. Br J Clin Pharmacol. 1986;22:97-99
Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM, Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5HT uptake inhibitors. Clin Pharm Therap. 1994;55:141
Otton SV, Inaba T, Kalow W, Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci. 1983;32:795-800
Overmars H, Scherpenisse PM, Post LC, Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet. 1983;8:269-280
Overo KF, Preliminary studies of the kinetics of citalopram in man. Eur J Clin Pharmacol. 1978;14:69-73
Owens M, Ieni J, The serotonergic antidepressant nefazodone inhibits the serotonin transporter: In vivo and ex vivo studies. Life Science 1995;57:373-80
Ozdemir V, Naranjo CA, Hermann N, et al, The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J Clin Psychopharmacol 1998;18:55-61
Ozdemir V, Naranjo CA, Herrmann N, et al, Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997;62:334-47
Palmer KJ, Benfield P, Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in nondepressive disorders. CNS Drugs. 1994; 1:57-87
Panchagnula R, Thomas NS, Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm 2000;201:131-50
Parker AC, Preston T, Heaf D, Kitteringham NR, Coonara I, Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Pharm 1994;38(6):573-6
Parker G, Roy K, Hadzi-Pavlovic D, Pedic F, Psychotic (delusional) depression: a metaanalysis of physical treatments. J Affect Disord. 1992;24:17-24
Pato MT, Murphy DL, DeVane CL, Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol. 1991;11:224-225
Pearson HJ, Interaction of fluoxetine with carbamazepine. J Clin Psychiatry.1990;51:126
Peet M, Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164:549-550
Perel JM, Shostak M, Gann E, Kantor SJ, Glassman AH, Pharmacodynamics of imipramine and clinical outcome in depressed patients. In: Gottschalk LA, Merlis S, eds. Pharmacokinetics of Psychoactive Drugs. New York, NY: Spectrum Publications; 1976:229-241
Perucca E, Gatti G, Cipolla G, et al, Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther. 1994;56:471-476
Perucca E, Gatti G, Spina E, Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1994;27:175-190
Petit JM, Spiker DG, Ruwitch JF, et al, Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin Pharmacol Ther 1977;21:47-51
Pfandi B, Morike K, Winne D, Schareck W, Breyer-Pfaff U, Steroselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica. 1992;22:721-730
Pharmaceutical Research and Manufacturers of America, The 1990s: A great decade for patients. March 2001. Accessed January 9, 2002.
Phillipson OT, Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J Comp Neurol 1979;187:117-44
Pigott TA, OCD: where the serotonin selectivity story begins. J Clin Psychiatry. 1996;57(suppl 6):11-20
Pincus HA, Tanielian TL, Marcus SC, et al, Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA. 1998;279:526-531
Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK, The effect of enzyme induction on the cytochrome P450 mediated bioactivation of carbamazipine by mouse liver microsomes. Biochem Pharmacol. 1992;44:2307-2314
Pirmohamed M, Kitteringham NR, Guenther TM, Breckenridge AM, Park BK, An investigation of the formation of cytotoxic protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol. 1992; 43:1675-1682
Pirmohamed M, Williams D, Madden S, Templeton E, Park BK, Metabolism and bioactivation of clozapine by human liver in vitro. J Pharm Exp Therap. 1995;272:984-990
Pletscher A, Platelets as models: Use and limitations. Experientia 1988;44:152-5
Pollock B, Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry. 1994; 2:204-213
Pollock BG, Mulsant BH, Nebes R, et al, Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry. 1998;155:1110-1112
Potter WZ, Rudorfer MV, Manji H, The pharmacologic treatment of depression. N Engl J Med. 1991;325:633-642
Preskorn SH, A dangerous idea. J Pract Psychiatry Behav Health 1996;2:231-4
Preskorn SH, A message from Titanic. J Prac Psych Behav Hlth. 1998;4:236-242
Preskorn SH, A tale of two patients. J Pract Psychiatry Behav Health 1999;5:160-164
Preskorn SH, Antidepressant drug selection: criteria and options. J Clin Psychiatry. 1994;55(suppl A):6-22, 23-24, 98-100
Preskorn SH, Antipsychotic drug development in the pre-human genome era: A full circle. Journal of Psychiatric Practice 2001;7:209-213
Preskorn SH, Appearance of knowledge. J Pract Psychiatry Behav Health 1997;3:233-8
Preskorn SH, Beyond DSM-IV. What is the cart and what is the horse?. Psychiatric Annals 1995;25:53 62
Preskorn SH, Bridging the gap.
Preskorn SH, Bupropion: What mechanism of action?. Journal of Psychiatric Practice 2000;6:39-44
Preskorn SH, Case 1. Sudden death in a 36-year-old man. In Outpatient management of depression. Caddo, OK Professional Communications; 1999:184-6
Preskorn SH, Case 2: Severe parkinsonism and confusion in a 78-year-old woman. In Outpatient management of depression. Caddo, OK Professional Communications; 1999:186-8
Preskorn SH, Case 3: A 44-year old man at risk for seizures. In Outpatient management of depression. Caddo, OK Professional Communications; 1999:188-9
Preskorn SH, Case 4: The 28-year-old man with abdominal cramps, chills, and rummy nose. In Outpatient management of depression. Caddo, OK Professional Communications; 1999:189-90
Preskorn SH, Cases 2-4: In Outpatient management of depression. Caddo, OK: Professional Communications; 1999: 186-90
Preskorn SH, Clinical pharmacology case conference: A suicide attempt?. Journal of Psychiatric Practice 2002;8:306-10
Preskorn SH, Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Caddo, Okla: Professional Communications, Inc; 1996
Preskorn SH, Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32:1-21
Preskorn SH, Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. J Clin Psychiatry. 1995;56(suppl 6):12-21
Preskorn SH, Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J Psychopharmacol. 1998;12:S89-S97
Preskorn SH, Defining "Is.". J Pract Psychiatry Behav Health 1999;5:224-8
Preskorn SH, De-spinning in vitro data. J Pract Psychiatry Behav Health 1999;5:283-7
Preskorn SH, Do you believe in magic?. J Pract Psychiatry Behav Health 1997;3:99-103
Preskorn SH, Do you feel lucky?. J Prac Psycho Behav Hlth. 1998;4:37-40
Preskorn SH, Dose-effect and concentration-effect relationships with new antidepressants. In: Gram LF, Balant LP, Meltzer SG, Dahl SG, eds. Clinical Pharmacology in Psychiatry: Strategies in Psychotropic Drug Development. Berlin: Heidelberg; 1993:174-189
Preskorn SH, Drug approvals and withdrawals over the last 60 years. Journal of Psychiatric Practice 2002;7:410
Preskorn SH, Drug development in psychiatry and genomics: From E. coli to man. Journal of Psychiatric Practice 2001;7:415-9
Preskorn SH, Drug development in psychiatry and the human genome project: The explosion in knowledge and potential targets. Journal of Psychiatric Practice 2001;7:336-40
Preskorn SH, Drug discovery in psychiatry: Drilling down on the target of interest. Journal of Psychiatric Practice 2001;7:267-72
Preskorn SH, Factors affecting the biphasic concentration: Effect relationships of tricyclic antidepressants. In: Usdin E, Dahl SG, Gram LF Lingjaerde O, eds. Clinical pharmacology in psychiatry. [CITY?] Macmillan; 1981:297-306
Preskorn SH, Fatal drug-drug interaction as a differential consideration in apparent suicides. Journal of Psychiatric Practice 2002;8:233-8
Preskorn SH, Finding the signal through the noise: The use of surrogate markers. J Pract Psychiatry Behav Health 1999;5:104-109
Preskorn SH, Have you phenotyped your patient lately?. J Pract Psychiatry Behav Health 1996;2(2):115-7
Preskorn SH, I don’t see ’em. J Prac Psych Behav Hlth. 1997; 3:302-307
Preskorn SH, If lack of concentration didn’t cause the fall, what did?. J Pract Psychiatry Behav Health 1996;2:364-7
Preskorn SH, Imipramine, Mirtazapine, and Nefazodone: Multiple targets. Journal of Psychiatric Practice 2000;6:97-102
Preskorn SH, Introduction: pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl 9):3-7
Preskorn SH, Let the data speak to you. J Pract Psychiatry Behav Health 1997;3(1):45-8
Preskorn SH, Marooned: Only one choice. J Prac Psych and Behav Hlth 1998;4:110-4
Preskorn SH, Modern drug development and the Human Genome Project. (collection of 4 columns published in the Journal of Psychiatric Practice). Accessed June 25, 2001
Preskorn SH, Outpatient management of depression: A guide for the primary-care practitioner, 2nd Edition. Caddo, OK: Professional Communications; 1999
Preskorn SH, Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl 9):14-34
Preskorn SH, Pharmacokinetics of psychotropic agents: Why and how they are relevant to treatment. J Clin Psychiatry 1993; 54(suppl 9):3-7
Preskorn SH, Polypharmacy in a patient with refractory major depression: Part I. The case. Journal of Psychiatric Practice 2002;8:370-6
Preskorn SH, Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ, eds. European Cooperation in the Field of Scientific and Technical Research. Belguim: European Commission; 1998:45-61
Preskorn SH, Reducing the risk of drug-drug interactions: A goal of rational drug development. J Clin Psychiatry 1996;57(suppl 1):3-6
Preskorn SH, Section 3. The rationale for and clinical implications of dose-response curves. (five columns published in the Journal of Practical Psychiatry and Behavioral Health in 1996)
Preskorn SH, Selection of an antidepressant: mirtazapine. J Clin Psychiatry. 1997;58(suppl 6):3-8
Preskorn SH, Series of columns in this journal beginning with March 1998 and continuing from July 1999 through July 2000.
Preskorn SH, Serotonin receptor subtypes and their implications for psychiatric disorders. In: Hagerman RJ, KcKenzie P, edsl.1992 International Fragile X Conference Proceddings. Dillon, Colo: Spectra Publishing Co; 1992: 179-194
Preskorn SH, Should bupropion dosage be adjusted based upon therapeutic drug monitoring?. Psychopharmacol Bull. 1991;27:637-643
Preskorn SH, Should rational drug development in psychiatry target more than one mechanism of action in a single molecule?. Intl Rev Psychiatry. 1995;7:17-28
Preskorn SH, Sudden death and tricyclic antidepressants (TCAs): A rare adverse event linked to high TCA plasma levels. Nord J Psychiatry. 1993;47(suppl 30):49-55
Preskorn SH, Sweetness!. J Prac Psych and Behav Hlth 1998;4:304-8
Preskorn SH, Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Intl Clin Psychopharmacol. 1994;9(suppl 3):13-19
Preskorn SH, The adverse effect profiles of the selective serotonin reuptake inhibitors: Relationship to in vitro pharmacology. Journal of Psychiatric Practice 2000;6:153-7
Preskorn SH, The appearance of knowledge. J Prac Psych Behav Hlth. 1997;3:233-238
Preskorn SH, The future and psychopharmacology: potentials and needs. Psychiatr Ann. 1990;20(suppl 11):625-633
Preskorn SH, The human genome project and drug discovery in psychiatry: Identifying novel targets. Journal of Psychiatric Practice 2001;7:133-7
Preskorn SH, The human genome project and modern drug development in psychiatry. Journal of Psychiatric Practice 2000;6:272-276
Preskorn SH, The polypharmacology section. (collection of columns published in the Journal of Psychiatric Practice). Accessed July 10, 2002
Preskorn SH, The polypharmacy section. (collection of columns published in the Journal of Psychiatric Practice). Accessed March 8, 2002
Preskorn SH, The rationale for and clinical implications of dose-response curvese project. (collection of columns published in J Pract Psychiatry Behav Health).
Preskorn SH, The relative adverse effect profile of non-SSRI antidepressants: Relationship to in vitro pharmacology. Journal of Psychiatric Practice 2000;6:218-23
Preskorn SH, The revolution in psychiatry. Phi Kappa Phi. Winter 1993:22-25
Preskorn SH, The slippery slide. J Pract Psychiatry Behav Health 1999;5:50-5
Preskorn SH, The stages of drug development and the human genome project: Drug discovery. Journal of Psychiatric Practice 2000;6:341-4
Preskorn SH, Therapeutic drug monitoring of tricyclic antidepressants: A means of avoiding toxicity. In: Dahl S, Graham L, Eds. Clinical pharmacology in psychiatry: From molecular studies to clinical reality. Berlin: Springer-Verlag; 1989:237-43
Preskorn SH, Therapeutic drug monitoring. In: Preskorn SH, Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications; 1996: 99-105.
Preskorn SH, To monitor or not to monitor, II: The glass is more than half full. J Pract Psychiatry Behav Health 1996;2:307-10
Preskorn SH, To monitor or not to monitor?. J Pract Psychiatry Behav Health 1996;2:172-5
Preskorn SH, Tricyclic antidepressants: the whys and hows of therapeutic drug monitoring. J Clin Psychiatry. 1989;50 (suppl):34-42, 43-46
Preskorn SH, Two in one: The venlafaxine story. J Pract Psychiatry Behav Health 1999;5:346-50
Preskorn SH, Understanding the basics of antidepressant pharmacotherapy. (collection of columns published in the Journal of Psychiatric Practice) Accessed June 25, 2001
Preskorn SH, Use of antidepressants with other medications. In: Preskom SH. Outpatient management of depression. Caddo, OK Professional Communications; 1999:179-91
Preskorn SH, What happened to Tommy?. J Pract Psychiatry Behav Health 1996;1:39-43
Preskorn SH, What happened to Tommy?. J Pract Psychiatry Behav Health 1998;4:363-7
Preskorn SH, What is the message in the alphabet soup of cytochrome P450 enzymes?. J Prac Psychiatry Behavioral Hlth. 1995;1:237-240
Preskorn SH, Why did Terry fall off the dose-response curve?. J Pract Psychiatry Behav Health 1998;4:363-7
Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S, Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90-98
Preskorn SH, Baird S, 11.2 billion dollars: Is it worth it?. J Pract Psychiatry Behav Health 1998;4:163-8
Preskorn SH, Baker B, Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA. 1997;277:1682. Letter
Preskorn SH, Bupp S, Weller E, Weller R, Plasma levels of imipramine and metabolites in 68 hospitalized children. J Am Acad Child Adoesc Psychiatry. 1989;28:373-375
Preskorn SH, Burke M, Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry. 1992;53(suppl 9):5-18
Preskorn SH, Burke M, Fast G, Therapeutic drug monitoring: Principles and practices. In: Dunner D, ed. The Psychiatric Clinics of North America. Philadelphia: WB Saunders; 1993:611-46
Preskorn SH, Burke M, Harvey A, Carmichael C, Polypharmacy in psychiatry. Presented at the 129th NCDEU meeting; May 28-31, 1996; Boca Raton, Fla
Preskorn SH, Fast GA, Beyond signs and symptoms: the case against a mixed anxiety and depression category. J Clin Psychiatry. 1993;54(suppl):24-32
Preskorn SH, Fast GA, Therapeutic drug monitoring for antidepressants: Efficacy, safety and cost effectiveness. J Clin Psychiatry. 1991;52(suppl 6):23-33
Preskorn SH, Fast GA, Therapeutic drug monitoring for antidepressants: Efficacy, safety and cost effectiveness [published erratum appears in J Clin Psychiatry. 1991;52:353]. J Clin Psychiatry. 1991;52(suppl):23-33
Preskorn SH, Fast GA, Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry. 1992;53:160-162
Preskorn SH, Goodwin WG, Erickson HM, DSM-III R and pharmacotherapy. In: Hersen M, Turner SM, eds. Adult psychopathology and diagnosis, 2nd edition. New York: Wiley; 1991:482 99
Preskorn SH, Harvey A, Biochemical and clinical dose-response curves with sertaline. Clin Pharmacol Ther. 1996; 59:180
Preskorn SH, Harvey A, Cytochrome P450 enzymes and psychopharmacology. In: Watson S, ed. Psychopharmacology: The fourth generation of progress [CD ROM version]. Philadelphia: Raven; in press
Preskorn SH, Harvey A, Stanga C, Drug interactions and their role in patient care. Curr Rev Mood Anxiety Disord. 1997;1: 203-214
Preskorn SH, Harvey AT, Stanga C, Drug interactions: how to understand them and their role in patient care. In: Rush AJ, ed. Current Review of Mood Disorders. 1996. In press
Preskorn SH, Hughes, Ethanol effects on brain concentrations of amitriptyline and the relationship to psychomotor function. Psychopharmacology 1983;80:217-20
Preskorn SH, Irwin HA, Toxicity of tricyclic antidepressants-kinetics, mechanism, intervention: a review. J Clin Psychiatry. 1982;43:151-156
Preskorn SH, Janicak PG, Davis JM, Ayd FJ, Advances in the pharmacotherapy of depressive disorders. In: Janicak PG, ed. Principles and Practices of Psychopharmacotherapy. Baltimore, Md: Williams and Wilkins; 1995:4
Preskorn SH, Jerkovich GS, Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors and the role of therapeutic drug monitoring. J Clin Psychopharmacol. 1990;10:88-95
Preskorn SH, Jerkovich GS, Beber JH, Widener P, Therapeutic drug monitoring of tricyclic antidepressants: a standard of care issue. Psychopharmacol Bull. 1989;25:281-284
Preskorn SH, Katz SE, Bupropion plasma levels: Intraindividual and interindividual variability. Ann Clin Psychiatry 1989;1:59-61
Preskorn SH, Kent TA, Mechanisms and interventions in tricyclic antidepressant overdoses. In: Stancer HC, Garfinkel PE, Rakoff VM, eds. Guidelines for the Use of Psychotropic Drugs: A Clinical Handbook. Spectrum Publications, Inc; 1984:63-75
Preskorn SH, Lacey R, Polypharmacy: when is it rational?. J Prac Psych Behav Hlth. 1995;1:92-98
Preskorn SH, Lane RM, Sertraline 50 mg daily: The optimal dose in the treatment of depression. Intl Clin Psychopharmacol. 1995;10:129-141
Preskorn SH, Mac DS, The implication of concentration/response studies of tricyclic antidepressants for psychiatric research and practice. Psychiatric Develop. 1984;2:201-222
Preskorn SH, Magnus R, The clinical relevant pharmacology of serotonin selective reuptake inhibitors. Clin Pharmacokinet. In press
Preskorn SH, Magnus RD, Inhibition of hepatic P450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull. 1994;30:251-259
Preskorn SH, Omo K, Magnus RD, Shad MU, Assessment of potential drug-drug interactions following immediate crossover from fluoxetine to mirtazapine. Poster session, American Psychiatric Association Meeting, San Diego, 1998
Preskorn SH, Othmer SC, Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy. 1984;4:20-34
Preskorn SH, Shad MU, Alderman J, Lane R, Fluoxetine: Age and dose dependent pharmacokinetics and CYP 2C19 inhibition. Am Soc Clin Pharmacol Ther. 1998;63:166. Abstract
Preskorn SH, Silkey B, Multiple medications, multiple considerations. Journal of Psychiatric Practice 2001;7:48-52
Preskorn SH, Silkey B, Beber J, Dorey C, Antidepressant response and plasma concentrations of fluoxetine. Ann Clin Psychiatry. 1991;3:147-151
Price JS, Waller PC, Wood SM, MacKay AV, A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996;42:757-763
Prien RF, Kupfer DJ, Continuation drug therapy for major depressive episodes: how long should it be maintained?. Am J Psychiatry. 1986;143:18-23
Prim RF, Caffey EM, Klett CJ, Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972;26:146-53
Prisco S, Esposito E, Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Brit J Pharm 1995;116:1923-31
Prisco S, Pagannone S, Esposito E, Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther 1994;271:83-90
Propping P, Nothen M, Genetic variation of CNS receptors: A new perspective for pharmacogenetics. Pharmacogenetics 1995;5:318-25
Prouty RW, Anderson WH, Postmortem redistribution of drugs. In: Jones GR, Singer PP, eds. Proceedings of the 24th International Meeting. International Association of Forensic Toxicologists. Edmunton, Alberta, Canada: University of Alberta Printing Services; 1988:1-21
Przegalinski E., Tatarczynska E., Chojnacka-Wojcik E, Antidepressant-like activity of ipsapirone, buspirone and gepirone in the forced swimming test in rats pretreated with proadifen. Journal of Psychopharmacology. 4(4):204-9;1990
Quitkin FM, Harrison W, Liebowitz M, et al, Defining the boundaries of atypical depression. J Clin Psychiatry. 1984; 045:19-21
Raghoebar M, Roseboom H, Kinetics of fluvoxamine in special populations. Poster presented at Symposium on Variability in Pharmacokinetics and Drug Response; October 3-5, 1988; Gothenburg, Germany
Ramamoorthy S, Bauman AL, Moore KR, et al, Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci 1993; 90:2542-6
Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K, Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry. 1996;57(suppl 1):24-28
Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K, Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry. 1996;57(suppl 1):20-23
Rasmussen BB, Maenpaa J, Pelkonen O, et al, Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol. 1995;39:151-159
Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III, Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363-369
Razin S, Comparative genomics of mycoplasmas. Wien Klin Wochenschr 1997;109:551-6
Reichert JM, New biopharmaceuticals in the USA: Trends in development and marketing approvals 1995-1999. Trends Biotechnol 2000;18:364-9
Reilly JG, Ayis SA, Ferrier IN, et al, Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002;180:515-22
Reimherr FW, Chouinard G, Cohn CK, et al, Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990;51(suppl B):18-27
Rettie AE, Korzekwa KR, Kunze KL, et al, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992;5:54-59
Reus VI, Rational polypharmacy in the treatment of mood disorders. Ann Clin Psychiatry 1993;5:91-100
Reynolds RD, Serotonin syndrome: what family physicians need to know. Am Fam Physician. 1995;52:1263, 1266, 1271. Editorial
Richard IH, Karlan R, Tanner C, et al, Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinsons disease. Neurology 1997;48:1070-7
Richelson E, Pharmacokinetic drug interactions of new-age antidepressants: A review for the practitioner on effects on the metabolism of other drugs. Mayo Clin Proc 1997;72:835-47
Richelson E, Pharmacology of antidepressants: Characteristics of the ideal drug. Mayo Clin Proc. 1994;69:1069-1081
Richelson E, Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry 1999;60(suppl 10):5-14
Robert P, Montgomery SA, Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6-month study. Intl Clin Psychopharmacol. 1995;10(suppl 1):29-35
Robertson MM, Trimble MR, Depressive illness in patients with epilepsy: a review. Epilepsia. 1983;24(suppl 2):S109-S116
Robillard M., Lieff S, Augmentation of antidepressant therapy by buspirone: Three geriatric case histories. Can J Psychiatry. 40(10):639-40;1995
Robins E, Completed suicide. In: Roy A, ed. Suicide. Baltimore, Md: Williams & Wilkins; 1986:123-133
Robins E, The Final Months: A Study of the Lives of 134 Persons Who Committed Suicide. New York, NY: Oxford University Press; 1981
Robinson DS, Roberts DL, Smith JM, et al, The safety profile of nefazodone. J Clin Psychiatry. 1996;57(suppl 2):31-38
Rochat B, Amey M, Baumann P, Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Therap Drug Monit. 1995;17:273-279
Rodriguez AD, Evaluating drug-drug interactions: A report from the frontlines. Lecture given at ASCPT; March 15-17, 2000
Ronfeld R, Tremaine L, Wilner K, Pharmacokinetics of sertraline and its n-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32:22-30
Ronfeld RA, Tremaine LM, Wilner KD, Henry EB, Evaluation of the pharmacokinetic properties of sertraline and desmethylsertraline in elderly and young normal volunteers. Clin Pharmacokinet. In press
Roose SP, Glassman AH, Attia E, Woodring S, Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melanchia. Am J Psychiatry. 1994;151:1735-1739
Roth A, Akyol S, Nelson JC, Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry. 1994;55:492-495
Rouillon F, Gorwood P, The use of lithium to augment antidepressant medication. J Clin Psychiatry. 1998;59(suppl 5):32-39
Rowe H, Carmichael R, Lemberger L, The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci. 1978;23:807-812
Rowland DL, Myers L, Culver A, Davidson JM, Bupropion and sexual function: a placebo-controlled prospective study on diabetic men with erectile dysfunction. J Clin Psychopharmacol. 1997;17:350-357
Rush AJ, Armitage R, Gillin JC, et al, Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry. 1998;44:3-14
Rush AJ, Kupfer DJ, Strategies and tactics in the treatment of depression. In: Gabbard GO, ed. Treatments of Psychiatric Disorders. 2nd ed. Washington, DC: American Psychiatric Press, Inc; 1996
Sackeim HA, Devanand DP, Nobler MS, Electroconvulsive therapy. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994:1123-1142
Safar KR, Klein DF, Gittleman-Klein R, Groof S, Imipramine side effects in children. Psychopharmacologia 1974;37:265-74
Saletu B, Frey R, Krupka M, Anderer P, Grünberger J, See WR, Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep. 1991;14:439-447
Sanders-Bush E, Mayer SE, 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists. In: Gilman AG, consulting ed; Hardman JG, Limbird LE, eds-in-chief; Molinoff PB, Ruddon RW, eds. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics. 9th ed. New York, NY:
Sautel M, Milligan G, Molecular manipulation of G-protein-coupled receptors: a new avenue into drug discovery. Curr Med Chem 2000;1 889-96
Schaechter M, Neidhardt FC, Introduction. In: Neidhardt FC, Ingraham JL, Low KB, et al. eds. Escherichia coli and Salonella typhimurium: Cellular and molecular biology, volume 1. Washington, DC: American Society for Microbiology; 1987: 1-2
Schatzberg AF, Haddad P, Kaplan EM, et al, Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry. 1997;58(suppl 7):23-27
Schenker S, Bergstrom RF, Wolen RL, Lemberger L, Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1988;44:353-359
Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI, N-demethylation of amitriptyline in vitro: role of cytochrome P450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther. 1995;275: 592-597
Schmidt W, Lang K, Life-threatening dysrhythmias in severe thioridazine poisoning treated with physotigmine and transient atrial pacing. Crit Care Med 1997;25:19250
Schroeder DH, Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44(Suppl 5):79-81
Schwartz JC, Arrang JM, Garbarg M, Traiffort E, Histamine. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994;397-406
Serafin, WE, Drugs used in the treatment of asthma. In: Hardman JG, Limbird LE, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:672-9
Series HG, Drug treatment of depression in medically ill patients. J Psychosom Res. 1992;36:1-16
Serres MH, Gopal S, Nahum LA, et al, A functional update of the Escherichia coli K-12 genome. Genome Biol 2001;2:RESEARCH0035
Settle EC Jr, Settle GP, A case of mania associated with fluoxetine. Am J Psychiatry. 1984;141:280-281
Shad MU, Carmichael CA, Preskorn S, Horst WD, Prevalence of polypharmacy in different clinical settings and its relation to drug-drug interactions. Presented at the annual American Psychiatric Association meeting, San Diego, CA, May 17-22, 1997
Shad MU, Carmichael CA, Preskorn SH, et al, The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. Clin Pharmacol Ther 1999;65:183 (abstract)
Shad MU, Preskorn SH, A drug-drug interaction in reverse: Possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. Journal of Clinical Psychopharmacology 19(5):471-472, 1999
Shad MU, Preskorn SH, A possible bupropion and imipramine interaction. J Clin Psychopharmacol. 1997;17:118-119. Letter
Shad MU, Preskorn SH, Antidepressants. In: Levy R, Thummel KE, Trager W, Hansten PD, Eichelbaum M, eds. Metabolic Drug Interactions - Drugs as Inhibitors of Metabolic Enzymes Treatment of CNS Diseases. Philadelphia, Pa: Lippincott, Williams & Wilkins. In press
Shader RI, Greenblatt DJ, von Moltke LL, Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol. 1994;14:375-376. Editorial
Shank RP, Vaught JL, Pelley KA, Setler PE, McComsey DF, Maryanoff BE, McN-5652: a highly potent inhibitor of serotonin uptake. J Pharm Exp Therap. 1988;247:1032-1038
Sharp T., McQuade R., Bramwell S., Hjorth S, Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo. Naunhyn Schmiedebergs Arch Pharmacol. 348(4):339-46;1993
Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ, The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology. 1996;126:50-54
Shaw CA, Sullivan JT, Kadlec KE, Kaplan HL, Naranjo CA, Sellers EM, Ethanol interactions with serotonin uptake selective and nonselective antidepressants: fluoxetine and amitriptyline. Human Psychopharmacol. 1989;4:113-120
Sheehan DJ, Hitchcock CA, Sibley CM, Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79
Shen DD, Madani S, Banfield C, Clement RP, H1-receptor antagonists. In: Levy RH, Thummel KE, Trager WF, Hansten P, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins; 2000:435-46
Silkey B, Preskorn S, Shah R, et al, Multiple medication use and cytochrome P-450-based drug interaction patterns in patients on antidepressants in a regional veterans affairs health care network. Clin Pharmacol Ther (abstract), in press
Sindrup S, Brøsen, Bjerring P, et al, Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clinical Pharmacology and Therapeutics 1991;49: 686-93
Sindrup SH, Brøsen K, Gram LF, Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: non-linearity and relation to the sparteine oxidation polymorphism. Clin Pharm Ther. 1992;51:288-295
Sindrup SH, Brøsen K, Gram LF, et al, The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992;51:278-287
Sindrup SH, Brøsen K, Hansen MG, Aaes-Jorgensen T, Overo KF, Gram LF, Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993;15:11-17
Sjoerdsma T, Palfregman A, History of serotonin. In: Peroutka S, Whitaker-Azmitia P, eds. Neuropharmacology of Serotonin. New York, NY: Annals of the New York Academy of Science; 1990;600:2-9
Skjelbo E, Brøsen K, Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 1992; 34:256-261
Skjelbo E, Brøsen K, Hallas J, Gram LF, The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharm Therap. 1991; 49:18-23
Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Rez J, Catalano M, Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychiatry 1998;3:508-11
Smith SJ, Cardiovascular toxicity of antihistamines. Otolaryngol Head Neck Surg. 1994;111:348-354
Sneddon JM, Blood platelets as a model for monoamine-containing neurons. Prog Neurobiol 1973;1:151-98
Solai LK, Mulsant BH, Pollock BG, et al, Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997;58:440-3
Sperber AD, Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety. 1991;6:460-462
Spielberg SP, N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm. 1996;24:509-519
Spiker DG, Hanin I, Perel JM, Cofsky JE, Rossi AJ, Sorisio D, Pharmacological treatment of delusional depressives. Psychopharmacol Bull 1982;18:184-6
Spiker DG, Perel JM, Hanin I, et al, The pharmacological treatment of delusional depression. Part II. J Clin Psychopharmacol 1986;6:339-42
Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F, Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit. 1993;15:247-250
Spina E, Birgersson C, von Bahr C, et al, Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharm Therap. 1984;36:677-682
Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP, Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15:243-246
Spitzer RL, Endicott J, Robbing E, Clinical criteria for psychiatric diagnosis and DSM-III. Am J Psychiatry 1975;132: 1187 92
Spitzer RL, Endicott J, Robbing E, Research diagnostic criteria. New York: Biometrics Research, New York Department of Mental Hygiene; 1974
Spitzer RL, Endicott J, Robbins E, Research diagnostic criteria. Arch Gen Psychiatry 1978;35:773 82
Sporer KA, The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995;13:94-104
Sproule B, Otton SV, Cheung SW, et al, CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997; 17:102-6
Sproule BA, Naranjo CA, Brenmer KE, et al, Selective serotonin reuptake inhibitors and CNS drug interactions: A critical review of the evidence. Clin Pharmacokinet 1997;33: 454-471
Stahl MM, Lindquist M, Pettersson M, et al, Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol. 1997;53: 163-169
Stahl SM, The human platelet. Arch Gen Psychiatry 1977;34:509-516
Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J, Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep. 1995;18:470-477
Stein G, Bernadt M, Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993;162:634-640
Steinbusch HWM; Björklund A, Hökfelt T, Kuhar MJ, eds, Handbook of Chemical Neuroanatomy. Amsterdam: Elsevier, 1984; Serotonin-immunoreactive neurons and their projections in the CNS. Classical transmitters and transmitter receptors in the CNS. Part II. p. 68-125
Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F, Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharm Therap. 1988;44:431-435
Sternbach H, Danger of MAOI therapy after fluoxetine withdrawal. Lancet. 1988;2:850-851. Letter
Sternbach H, The serotonin syndrome. Am J Psychiatry. 1991;148:705-713
Stevens JC, Wrighton SA, Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharm Exp Therap. 1993;266:964-971
Strand FL, Rose KJ, Zuccarelli LA, et al, Neuropeptide hormones as neurotrophic factors. Physiol Rev 1991;71:1017-37
Stuppaeck CH, Geretsegger C, Whitworth AB, et al, A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol. 1994;14:241-246
Sussman N, Anxiolytic antidepressant augmentation. J Clin Psychiatry. 1998;59(suppl 5):42-48
Swims MP, Potential terfenadine-fluoxetine interaction. Ann Pharmacotherapy. 1993;17:1404
Taff ML, Siegal FP, Geller SA, Outbreak of an acquired immunodeficiency syndrome associated with opportunistic infections and Kaposi’s sarcoma in male homosexuals: An epidemic with forensic implications. Am J Forensic Med Pathol 1982;3:259-64
Tallman JF, Dahl SG, New drug design in psychopharmacology: the impact of molecular biology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994:1861-1874
Tamargo J, Drug-induced torsades de pointes: From molecular biology to bedside. Jpn J Pharmacol 2000;83:1-19
Tanaka K, Masu M, Nakanishi S, Structure and functional expression of the cloned rat neurotensin receptor. Neuron 1990;4:847-54
Tasker TCG, Kaye CM, Zussman BD, Link CGG, Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand. 1989;80(suppl 350): 152-155
Taylor DP, Carter RB, Eison AS, et al, Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56(suppl 6):3-11
Tecott LH, Sun LM, Akana SF, et al, Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374:542-546
Teh LK, Ismail R, Yusoff R, et al, Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001;26:205-11
Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA, Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339:875-882
Thase ME, Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502-508
Thase ME, The undertreatment of patients with depression. Depressive Disorders: Index and Reviews. 1996;1:4, 16-17
Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG, Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997;58:16-21
Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ, Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry. 1992;53:5-11
Thase ME, Howland RH, Friedman ES, Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry. 1998;59(suppl 5):5-12, 13-15
Thase ME, Rush AJ, Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994: 1081-1097
Thase ME, Rush AJ, When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-29
The APA Task Force on Laboratory Tests in Psychiatry, The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry. 1987;144:1253-1262
Thomas DR, Nelson DR, Johnson AM, Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology. 1987;93: 193-200
Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M, Interaction between fluvoxamine and theophylline. Pharmaceutical J. 1992;1:137
Thummel KE, Wilkinson GR, In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430
Tielens JA, Vitamin C for paroxetine- and fluvoxamine-associated bleeding. Am J Psychiatry. 1997;154:883-884. Letter
Tork I, Anatomy of the serotonergic system. In: Peroutka S, Whitaker-Azmitia P, eds. Neuropharmacology of Serotonin. New York, NY: Annals of the New York Academy of Science; 1990;600:9-35
Torok-Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ, Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatography. 1992;579:99-106
Tremaine LM, Wilner KD, Henry EB, Ronfeld RA, Absence of a biologically meaningful effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet. In press
Tucker P, Adamson P, Miranda R Jr, et al, Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol. 1997;17:370-376
Turner SM, Jacob RG, Beidel DC, Griffin S, A second case of mania associated with fluoxetine. Am J Psychiatry. 1985;142: 274-275. Letter
U. S. General Accounting Office, GAO-01-286R Drugs withdrawn from market. January 19, 2001.
Van den Hooff P., Galvan M, Actions of 5-hydroxytryptamine and 5-HT1A receptor ligands on rat dorso-lateral septal neurons in vitro. Br J Pharmacol. 106(4):893-9;1992
van Harten J, Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993;24: 203-220
van Harten J, Stevens LA, Raghoebar M, Holland RL, Wesnes K, Cournot A, Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther. 1992;52:427-435
Van Tol HHM, Wu CM, Guan H-C, et al, Multiple dopamine D4 receptor variants in the human population. Nature 1992;358:149-52
Varhe A, Olkkola KT, Neuvonen PJ, Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther. 1994;56:601-607
Vaughan DA, Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988;145:1478
Vogel GW, Vogel F, McAbee RS, Thurmond AJ, Improvement of depression by REM sleep deprivation. New findings and a theory. Arch Gen Psychiatry. 1980;37:247-253
von Moltke LL, Greenblatt DJ, Cotreau-Bibbo M, Harmatz J, Shader R, Inhibitors of alprazolam metabolism in vitro: effect of serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol. 1994; 38:23-31
von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharm Exp Therap. 1994;268:1278-1283
von Moltke LL, Greenblatt DJ, Court MH, et al, Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharm. 1995;15:125-131
von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI, In vitro prediction of the terfenadine-keto-conazole pharmacokinetic interaction. J Clin Pharmacol. 1994;34:1222-1227
von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Narmatz JS, Shader RI, In vitro biotransformation of phenacetin to acetaminophen. Clin Pharm Therap. 1996;59:175
von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI, Cytochromes in psychopharmacology. J Clin Psychopharmacol. 1994;14:1-4. Editorial
von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI, Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet. 1995;29(suppl 1):33-44
Von Moltkte LL, Greenblatt DJ, Giancarlo GM, et al, Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;19:1102-9
Walczak DD, Apter JT, Halikas JA, et al, The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry. 1996;8:139-51
Waldinger MD, Hengeveld MW, Zwinderman AH, Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. Br J Urol. 1997;79:592-595
Waldinger MD, Hengeveld MW, Zwinderman AH, Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 1994:151:1377-1379
Walker PW, Cole JO, Gardner EA, et al, Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;54:459-465
Walley T, Pirmohamed M, Proudlove C, et al, Interaction of metoprolol and fluoxetine. Lancet 1993;341:967-8. PSYCHOPHARMACOLOGY Journal of Psychiatric Practice 52 January 2001
Warrington SJ, Clinical implications of the pharmacology of sertraline. Intl Clin Psychopharmacol. 1991;6(suppl 2): 11-21
Watkins PB, Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin N Am. 1992;21: 511-526
Waxman L, Darke PL, The herpesvirus proteases as targets for antiviral chemotherapy. Antivir Chem Chemother 2000;11:1-22
Weilburg JB, Rosenbaum JF, Meltzer-Brody S, Shushtari J, Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry. 1991;3:209-213.
Weissman MM, Affective disorders. In: Robins LN, Regier DA, eds. Psyhchiatric Disorders in America: The Epidemiological Catchment area Study. New York, NY: Free Press; 1991:53-80
Weissman MM, Klerman GL, Sex differences in the epidemiology of depression. Arch Gen Psychiatry. 1977;34:98-111
Weissman MM, Leaf PJ, Holzer CE III, Myers JK, Tischler GL, The epidemiology of depression. An update on sex differences in rats. J Affect Disord. 1984;7:179-188
Weissman MM, Wickramaratne P, Merikangas KR, et al, Onset of major depression in early adulthood. Increased familial loading and specificity. Arch Gen Psychiatry. 1984;41:1136-1143
Weller EB, Weller RA, Fristad MA, Preskorn SH, The dexamethasone suppression test in hospitalized prepubertal depressed children. Am J Psychiatry. 1984;141:290-291
Wells KB, Stewart A, Hays RD, et al, The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914-919
Wender PH, Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 1998;59(suppl 7):76-79
Wernicke JF, The side effect profile and safety of fluoxetine. J Clin Psychiatry. 1985;46:59-67
Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M, Low dose fluoxetine therapy for depression. Psychopharmacol Bull. 1988;24:183-188
Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL, Fixed dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23:164-168
Wheatley DP, van Moffaert M, Timmerman L, Kremer CM, Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry. 1998;59:306-312
Wilde MI, Plosker GL, Benfield P, Fluvoxamine: an updated review of its pharmacology and therapeutic use in depressive illness. Drugs. 1993;46:895-924
Williams R, Commentary on an integrated approach to the evaluation of clinically significant drug-drug interactions. American Society for Clinical Pharmacology and Therapeutics (ASCPT) March 15-17, 2000: (Abstract)
Wilner KD, Apseloff G, Gerber N, Henry EB, Lazar JD, Tremaine LM, Absence of a biologically meaningful effect of sertraline on the pharmacodynamics and protein binding of warfarin. Clin Pharmacokinet. In press
Wilner KD, Preskorn SH, The pharmacokinetics of sertraline. Clin Pharmacokinet. In press
Winokur G, Unipolar depression: is it divisible into autonomous subtypes?. Arch Gen Psychiatry. 1979;36:47-52
Winokur G, Tsuang MT, Crowe RR, The Iowa 500: affective disorder in relatives of manic and depressed patients. Am J Psychiatry. 1982;139:209-212
Wittenberger T, Schaller HC, Hellebrand S, An expressed sequence tag (EST) data mining strategy succeeds the discovery of new G-protein coupled receptors. J Mol Biol 2001;307:799-813
Wolf ME, Bukowski ED, Conran J, et al, Polypharmacy: a problem of the decade of the nineties. American Psychiatric Association, 148th annual meeting; May 20-25, 1995; Miami, Fla. Abstract
Wolkenstein P, Cremniter D, Roujeau JC, Toxic epidermal necrolysis after paroxetine treatment. Eur Psychiatry. 1995;10:162. Letter
Wolkowitz OW, Rational polypharmacy in schizophrenia. Ann Clin Psychiatry 1993;6:79-90
Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW, Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology. 1993;8:337-344
Wong DT, Fuller RW, Robertson DW, Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm Nord. 1990;2:171-180
Wood K, Swade C, Abou-Saleh M, Milln P, Coppen A, Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders. Br J Clin Pharmacol. 1983;15(suppl 3):365S-368S
Woods DJ, Coulter DM, Pillans P, Interaction of phenytoin and fluoxetine. N Z Med J. 1994;107:19
Wrighton SA, Thummel KE, CYP3A. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins; 2000: 115-34
Wurm RM, Dunn JA, Silver I, Patel DK, In vitro metabolism of bupropion by human liver microsomes and cDNA expressed human cytochrome P450s. Proceedings of the International Society for the Study of Xenobiotics 1996;10:371
Yamamoto Y, Aiba H, Baba T, et al, Construction of a contiguous 874kb sequence of the Escherichia coli-K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res 1997;4:91-113
Yasui N, Otani K, Kaneko S, et al, A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59:514-9
Yasumori T, Nagata K, Yang SK, et al, Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics. 1993;3:291-301
Ye Y, Jackson K, O’Donnell JM, Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem 2000;74:1257-62
Yocca FD, Hyslop DK, Taylor DP, Nefazodone: a potential broad spectrum antidepressant. Trans Am Soc Neurochem. 1985;16:115
Yokota Y, Sasai Y, Tanaka K, et al, Molecular characterization of a functional cDNA for rat substance P receptor. J Biol Chem 1989;264:17649-52
Young C, A case of neuroleptic malignant syndrome and serotonin disturbance (letter to the editor). J Clin Psychopharmacol 1997;17(1):65-6
Yun CH, Okerholm RA, Guengerich FP, Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metabolism and Disposition Diol Fate Chem. 1993;21:403-409
Zajecka J, Fawcett J, Schaff M, et al, The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991;52:66-68
Zajecka J, Tracy KA, Mitchell S, Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997;58:291-297
Zakowski P, Fligiel S, Berlin GW, et al, Disseminated Mycobacterium avium intracellulare infection in homosexual men dying of acquired immunodeficiency. JAMA 1982;248: 2980-2
Zanger U Eichelmaum M, 2136. In: Levy R, Thummel K, Trager W, et al. (eds). Metabolic drug interactions. Philadelphia: Upincott Williams & Wilkins; 2000:87-94
Zimmermann M, Duruz H, Guinand O, et al, Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J. 1992;13:1002-1003
Zussman BD, Davie CC, Fowles SE, et al, Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol. 1995;39:550-551
Zygmont M, Prigerson HG, Houck PR, et al, A post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. J Clin Psychiatry. 1998;59:241-245
Treatment of panic disorder. NIH Consensus Statement Online. 1991; September 25-27; 9(2):1-24
www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed.
Zoloft (sertraline hydrochloride). In: Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc; 1999:2443-2448
Zyban (bupropion hydrochloride). In: Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc; 1999:1277-1282
Weissman MM, Affective disorders. In: Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiological Catchment Area Study. New York, NY: Free Press; 1991:53-80
FDA website. Accessed July 9, 2002
Segel I., Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-state Enzyme Systems. New York, NY: J Wiley and Sons; 1975:105
Preskorn S, Foreward. Journal of Clinical Pharmacokinetics 32(suppl 1):0, 1997
Tremaine L, Wilner K, Preskorn S, A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Journal of Clinical Pharmacokinetics 32(suppl 1):31-36, 1997
Gardner M, Baris B, Wilner K, Preskorn S, Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Journal of Clinical Pharmacokinetics 32(suppl 1):43-49, 1997
Preskorn SH, Alderman J, Greenblatt DJ, Horst WD, Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacology Bulletin 33(4):659-665, 1997
Preskorn SH, Pharmacotherapeutic profile of venlafaxine. Euoropean Psychiatry 12(S4):285-294, 1997
Bhatara VS, Magnus RD, Paul KL, Preskorn SH, Serotonin syndrome induced by venlafaxine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. The Annals of Pharmacotherapy 32(4):432-436, 1998
Preskorn SH, Catterson M, Antidepressants and the elderly: Focus on newer agents. International Journal of Geriatric Psychopharmacology 1:66-77, 1998
Horst WD, Preskorn SH, Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion. Journal of Affective Disorders 51:237-254, 1998
Horst WD, Preskorn SH, The pharmacology and mode of action of venlafaxine. Review of Contemporary Pharmacotherapy 9:293-302, 1998
Catterson M, Martin RL, Preskorn SH, Psychopharmacologic drug-drug interactions in the elderly. Clinical Geriatrics 7(9):46-54, 1999
Harvey AT, Rudolph RL, Preskorn SH, Evidence of the dual mechanisms of action of venlafaxine in healthy male volunteers. Archives of General Psychiatry 57(5)503-509, 2000
Shad MU, Marsh C, Preskorn SH, The economic consequences of a drug-drug interaction. Journal of Clinical Psychopharmacology 21(1):119-20, 2001
Findling RL, Marcus RN, D’Amico F, Reed MD, Preskorn SH, Magnus RD, Marathe P, Nefazodone pharmacokinetics in depressed children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 39(8):1008-1016, 2000
Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M, Efficacy and safety in mirtazapine in depressed patients after SSRI treatment failure: An open-label trial. Journal of Clinical Psychiatry 62(6):413-420, 2001
Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild A, Snavely D, Ghosh K, Ball W, Reines S, and SPA Depression Study Group, Demonstration of the efficacy and safety of a novel substance P(NK1) receptor antagonist (SPA) in major depression. Clinical Neuropharmacology Submitted Sep 15, 2002
Werder SF, Preskorn SH, Managing polypharmacy walking the fine line. Current Psychiatry Submitted Jan 1, 2002
Preskorn SH, Pandora’s Box: Pregnancy and antidepressants. Journal of Practical Psychiatry and Behavioral Health 3(6):363-365, 1997
Preskorn SH, Silkey B, Jones T, Physician perceptions of drug-drug interactions and how to avoid them. Journal of Psychiatric Practice 8(2):112-115, March 2002
Preskorn SH, Baker B, The overlap of DSM-IV syndromes: Potential implications for the practice of polypsychopharmacology, psychiatric drug development, and the human genome project. Journal of Psychiatric Practice 8(3):170-177, May 2002
Preskorn SH, Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management. Journal of Psychiatric Practice 9(1), January 2003
Preskorn SH, Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). Journal of Psychiatric Practice 9(2), March 2003
Janicak PG, Philip G, Davis JM, Preskorn SH, Ayd, Jr. FJ, Principals and Practice of Psychopharmacotherapy 2nd ed.. Williams & Wilkins, Baltimore, 1997
Janicak PG, Philip G, Davis JM, Preskorn SH, Ayd,Jr. FJ, Principals and Practice of Psychopharmacotherapy. 3rd ed.. Lippincott Williams & Wilkins, Philadelphia, 2001
Preskorn SH, Catterson ML, Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives. (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Stanga C, Preskorn SH, Use of the laboratory in psychiatry. In: Current Psychiatric Therapy II (ed) Dunner DL., W.B. Saunders Company, Phildelphia, Chapter 7, pp 59-74, 1997
Horst WD, Preskorn SH, Intracellular and intercellular principles of the pharmacotherapy of patients with neuropsychiatric disorders. In: American Psychiatric Press Textbook of Neuropsychiatry, 3rd Edition. American Psychiatric Press Inc., Washington DC. Chapter 3, pp 55-75, 1997
Catterson ML, Preskorn SH, Martin RL, Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatric Clinics of North America. 20(1):205-218, 1997
Preskorn SH, Catterson ML, Pharmacokinetics of Antidepressants. In: Handbook of Experimental Pharmacology. Antidepressants : Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Methodological Issues in Psychopharmacogenetics. In: Pharmacogenetics of Psychotropic Drugs, (ed) Bernard Lerer, Cambridge University Press, New York, 2002
Preskorn SH, Mood Disorders. In: Conn’s Current Therapy 2003 edition, (eds.) Robert E. Rakel, Edward T. Bope, Saunders (Elsevier Science), Philadelphia, 2003
Preskorn SH, Khan AY, Pharmacokinetic principles and drug interactions. In: Handbook of Medical Psychiatry, (eds) Soares/Gershon, Marcel Dekker, Inc., New York, in press
Preskorn SH, Catterson ML, General principles of pharmacokinetics. In: Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Burke MJ, Therapeutic drug monitoring of antidepressants. In: Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Ross R, Overview of currently available antidepressants. In: Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Ross R, Stanga CY, Selective serotonin reuptake inhibitors. In: Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Ross R, Stanga CY, Other antidepressants. In: Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Bober JF, Children and adolescents. In: Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Role of Pharmacogenetics/pharmacogenomics in the development of new antidepressants. In: Handbook of Experimental Pharmacology. Antidepressants: Current and Future Perspectives, (eds) Preskorn SH, Feighner JP, Stanga CY, Ross R, Springer-Verlag, Heidelberg, Germany, in press
Preskorn SH, Central adrenergic regulation of cerebromicrocirculation: Relevance to psychiatry. Neuropharmacology in press. (In Press?)
Miceli J, Preskorn SH, Wilner K, Folger C, Tensfeld T, Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. Clinical Pharmacological Therapeutics 65:171, 1999
Preskorn, SH, Pharmacogenetic research in clinical psychopharmacology: Design and methodological challenges. International Journal of Neuropsychopharmacology 3( Suppl 1):5, 2000
Silkey B, Preskorn SH, Golbeck A, Horst W, Addressing health risks/costs associated with multiple medication use in a veterans integrated service network. Poster presentation at Drug Information Association 2nd Annual Workshop on "Pharmaceutical Outcomes Research," Seattle, Washington, May 11-12, 2000
Silkey B, Preskorn SH, Golbeck A, Interindividual variability in steady-state plasma levels of bupropion and its major metabolites. Poster presentation at 40th Annual NCDEU, Boca Raton, Florida, May 30-June 2, 2000
Reyes LF, Preskorn SH, Khan A, Kumar S, Cullen E, Pratt R, Pharmacokinetics (PK) of donepezil and risperidone in males with schizophrenia. Clinical Pharmacolology and Therapeutics 69:44, 2001
Harvey A, Preskorn SH, The influence of extended-release venlafaxine on QT intervals of normal volunteers. Poster presentation at NCDEU 41st Annual Meeting, Phoenix, Arizona, May 28-31, 2001
Khan A, Friesen S, Klick-Davis A, Preskorn SH, How inclusion and exclusion criteria affect the ability to randomize patients in a clinical trial for schizophrenia/schizo-affective disorder. Poster presentation at NCDEU 41st Annual Meeting, Phoenix, Arizona, May 28- 31, 2001
Preskorn SH, Baker B, The clinical pharmacology of antidepressants: Relevance to the optimum management of the depressed patient. Poster presentation at AANP 2001
Harvey A, Preskorn SH, The influence of intramuscular (IM) haloperidol (HAL) or lorazepam (LOR) on QT intervals of volunteers with schizophrenia. Clinical Pharmacology and Therapeutics 71(2), P53, 2002
Wesnes KA, Preskorn SH, Friesen S, Edgar C, Mikkelson BO, NS 2330 enhances cognitive function in normal volunteers and volunteers with possible Alzheimer’s disease (AD). Clinical Pharmacology and Therapeutics 71(2), P17, 2002
Shad MU, Preskorn SH, Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome. Journal of Clinical Psychopharmacology 18(4): 346-347, 1998
Shad MU, Preskorn SH, Izgur Z, Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder. Journal of Clinical Psychiatry 20(3):390-391, 2000
Khan A, Shad MU, Preskorn SH, Lack of sertraline efficacy probably due to an interaction with carbamazepine. Journal of Clinical Psychiatry 61(7):526-527, 2000
Preskorn SH, Greenblatt DJ, Harvey AT, Lack of effect of sertraline on the pharmacokinetics of alprazolam. Journal of Clinical Psychopharmacology 20(5):585-586, 2000
Khan AY, Preskorn, SH, Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. Journal of Clinical Psychiatry 62(5), 375-376
Preskorn SH, Pharmacokinetic interactivity of psychotropic drugs. Part I. Currents in Affective Illness. (eds) Rosenblatt JE, Rosenblatt NC, 17:4,4 April, 1998
Preskorn SH, Pharmacokinetic interactivity of psychotropic drugs-conclusion. Currents in Affective Illness. (eds) Rosenblatt JE, Rosenblatt NC, 17:5,5 May, 1998
Preskorn SH, New paradigms for drug development. Part I. Currents in Affective Illness. (eds) Rosenblatt JE, Rosenblatt NC, 20:3; 5-11 March, 2001
Preskorn SH, New paradigms for drug development. Part II. Currents in Affective Illness. (eds) Rosenblatt JE, Rosenblatt NC, 20:4; 5-9 April, 2001
Burris KD, Molski TF, Xu C, et al, Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302: 381-9
Preskorn SH, Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). Journal of Psychiatric Practice 2003;9:228-36
Yokoi F, Grunder G, Biziere K, et al, Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248-59
Preskorn SH, Relating clinical trials to psychiatric practice: Part I: the case of a 13-year old on aripiprazole and fluoxetine. Journal of Psychiatric Practice 9(4), July 2003
Preskorn SH, Relating Clinical Trials To Psychiatric Practice: Part II:The Gap Between the Usual Patient in Registration Trials and in Practice. Journal of Psychiatric Practice 9(6), November 2003
Offord SJ, Wong DF, Nyberg S., The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. J Clin Pharmacol 1999;Aug (suppl):17S-24S
Kuhlmann J, Muck W., Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 2001;24:715-25
Evans WE, Johnson JA., Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9-39
Herrmann SM, Nicaud V, Tiret L, et al., Polymorphisms of the beta2-adrenoceptor (ADRB2) gene and essential hypertension: The ECTIM and PEGASE studies. J Hypertens 2002;20: 229-35
Gingrich JA., Mutational analysis of the serotonergic system: Recent findings using knockout mice. Curr Drug Target CNS Neurol Disord 2002;1:449-65
Siest G, Ferrari L, Accaoui MJ, et al., Pharmacogenomics of drugs affecting the cardiovascular system. Clin Chem Lab Med. 2003;41:590-9
Brunner HG, Nelen M, Breakefield XO, et al., Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993;262:578-80
Schuback DE, Mulligan EL, Sims KB, et al., Screen for MAOI mutations in target human groups. Am J Med Genet 1999;88: 25-8
Shih JC, Chen K, Ridd MJ., Monoamine oxidase: From genes to behavior. Annu Rev Neurosci 1999;22:197-217
Shih JC, Thompson RF., Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 1999;65:593-8
Janicak P, Davis JM, Preskorn SH, et al., Treatment with antidepressants. In: Principles and practice of psychopharmacotherapy, 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2001: 215-325
Chaikin P, Rhodes GR, Bruno R, et al., Pharmacokinetics/pharmacodynamics in drug development: An industrial perspective. J Clin Pharmacol 2000;40:1428-38
Caldwell GW, Ritchie DM, Masucci JA, et al., The new pre-preclinical paradigm: Compound optimization in early and late phase drug discovery. Curr Top Med Chem 2001;1:353-66
DiMasi JA., The value of improving the productivity of the drug development process: Faster times and better decisions. Pharmacoeconomics. 2002;20 (Suppl 3):1--10
ICH Guideline for Good Clinical Practice Title 21: Food and Drugs. Code of Federal Regulations, April 1, 2003
Rodrigues AD, Rushmore TH., Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr Drug Metab 2002;3:289-309
Bu HZ, Magis L, Knuth K, et al., High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 2001;15:741-8
Masimirembwa CM, Thompson R, Andersson TB., In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen 2001;4:245-63
Bonnabry P, Sievering J, Leemann T, et al., Quantitative drug interactions prediction system (Q-DIPS): A dynamic computerbased method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 2001;40:631-40
Kariv I, Fereshteh MP, Oldenburg KR., Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. J Biomol Screen 2001;6:91-9
Gao F, Johnson DL, Ekins S, et al., Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen 2002;7:373-82
Bjornsson TD, Callaghan JT, Einolf HJ, et al., and Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups, The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J Clin Pharmacol 2003;43:443--69
Kremers P., Can drug-drug interactions be predicted from in vitro studies?. Scientific World Journal 2002;2:751-66
Kaufman DW, Kelly JP, Rosenberg L, et al., Recent patterns of medication use in the ambulatory adult population of the United States: The Slone Survey. JAMA 2002;287:337-44
Redfern WS, Wakefield ID, Prior H, et al., Safety pharmacology -- A progressive approach. Fundam Clin Pharmacol 2002;16: 161-73
Riley RJ, Parker AJ, Trigg S, et al., Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm Res 2001;18:652-5
Madsen H, Enggaard TP, Hansen LL, et al., Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001;69:41-7
Shad MU, Preskorn SH, Antidepressants. In: Levy RH, Thummel KE, Trager WF, et al., eds. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins; 2000:563-77
Weber WW., Populations and genetic polymorphisms. Mol Diagn 1999;4:299-307
Kohler D, Hartter S, Fuchs K, et al, CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 1997;7:453-61
Bertilsson L, Dahl ML, Dalen P, et al., Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22
Lovlie R, Daly AK, Molven A, et al., Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996;392:30-4
Laine K, Tybring G, Hartter S, et al., Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001;70:327-35
Patel, V., Chisholm, D., Rabe-Hesketh, S., Dias-Saxena, F., Andrew, G., and Mann, A., Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial. Lancet 2003 Jan4;361[9351]:33-39
Ranga, K. and Krishnan, R., Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry 2002;63 Suppl 11:25-29
Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., and Tomenson, B., The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003 Feb;124[2]:303-317
Braconnier, A., Le Coent, R., and Cohen, D., Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003 Jan;42[1]:22-29
Harmer, C. J., Bhagwagar, Z., Perrett, D. I., Vollm, B. A., Cowen, P. J., and Goodwin, G. M., Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 2003 Jan;28[1]:148-152
Chial, H. J., Camilleri, M., Burton, D., Thomforde, G., Olden, K. W., and Stephens, D., Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003 Jan;284[1]:G130-G137
Stein, D. J., Versiani, M., Hair, T., and Kumar, R., Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002 Dec;59[12]:1111-1118
Katon, W. J., Roy-Byrne, P., Russo, J., and Cowley, D., Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psychiatry 2002 Dec;59[12]:1098-1104
Halbreich, U., Bergeron, R., Yonkers, K. A., Freeman, E., Stout, A. L., and Cohen, L., Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002 Dec;100[6]:1219-1229
Atmaca, M., Kuloglu, M., Tezcan, E., and Unal, A., Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol 2002 Dec;17[8]:401-405
Treating depression after a heart attack. Harv Heart Lett 2002 Nov;13[3]:1
Rinne, T., van den, Brink W., Wouters, L., and van Dyck, R., SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002 Dec;159[12]:2048-2054
Liebowitz, M. R., Turner, S. M., Piacentini, J., Beidel, D. C., Clarvit, S. R., Davies, S. O., Graae, F., Jaffer, M., Lin, S. H., Sallee, F. R., Schmidt, A. B., and Simpson, H. B., Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002 Dec;41[12]:1431-1438
Arnold, L. M., McElroy, S. L., Hudson, J. I., Welge, J. A., Bennett, A. J., and Keck, P. E., A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002 Nov;63[11]:1028-1033
Hunter, M. S., Ussher, J. M., Browne, S. J., Cariss, M., Jelley, R., and Katz, M., A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002 Sep;23[3]:193-199
Piasecki, M. P., Steinagel, G. M., Thienhaus, O. J., and Kohlenberg, B. S., An exploratory study: the use of paroxetine for methamphetamine craving. J Psychoactive Drugs 2002 Jul;34[3]:301-304
Salloway, S., Correia, S., Boyle, P., Malloy, P., Schneider, L., Lavretsky, H., Sackheim, H., Roose, S., and Krishnan, K. R., MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression. J Neurol Sci 2002 Nov15;203-204:227-233
Roca, C. A., Schmidt, P. J., Smith, M. J., Danaceau, M. A., Murphy, D. L., and Rubinow, D. R., Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry 2002 Nov;159[11]:1876-1881
Netter, P., Toll, C., Lujic, C., Reuter, M., and Hennig, J., Addictive and nonaddictive smoking as related to responsivity to neurotransmitter systems. Behav Pharmacol 2002 Sep;13[5-6]:441-449
Emslie, G. J., Heiligenstein, J. H., Wagner, K. D., Hoog, S. L., Ernest, D. E., Brown, E., Nilsson, M., and Jacobson, J. G., Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002 Oct;41[10]:1205-1215
Turkington, D., Grant, J. B., Ferrier, I. N., Rao, N. S., Linsley, K. R., and Young, A. H., A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. J Clin Psychiatry 2002 Sep;63[9]:778-781
Kampman, M., Keijsers, G. P., Hoogduin, C. A., and Hendriks, G. J., A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry 2002 Sep;63[9]:772-777
Stein, M. B., Kline, N. A., and Matloff, J. L., Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002 Oct;159[10]:1777-1779
Covey, L. S., Glassman, A. H., Stetner, F., Rivelli, S., and Stage, K., A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry 2002 Oct;159[10]:1731-1737
Gilmor, M. L., Owens, M. J., and Nemeroff, C. B., Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 2002 Oct;159[10]:1702-1710
Martenyi, F., Brown, E. B., Zhang, H., Koke, S. C., and Prakash, A., Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 2002 Oct;181:315-320
Solai, L. K., Pollock, B. G., Mulsant, B. H., Frye, R. F., Miller, M. D., Sweet, R. A., Kirshner, M., Sorisio, D., Begley, A., and Reynolds, C. F., III., Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 2002 Oct;22[5]:481-486
Perlis, R. H., Nierenberg, A. A., Alpert, J. E., Pava, J., Matthews, J. D., Buchin, J., Sickinger, A. H., and Fava, M., Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol 2002 Oct;22[5]:474-480
Koke, S. C., Brown, E. B., and Miner, C. M., Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am J Obstet Gynecol 2002 Sep;187[3]:551-555
Takata, T. S., Wasmund, S. L., Smith, M. L., Li, J. M., Joglar, J. A., Banks, K., Kowal, R. C., Page, R. L., and Hamdan, M. H., Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers. Circulation 2002Sep17;106[12]:1500-1504
Szadoczky, E. and Furedi, J., [Efficacy and acceptability of tianeptine and sertraline in the acute treatment phase of depression]. Encephale 2002 Jul;28[4]:343-349
Cohen, L. S., Miner, C., Brown, E. W., Freeman, E., Halbreich, U., Sundell, K., and McCray, S., Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002 Sep;100[3]:435-444
Petersen, T., Hughes, M., Papakostas, G. I., Kant, A., Fava, M., Rosenbaum, J. F., and Nierenberg, A. A., Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom 2002 Sep;71[5]:269-274
Dannon, P. N., Iancu, I., and Grunhaus, L., Psychoeducation in panic disorder patients: effect of a self-information booklet in a randomized, masked-rater study. Depress Anxiety 2002;16[2]:71-76
Hunter, M. S., Ussher, J. M., Cariss, M., Browne, S., Jelley, R., and Katz, M., Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. J Psychosom Res 2002 Sep;53[3]:811-817
Schatzberg, A. F., Kremer, C., Rodrigues, H. E., and Murphy, G. M., Jr., Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002 Sep;10[5]:541-550
Ladabaum, U. and Glidden, D., Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. Neurogastroenterol Motil 2002 Aug;14[4]:395-402
Fassino, S., Leombruni, P., Daga, G., Brustolin, A., Migliaretti, G., Cavallo, F., and Rovera, G., Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol 2002 Oct;12[5]:453-459
Dean, A. J., Bell, J., Mascord, D. J., Parker, G., and Christie, M. J., A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord 2002 Oct;72[1]:85-90
Farren, C. K. and O’Malley, S., A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence. Am J Addict 2002;11[3]:228-234
Bhagwagar, Z., Hafizi, S., and Cowen, P. J., Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology (Berl) 2002 Aug;163[1]:118-120
Harmer, C. J., Bhagwagar, Z., Cowen, P. J., and Goodwin, G. M., Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology (Berl) 2002 Aug;163[1]:106-110
Bech, P., Tanghoj, P., Andersen, H. F., and Overo, K., Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl) 2002 Aug;163[1]:20-25
Levkovitz, Y., Caftori, R., Avital, A., and Richter-Levin, G., The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res Bull 2002Aug15;58[4]:345-350
Niaura, R., Spring, B., Borrelli, B., Hedeker, D., Goldstein, M. G., Keuthen, N., DePue, J., Kristeller, J., Ockene, J., Prochazka, A., Chiles, J. A., and Abrams, D. B., Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 2002 Aug;70[4]:887-896
van den Brink, R. H., van Melle, J. P., Honig, A., Schene, A. H., Crijns, H. J., Lambert, F. P., and Ormel, J., Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). Am Heart J 2002 Aug;144[2]:219-225
Loo, H., Hale, A., and D’haenen, H., Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002 Sep;17[5]:239-247
Andreoli, V., Caillard, V., Deo, R. S., Rybakowski, J. K., and Versiani, M., Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002 Aug;22[4]:393-399
Fava, M., Alpert, J., Nierenberg, A., Lagomasino, I., Sonawalla, S., Tedlow, J., Worthington, J., Baer, L., and Rosenbaum, J. F., Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002 Aug;22[4]:379-387
Glassman, A. H., O’Connor, C. M., Califf, R. M., Swedberg, K., Schwartz, P., Bigger, J. T., Jr., Krishnan, K. R., van Zyl, L. T., Swenson, J. R., Finkel, M. S., Landau, C., Shapiro, P. A., Pepine, C. J., Mardekian, J., Harrison, W. M., Barton, D., an, Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002 Aug14;288[6]:701-709
Agosti, V. and McGrath, P. J., Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression. J Affect Disord 2002 Sep;71[1-3]:113-120
Krymchantowski, A. V., Silva, M. T., Barbosa, J. S., and Alves, L. A., Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002 Jun;42[6]:510-514
Kocsis, J. H., Schatzberg, A., Rush, A. J., Klein, D. N., Howland, R., Gniwesch, L., Davis, S. M., and Harrison, W., Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry 2002 Aug;59[8]:723-728
Golden, R. N., Nemeroff, C. B., McSorley, P., Pitts, C. D., and Dube, E. M., Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002 Jul;63[7]:577-584
Smith, W. T., Londborg, P. D., Glaudin, V., and Painter, J. R., Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?. J Affect Disord 2002 Aug;70[3]:251-259
Singh, N. N. and Misra, S., Sertraline in chronic tension-type headache. J Assoc Physicians India 2002 Jul;50:873-878
Lanctot, K. L., Herrmann, N., van Reekum, R., Eryavec, G., and Naranjo, C. A., Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer’s disease. Int J Geriatr Psychiatry 2002 Jun;17[6]:531-541
Eriksson, M., Berggren, U., Fahlke, C., Hard, E., and Balldin, J., Mental well-being in subjects with long-term excessive alcohol consumption: an experimental study. Alcohol 2002 Jun;27[2]:99-105
Davidson, J. R., Landerman, L. R., Farfel, G. M., and Clary, C. M., Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol Med 2002 May;32[4]:661-670
Fava, M., Schmidt, M. E., Zhang, S., Gonzales, J., Raute, N. J., and Judge, R., Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment. Psychother Psychosom 2002 Jul;71[4]:195-199
Schmidt, M. E., Fava, M., Zhang, S., Gonzales, J., Raute, N. J., and Judge, R., Treatment approaches to major depressive disorder relapse. Part 1: dose increase. Psychother Psychosom 2002 Jul;71[4]:190-194
Klysner, R., Bent-Hansen, J., Hansen, H. L., Lunde, M., Pleidrup, E., Poulsen, D. L., Andersen, M., and Petersen, H. E., Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002 Jul;181:29-35
Vieta, E., Martinez-Aran, A., Goikolea, J. M., Torrent, C., Colom, F., Benabarre, A., and Reinares, M., A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002 Jun;63[6]:508-512
Kim, S. W., Grant, J. E., Adson, D. E., Shin, Y. C., and Zaninelli, R., A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002 Jun;63[6]:501-507
Roberts, R. L., Joyce, P. R., Mulder, R. T., Begg, E. J., and Kennedy, M. A., A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypoee comparison treatmentstension in patients treated for major depression. Pharmacogenomics J 2002;2[3]:191-196
Browne, G., Steiner, M., Roberts, J., Gafni, A., Byrne, C., Dunn, E., Bell, B., Mills, M., Chalklin, L., Wallik, D., and Kraemer, J., Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 2002 Apr;68[2-3]:317-330
Brunswick, D. J., Amsterdam, J. D., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., and Beasley, C. M., Jr., Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment. J Affect Disord 2002 Apr;68[2-3]:243-249
Cook, I. A., Leuchter, A. F., Morgan, M., Witte, E., Stubbeman, W. F., Abrams, M., Rosenberg, S., and Uijtdehaage, S. H., Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002 Jul;27[1]:120-131
Loubinoux, I., Pariente, J., Rascol, O., Celsis, P., and Chollet, F., Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. Neuropsychologia 2002;40[11]:1815-1821
Joyce, P. R., Mulder, R. T., Luty, S. E., Sullivan, P. F., McKenzie, J. M., Abbott, R. M., and Stevens, I. F., Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002 Jun;36[3]:384-391
van Gurp, G., Meterissian, G. B., Haiek, L. N., McCusker, J., and Bellavance, F., St John’s wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 2002 May;48:905-912
Blanco, C., Petkova, E., Ibanez, A., and Saiz-Ruiz, J., A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002 Mar;14[1]:9-15
Kwasucki, J., Stepien, A., Maksymiuk, G., and Olbrych-Karpinska, B., [Evaluation of analgesic action of fluvoxamine compared with efficacy of imipramine and tramadol for treatment of sciatica--open trial]. Wiad Lek 2002;55[1-2]:42-50
Hicks, J. A., Argyropoulos, S. V., Rich, A. S., Nash, J. R., Bell, C. J., Edwards, C., Nutt, D. J., and Wilson, S. J., Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002 Jun;180:528-535
Poyurovsky, M., Pashinian, A., Gil-Ad, I., Maayan, R., Schneidman, M., Fuchs, C., and Weizman, A., Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002 Jun;159[6]:1058-1060
Tse, W. S. and Bond, A. J., Serotonergic intervention affects both social dominance and affiliative behaviour. Psychopharmacology (Berl) 2002 May;161[3]:324-330
Brenner, R., Madhusoodanan, S., and Pawlowska, M., Efficacy of continuation treatment with hypericum perforatum in depression. J Clin Psychiatry 2002 May;63[5]:455
Cassano, G. B., Puca, F., Scapicchio, P. L., and Trabucchi, M., Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002 May;63[5]:396-402
Narushima, K., Kosier, J. T., and Robinson, R. G., Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis 2002 May;190[5]:296-303
Behnke, K., Jensen, G. S., Graubaum, H. J., and Gruenwald, J., Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 2002 Jan;19[1]:43-52
Bogetto, F., Albert, U., and Maina, G., Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 2002 Jun;12[3]:181-186
Fernandes, L. C., Kilicarslan, T., Kaplan, H. L., Tyndale, R. F., Sellers, E. M., and Romach, M. K., Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J Clin Psychopharmacol 2002 Jun;22[3]:326-329
Kobak, K. A., Greist, J. H., Jefferson, J. W., and Katzelnick, D. J., Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002 Jun;22[3]:257-262
Schmaling, K. B., Dimidjian, S., Katon, W., and Sullivan, M., Response styles among patients with minor depression and dysthymia in primary care. J Abnorm Psychol 2002 May;111[2]:350-356
Burrows, A. B., Salzman, C., Satlin, A., Noble, K., Pollock, B. G., and Gersh, T., A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depress Anxiety 2002;15[3]:102-110
Normann, C., Hummel, B., Scharer, L. O., Horn, M., Grunze, H., and Walden, J., Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 2002 Apr;63[4]:337-344
Burke, W. J., Gergel, I., and Bose, A., Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002 Apr;63[4]:331-336
Kutcher, S., Leblanc, J., Maclaren, C., and Hadrava, V., A randomized trial of a specific adherence enhancement program in sertraline-treated adults with major depressive disorder in a primary care setting. Prog Neuropsychopharmacol Biol Psychiatry 2002 Apr;26[3]:591-596
Tranter, R., Healy, H., Cattell, D., and Healy, D., Functional effects of agents differentially selective to noradrenergic or serotonergic systems. Psychol Med 2002 Apr;32[3]:517-524
Mayberg, H. S., Silva, J. A., Brannan, S. K., Tekell, J. L., Mahurin, R. K., McGinnis, S., and Jerabek, P. A., The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002 May;159[5]:728-737
Furmark, T., Tillfors, M., Marteinsdottir, I., Fischer, H., Pissiota, A., Langstrom, B., and Fredrikson, M., Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 2002 May;59[5]:425-433
Licht, R. W. and Qvitzau, S., Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002 May;161[2]:143-151
Wade, A., Michael, Lemming O., and Bang, Hedegaard K., Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002 May;17[3]:95-102
Miner, C., Brown, E., McCray, S., Gonzales, J., and Wohlreich, M., Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002 Mar;24[3]:417-433
Bell, C., Forshall, S., Adrover, M., Nash, J., Hood, S., Argyropoulos, S., Rich, A., and Nutt, D. J., Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 2002 Mar;16[1]:5-14
Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA 2002Apr10;287[14]:1807-1814
Capuron, L., Gumnick, J. F., Musselman, D. L., Lawson, D. H., Reemsnyder, A., Nemeroff, C. B., and Miller, A. H., Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002 May;26[5]:643-652
Phillips, K. A., Albertini, R. S., and Rasmussen, S. A., A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 2002 Apr;59[4]:381-388
Goldstein, D. J., Mallinckrodt, C., Lu, Y., and Demitrack, M. A., Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002 Mar;63[3]:225-231
Martenyi, F., Brown, E. B., Zhang, H., Prakash, A., and Koke, S. C., Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 2002 Mar;63[3]:199-206
Mamo, D. C., Pollock, B. G., Mulsant, B., Houck, P. R., Bensasi, S., Miller, M. C., Redfern, M. S., and Reynolds III, C. F., Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. Am J Geriatr Psychiatry 2002 Mar;10[2]:199-205
Schmitt, J. A., Riedel, W. J., Vuurman, E. F., Kruizinga, M., and Ramaekers, J. G., Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology (Berl) 2002 Apr;160[4]:381-386
Delucchi, K. L., Batki, S. L., Moon, J., Jacob, P., III, and Jones, R. T., Urine toxicology samples in cocaine treatment trials: how many need to be tested?. J Addict Dis 2002;21[2]:17-26
Zohar, J., Amital, D., Miodownik, C., Kotler, M., Bleich, A., Lane, R. M., and Austin, C., Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002 Apr;22[2]:190-195
Potkin, S. G., Thyrum, P. T., Alva, G., Carreon, D., Yeh, C., Kalali, A., and Arvanitis, L. A., Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002 Apr;22[2]:174-182
Liston, H. L., DeVane, C. L., Boulton, D. W., Risch, S. C., Markowitz, J. S., and Goldman, J., Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002 Apr;22[2]:169-173
Bergeron, R., Ravindran, A. V., Chaput, Y., Goldner, E., Swinson, R., van Ameringen, M. A., Austin, C., and Hadrava, V., Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 2002 Apr;22[2]:148-154
Fava, M., Hoog, S. L., Judge, R. A., Kopp, J. B., Nilsson, M. E., and Gonzales, J. S., Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 2002 Apr;22[2]:137-147
Arnold, L. M., Hess, E. V., Hudson, J. I., Welge, J. A., Berno, S. E., and Keck, P. E., Jr., A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002Feb15;112[3]:191-197
Thornett, A. M. and Mynors-Wallis, L. M., Credibility of problem-solving therapy and medication for the treatment of depression among primary care patients. Med Sci Monit 2002 Mar;8[3]:CR193-CR196
Michelson, D., Kociban, K., Tamura, R., and Morrison, M. F., Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res 2002 May;36[3]:147-152
Thase, M. E., Rush, A. J., Howland, R. H., Kornstein, S. G., Kocsis, J. H., Gelenberg, A. J., Schatzberg, A. F., Koran, L. M., Keller, M. B., Russell, J. M., Hirschfeld, R. M., LaVange, L. M., Klein, D. N., Fawcett, J., and Harrison, W., Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002 Mar;59[3]:233-239
Stein, D. J., Stein, M. B., Pitts, C. D., Kumar, R., and Hunter, B., Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002 Feb;63[2]:152-155
Pollock, B. G., Mulsant, B. H., Rosen, J., Sweet, R. A., Mazumdar, S., Bharucha, A., Marin, R., Jacob, N. J., Huber, K. A., Kastango, K. B., and Chew, M. L., Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002 Mar;159[3]:460-465
de Kemp, E. C., Moleman, P., Hoogduin, C. A., Broekman, T. G., Goedhart, A., Schaap, C. P., and van den Berg, P. C., Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders. Psychopharmacology (Berl) 2002 Feb;160[1]:67-73
Tse, W. S. and Bond, A. J., Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacology (Berl) 2002 Jan;159[2]:216-221
Rampello, L., Chiechio, S., Raffaele, R., Vecchio, I., and Nicoletti, F., The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa. Clin Neuropharmacol 2002 Jan;25[1]:21-24
Bakker, A., Spinhoven, P., van der Does, A. J., van Balkom, A. J., and van Dyck, R., Locus of control orientation in panic disorder and the differential effects of treatment. Psychother Psychosom 2002 Mar;71[2]:85-89
Liebowitz, M. R., Stein, M. B., Tancer, M., Carpenter, D., Oakes, R., and Pitts, C. D., A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002 Jan;63[1]:66-74
Rapaport, M. H., Endicott, J., and Clary, C. M., Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry 2002 Jan;63[1]:59-65
Maina, G., Vitalucci, A., Gandolfo, S., and Bogetto, F., Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002 Jan;63[1]:38-43
Wulsin, L., Liu, T., Storrow, A., Evans, S., Dewan, N., and Hamilton, C., A randomized, controlled trial of panic disorder treatment initiation in an emergency department chest pain center. Ann Emerg Med 2002 Feb;39[2]:139-143
Barnett, S. D., Tharwani, H. M., Hertzberg, M. A., Sutherland, S. M., Connor, K. M., and Davidson, J. R., Tolerability of fluoxetine in posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002 Feb;26[2]:363-367
Elliott, A. J., Russo, J., and Roy-Byrne, P. P., The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry 2002 Jan;24[1]:43-47
Katon, W., Russo, J., Frank, E., Barrett, J., Williams, J. W., Jr., Oxman, T., Sullivan, M., and Cornell, J., Predictors of nonresponse to treatment in primary care patients with dysthymia. Gen Hosp Psychiatry 2002 Jan;24[1]:20-27
Frank, E., Rucci, P., Katon, W., Barrett, J., Williams, J. W., Jr., Oxman, T., Sullivan, M., and Cornell, J., Correlates of remission in primary care patients treated for minor depression. Gen Hosp Psychiatry 2002 Jan;24[1]:12-19
Cassano, G. B. and Jori, M. C., Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002 Jan;17[1]:27-32
Golding, M., Kotlyar, M., Garbutt, J. C., Guzzo, J., Sontz, E., Hinderliter, A., and Carson, S. W., Paroxetine modulates psychological and sympathetic responses during public speaking. J Clin Psychopharmacol 2002 Feb;22[1]:98-99
Addington, D., Addington, J., Patten, S., Remington, G., Moamai, J., Labelle, A., and Beauclair, L., Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 2002 Feb;22[1]:20-25
Salloway, S., Boyle, P. A., Correia, S., Malloy, P. F., Cahn-Weiner, D. A., Schneider, L., Krishnan, K. R., and Nakra, R., The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. Am J Geriatr Psychiatry 2002 Jan;10[1]:107-111
Mohr, D. C., Boudewyn, A. C., Goodkin, D. E., Bostrom, A., and Epstein, L., Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001 Dec;69[6]:942-949
Tucker, P., Zaninelli, R., Yehuda, R., Ruggiero, L., Dillingham, K., and Pitts, C. D., Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001 Nov;62[11]:860-868
Leuchter, A. F., Cook, I. A., Witte, E. A., Morgan, M., and Abrams, M., Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002 Jan;159[1]:122-129
Romano, S. J., Halmi, K. A., Sarkar, N. P., Koke, S. C., and Lee, J. S., A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002 Jan;159[1]:96-102
Koran, L. M., Hackett, E., Rubin, A., Wolkow, R., and Robinson, D., Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 2002 Jan;159[1]:88-95
Waintraub, L., Septien, L., and Azoulay, P., Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine. CNS Drugs 2002;16[1]:65-75
Loubinoux, I., Pariente, J., Boulanouar, K., Carel, C., Manelfe, C., Rascol, O., Celsis, P., and Chollet, F., A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage 2002 Jan;15[1]:26-36
Luty, S. E., Joyce, P. R., and Mulder, R. T., Comparison between noradrenergic and serotonergic medications using the social adjustment scale: is drive enhancement necessary for recovery of social functioning?. J Psychopharmacol 2001 Dec;15[4]:257-264
Pezzella, G., Moslinger-Gehmayr, R., and Contu, A., Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001 Nov;70[1]:1-10
Hitsman, B., Spring, B., Borrelli, B., Niaura, R., and Papandonatos, G. D., Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine. Exp Clin Psychopharmacol 2001 Nov;9[4]:355-362
Waldinger, M. D., Zwinderman, A. H., and Olivier, B., SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol 2001 Dec;21[6]:556-560
Pariente, J., Loubinoux, I., Carel, C., Albucher, J. F., Leger, A., Manelfe, C., Rascol, O., and Chollet, F., Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001 Dec;50[6]:718-729
Pryor, P. A., Hart, B. L., Cliff, K. D., and Bain, M. J., Effects of a selective serotonin reuptake inhibitor on urine spraying behavior in cats. J Am Vet Med Assoc 2001Dec1;219[11]:1557-1561
Randall, C. L., Johnson, M. R., Thevos, A. K., Sonne, S. C., Thomas, S. E., Willard, S. L., Brady, K. T., and Davidson, J. R., Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 2001;14[4]:255-262
Kroenke, K., West, S. L., Swindle, R., Gilsenan, A., Eckert, G. J., Dolor, R., Stang, P., Zhou, X. H., Hays, R., and Weinberger, M., Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001Dec19;286[23]:2947-2955
Kasckow, J. W., Mohamed, S., Thallasinos, A., Carroll, B., Zisook, S., and Jeste, D. V., Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatry 2001 Dec;16[12]:1163-1167
Furlan, P. M., Kallan, M. J., Ten Have, T., Pollock, B. G., Katz, I., and Lucki, I., Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers. Am J Geriatr Psychiatry 2001;9[4]:429-438
Mulsant, B. H., Pollock, B. G., Nebes, R., Miller, M. D., Sweet, R. A., Stack, J., Houck, P. R., Bensasi, S., Mazumdar, S., and Reynolds, C. F., III., A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001;9[4]:406-414
Schneider, L. S., Tariot, P. N., Lyketsos, C. G., Dagerman, K. S., Davis, K. L., Davis, S., Hsiao, J. K., Jeste, D. V., Katz, I. R., Olin, J. T., Pollock, B. G., Rabins, P. V., Rosenheck, R. A., Small, G. W., Lebowitz, B., and Lieberman, J., A. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001;9[4]:346-360
Hoehn-Saric, R., Schlaepfer, T. E., Greenberg, B. D., McLeod, D. R., Pearlson, G. D., and Wong, S. H., Cerebral blood flow in obsessive-compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Res 2001Nov30;108[2]:89-100
Oxman, T. E., Barrett, J. E., Sengupta, A., Katon, W., Williams, J. W., Jr., Frank, E., and Hegel, M., Status of minor depression or dysthymia in primary care following a randomized controlled treatment. Gen Hosp Psychiatry 2001 Nov;23[6]:301-310
Cipriani, R., Perini, G. I., and Rampinelli, S., Paroxetine in alopecia areata. Int J Dermatol 2001 Sep;40[9]:600-601
Michelson, D., Allgulander, C., Dantendorfer, K., Knezevic, A., Maierhofer, D., Micev, V., Paunovic, V. R., Timotijevic, I., Sarkar, N., Skoglund, L., and Pemberton, S. C., Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 2001 Dec;179:514-518
Rynn, M. A., Siqueland, L., and Rickels, K., Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001 Dec;158[12]:2008-2014
Marshall, R. D., Beebe, K. L., Oldham, M., and Zaninelli, R., Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001 Dec;158[12]:1982-1988
Davidson, J., Pearlstein, T., Londborg, P., Brady, K. T., Rothbaum, B., Bell, J., Maddock, R., Hegel, M. T., and Farfel, G., Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001 Dec;158[12]:1974-1981
Kim, S. W. and Grant, J. E., Personality dimensions in pathological gambling disorder and obsessive-compulsive disorder. Psychiatry Res 2001Nov30;104[3]:205-212
Rapaport, M. H., Wolkow, R., Rubin, A., Hackett, E., Pollack, M., and Ota, K. Y., Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001 Oct;104[4]:289-298
Fabian, T. J., Dew, M. A., Pollock, B. G., Reynolds, C. F., III, Mulsant, B. H., Butters, M. A., Zmuda, M. D., Linares, A. M., Trottini, M., and Kroboth, P. D., Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults. Biol Psychiatry 2001Nov15;50[10]:767-774
Yao, C., Kunze, K. L., Kharasch, E. D., Wang, Y., Trager, W. F., Ragueneau, I., and Levy, R. H., Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 2001 Nov;70[5]:415-424
Stein, D. J., Stein, M. B., Goodwin, W., Kumar, R., and Hunter, B., The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology (Berl) 2001 Nov;158[3]:267-272
Stein, D. J., Montgomery, S. A., Kasper, S., and Tanghoj, P., Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001 Nov;16[6]:357-361
Amore, M. and Jori, M. C., Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2001 Nov;16[6]:317-324
Rhodes, J. S., Hosack, G. R., Girard, I., Kelley, A. E., Mitchell, G. S., and Garland, T., Jr., Differential sensitivity to acute administration of cocaine, GBR 12909, and fluoxetine in mice selectively bred for hyperactive wheel-running behavior. Psychopharmacology (Berl) 2001 Nov;158[2]:120-131
Wu, W. H., Huo, S. J., Cheng, C. Y., Hong, C. J., and Tsai, S. J., Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 2001;44[4]:172-175
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., and Houle, S., Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001 Nov;158[11]:1843-1849
Parry, B. L. and Newton, R. P., Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology 2001 Nov;25[5 Suppl]:S102-S108
Dinan, T. G., Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. J Clin Psychiatry 2001;62 Suppl 22:48-52
de Klerk, E., Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2001;62 Suppl 22:43-47
Burke, W. J. and McArthur-Miller, D. A., Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. J Clin Psychiatry 2001;62 Suppl 22:38-42
Reimherr, F. W., Strong, R. E., Marchant, B. K., Hedges, D. W., and Wender, P. H, Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. J Clin Psychiatry 2001;62 Suppl 22:16-23
Ricca, V., Mannucci, E., Mezzani, B., Moretti, S., Di Bernardo, M., Bertelli, M., Rotella, C. M., and Faravelli, C., Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom 2001 Nov;70[6]:298-306
Serretti, A., Zanardi, R., Cusin, C., Rossini, D., Lorenzi, C., and Smeraldi, E., Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001 Oct;11[5]:375-380
Ribeiro, L., Busnello, J. V., Kauer-Sant’Anna, M., Madruga, M., Quevedo, J., Busnello, E. A., and Kapczinski, F., Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001 Oct;34[10]:1303-1307
Freeman, E. W., Rickels, K., Sondheimer, S. J., and Polansky, M., Concurrent use of oral contraceptives with antidepressants for premenstrual syndromes. J Clin Psychopharmacol 2001 Oct;21[5]:540-542
Cook, E. H., Wagner, K. D., March, J. S., Biederman, J., Landau, P., Wolkow, R., and Messig, M., Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001 Oct;40[10]:1175-1181
McFarlane, A., Kamath, M. V., Fallen, E. L., Malcolm, V., Cherian, F., and Norman, G., Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 2001 Oct;142[4]:617-623
Stein, M. B., Sareen, J., Hami, S., and Chao, J., Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001 Oct;158[10]:1725-1727
Plotkin, B. J., Rodos, J. J., Kappler, R., Schrage, M., Freydl, K., Hasegawa, S., Hennegan, E., Hilchie-Schmidt, C., Hines, D., Iwata, J., Mok, C., and Raffaelli, D., Adjunctive osteopathic manipulative treatment in women with depression: a pilot study. J Am Osteopath Assoc 2001 Sep;101[9]:517-523
Roy-Byrne, P. P., Katon, W., Cowley, D. S., and Russo, J., A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care. Arch Gen Psychiatry 2001 Sep;58[9]:869-876
Tse, W. S. and Bond, A. J., Serotonergic involvement in the psychosocial dimension of personality. J Psychopharmacol 2001 Sep;15[3]:195-198
Schmitt, J. A., Kruizinga, M. J., and Riedel, W. J., Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001 Sep;15[3]:173-179
Baldwin, D. S., Hawley, C. J., and Mellors, K., A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. J Psychopharmacol 2001 Sep;15[3]:161-165
Grant, J. E., Kim, S. W., and Brown, E., Characteristics of geriatric patients seeking medication treatment for pathologic gambling disorder. J Geriatr Psychiatry Neurol 2001;14[3]:125-129
Goldberg, M. R., Lowry, R. C., Musson, D. G., Birk, K. L., Fisher, A., De Puy, M. E., and Shadle, C. R., Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999 Feb;39[2]:192-199
Allard, S., Sainati, S. M., and Roth-Schechter, B. F., Coadministration of short-term zolpidem with sertraline in healthy women. J Clin Pharmacol 1999 Feb;39[2]:184-191
Silvestri, R., Pace-Schott, E. F., Gersh, T., Stickgold, R., Salzman, C., and Hobson, J. A., Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and withdrawal. J Clin Psychiatry 2001 Aug;62[8]:642-652
Coleiro, B., Marshall, S. E., Denton, C. P., Howell, K., Blann, A., Welsh, K. I., and Black, C. M., Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001 Sep;40[9]:1038-1043
Garcia-Toro, M., Pascual-Leone, A., Romera, M., Gonzalez, A., Mico, J., Ibarra, O., Arnillas, H., Capllonch, I., Mayol, A., and Tormos, J. M., Prefrontal repetitive transcranial magnetic stimulation as add on treatment in depression. J Neurol Neurosurg Psychiatry 2001 Oct;71[4]:546-548
Ljung, T., Ahlberg, A. C., Holm, G., Friberg, P., Andersson, B., Eriksson, E., and Bjorntorp, P., Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med 2001 Sep;250[3]:219-224
Zanardi, R., Serretti, A., Rossini, D., Franchini, L., Cusin, C., Lattuada, E., Dotoli, D., and Smeraldi, E., Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001Sep1;50[5]:323-330
Smajkic, A., Weine, S., Djuric-Bijedic, Z., Boskailo, E., Lewis, J., and Pavkovic, I., Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. J Trauma Stress 2001 Jul;14[3]:445-452
Alpert, M., Pouget, E. R., and Silva, R. R., Reflections of depression in acoustic measures of the patient’s speech. J Affect Disord 2001 Sep;66[1]:59-69
Wihlback, A. C., Sundstrom-Poromaa, I., Allard, P., Mjorndal, T., Spigset, O., and Backstrom, T., Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol 2001 Sep;98[3]:450-457
Serretti, A., Zanardi, R., Rossini, D., Cusin, C., Lilli, R., and Smeraldi, E., Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001 Sep;6[5]:586-592
Coleman, C. C., King, B. R., Bolden-Watson, C., Book, M. J., Segraves, R. T., Richard, N., Ascher, J., Batey, S., Jamerson, B., and Metz, A., A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001 Jul;23[7]:1040-1058
Friede, M., Henneicke von Zepelin, H. H., and Freudenstein, J., Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John’s wort. Pharmacopsychiatry 2001 Jul;34 Suppl 1:S38-S41
Demyttenaere, K., Mesters, P., Boulanger, B., Dewe, W., Delsemme, M. H., Gregoire, J., and Van Ganse, E., Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. J Affect Disord 2001 Aug;65[3]:243-252
Meeusen, R., Piacentini, M. F., Van Den, Eynde S., Magnus, L., and De Meirleir, K., Exercise performance is not influenced by a 5-HT reuptake inhibitor. Int J Sports Med 2001 Jul;22[5]:329-336
Bloch, M. R., Elliott, M., Thompson, H., and Koran, L. M., Fluoxetine in pathologic skin-picking: open-label and double-blind results. Psychosomatics 2001 Jul;42[4]:314-319
Petracca, G. M., Chemerinski, E., and Starkstein, S. E., A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer’s disease. Int Psychogeriatr 2001 Jun;13[2]:233-240
Borrelli, B., Spring, B., Niaura, R., Hitsman, B., and Papandonatos, G., Influences of gender and weight gain on short-term relapse to smoking in a cessation trial. J Consult Clin Psychol 2001 Jun;69[3]:511-515
Silverstone, P. H. and Salinas, E., Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001 Jul;62[7]:523-529
Gilaberte, I., Montejo, A. L., de la, Gandara J., Perez-Sola, V., Bernardo, M., Massana, J., Martin-Santos, R., Santiso, A., Noguera, R., Casais, L., Perez-Camo, V., Arias, M., and Judge, R., Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001 Aug;21[4]:417-424
Schreiber, S., Vinokur, S., Shavelzon, V., Pick, C. G., Zahavi, E., and Shir, Y., A randomized trial of fluoxetine versus amitriptyline in musculo-skeletal pain. Isr J Psychiatry Relat Sci 2001;38[2]:88-94
Goddard, A. W., Brouette, T., Almai, A., Jetty, P., Woods, S. W., and Charney, D., Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001 Jul;58[7]:681-686
Asnis, G. M., Hameedi, F. A., Goddard, A. W., Potkin, S. G., Black, D., Jameel, M., Desagani, K., and Woods, S. W., Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001Aug5;103[1]:1-14
Inder, W. J., Prickett, T. C., Mulder, R. T., Donald, R. A., and Joyce, P. R., Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology (Berl) 2001 Jun;156[1]:73-78
Appelberg, B. G., Syvalahti, E. K., Koskinen, T. E., Mehtonen, O. P., Muhonen, T. T., and Naukkarinen, H. H., Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001;62[6]:448-452
McCartan, D., Bell, R., Green, J. F., Campbell, C., Trimble, K., Pickering, A., and King, D. J., The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers. J Psychopharmacol 2001 Jun;15[2]:96-104
Ruggiero, G. M., Laini, V., Mauri, M. C., Ferrari, V. M., Clemente, A., Lugo, F., Mantero, M., Redaelli, G., Zappulli, D., and Cavagnini, F., A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry 2001 Jul;25[5]:1049-1059
Parise, G., Bosman, M. J., Boecker, D. R., Barry, M. J., and Tarnopolsky, M. A., Selective serotonin reuptake inhibitors: Their effect on high-intensity exercise performance. Arch Phys Med Rehabil 2001 Jul;82[7]:867-871
Geller, D. A., Hoog, S. L., Heiligenstein, J. H., Ricardi, R. K., Tamura, R., Kluszynski, S., and Jacobson, J. G., Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001 Jul;40[7]:773-779
Keller, M. B., Ryan, N. D., Strober, M., Klein, R. G., Kutcher, S. P., Birmaher, B., Hagino, O. R., Koplewicz, H., Carlson, G. A., Clarke, G. N., Emslie, G. J., Feinberg, D., Geller, B., Kusumakar, V., Papatheodorou, G., Sack, W. H., Sweeney, M., Wagner, , Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001 Jul;40[7]:762-772
Blomhoff, S., Haug, T. T., Hellstrom, K., Holme, I., Humble, M., Madsbu, H. P., and Wold, J. E., Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001 Jul;179:23-30
Perna, G., Bertani, A., Caldirola, D., Smeraldi, E., and Bellodi, L., A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001 May;34[3]:85-90
Attenburrow, M. J., Mitter, P. R., Whale, R., Terao, T., and Cowen, P. J., Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology (Berl) 2001 May;155[3]:323-326
Koran, L. M., Gelenberg, A. J., Kornstein, S. G., Howland, R. H., Friedman, R. A., DeBattista, C., Klein, D., Kocsis, J. H., Schatzberg, A. F., Thase, M. E., Rush, A. J., Hirschfeld, R. M., LaVange, L. M., and Keller, M. B., Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001 Jun;65[1]:27-36
Martenyi, F., Dossenbach, M., Mraz, K., and Metcalfe, S., Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001 Jun;11[3]:227-232
Schmitz, J. M., Averill, P., Stotts, A. L., Moeller, F. G., Rhoades, H. M., and Grabowski, J., Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 2001Aug1;63[3]:207-214
Grunhaus, L., Hirschman, S., Dolberg, O. T., Schreiber, S., and Dannon, P. N., Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT. J ECT 2001 Jun;17[2]:124-128
Pollack, M. H., Zaninelli, R., Goddard, A., McCafferty, J. P., Bellew, K. M., Burnham, D. B., and Iyengar, M. K., Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001 May;62[5]:350-357
Londborg, P. D., Hegel, M. T., Goldstein, S., Goldstein, D., Himmelhoch, J. M., Maddock, R., Patterson, W. M., Rausch, J., and Farfel, G. M., Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 2001 May;62[5]:325-331
Cornelius, J. R., Salloum, I. M., Lynch, K., Clark, D. B., and Mann, J. J., Treating the substance-abusing suicidal patient. Ann N Y Acad Sci 2001 Apr;932:78-90
Bixo, M., Allard, P., Backstrom, T., Mjorndal, T., Nyberg, S., Spigset, O., and Sundstrom-Poromaa, I., Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology 2001 Aug;26[6]:551-564
Nebes, R. D., Butters, M. A., Houck, P. R., Zmuda, M. D., Aizenstein, H., Pollock, B. G., Mulsant, B. H., and Reynolds, C. F., III., Dual-task performance in depressed geriatric patients. Psychiatry Res 2001Jun1;102[2]:139-151
Allgulander, C. and Nilsson, B., A prospective study of 86 new patients with social anxiety disorder. Acta Psychiatr Scand 2001 Jun;103[6]:447-452
Navarro, V., Gasto, C., Torres, X., Marcos, T., and Pintor, L., Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr Scand 2001 Jun;103[6]:435-440
Montgomery, S. A., Loft, H., Sanchez, C., Reines, E. H., and Papp, M., Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 2001 May;88[5]:282-286
Palatnik, A., Frolov, K., Fux, M., and Benjamin, J., Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001 Jun;21[3]:335-339
Mitchell, J. E., Fletcher, L., Hanson, K., Mussell, M. P., Seim, H., Crosby, R., and Al Banna, M., The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. J Clin Psychopharmacol 2001 Jun;21[3]:298-304
Waldinger, M. D., Zwinderman, A. H., and Olivier, B., Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol 2001 Jun;21[3]:293-297
Bertani, A., Caldirola, D., Bussi, R., Bellodi, L., and Perna, G., The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. J Clin Psychopharmacol 2001 Jun;21[3]:262-267
Nemeroff, C. B., Evans, D. L., Gyulai, L., Sachs, G. S., Bowden, C. L., Gergel, I. P., Oakes, R., and Pitts, C. D., Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001 Jun;158[6]:906-912
Rush, A. J., Trivedi, M. H., Carmody, T. J., Donahue, R. M., Houser, T. L., Bolden-Watson, C., Batey, S. R., Ascher, J. A., and Metz, A., Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001 Jul;25[1]:131-138
Steiner, M., Romano, S. J., Babcock, S., Dillon, J., Shuler, C., Berger, C., Carter, D., Reid, R., Stewart, D., Steinberg, S., and Judge, R., The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BJOG 2001 May;108[5]:462-468
Michelson, D., Schmidt, M., Lee, J., and Tepner, R., Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment. J Sex Marital Ther 2001 May;27[3]:289-302
Clerc, G., Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 2001 May;16[3]:145-151
Schweizer, E., Rynn, M., Mandos, L. A., Demartinis, N., Garcia-Espana, F., and Rickels, K., The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001 May;16[3]:137-143
Forlenza, O. V., Almeida, O. P., Stoppe, A., Jr., Hirata, E. S., and Ferreira, R. C. R., Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 2001 Mar;13[1]:75-84
Davidson, J. R., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R., and Farfel, G. M., Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001 May;58[5]:485-492
Barrett, J. E., Williams, J. W., Jr., Oxman, T. E., Frank, E., Katon, W., Sullivan, M., Hegel, M. T., Cornell, J. E., and Sengupta, A. S., Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract 2001 May;50[5]:405-412
Penttila, J., Syvalahti, E., Hinkka, S., Kuusela, T., and Scheinin, H., The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 2001 Apr;154[4]:343-349
Miller, H. L., Ekstrom, R. D., Mason, G. A., Lydiard, R. B., and Golden, R. N., Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharmacology 2001 Jun;24[6]:617-623
Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychoparmacology Anxiety Study Group. N Engl J Med 2001Apr26;344[17]:1279-1285
Papakostas, Y. G., Markianos, M., Zervas, I. M., Theodoropoulou, M., Vaidakis, N., and Daras, M., Administration of citalopram before ECT: seizure duration and hormone responses. J ECT 2000 Dec;16[4]:356-360
Abdel-Hamid, I. A., El Naggar, E. A., and El Gilany, A. H., Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001 Feb;13[1]:41-45
Koran, L. M., Pallanti, S., and Quercioli, L., Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol 2001 Apr;11[2]:169-172
Niemi, M., Backman, J. T., Neuvonen, M., Laitila, J., Neuvonen, P. J., and Kivisto, K. T., Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001 Apr;69[4]:194-200
Amchin, J., Ereshefsky, L., Zarycranski, W., Taylor, K., Albano, D., and Klockowski, P. M., Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol 2001 Apr;41[4]:443-451
Wolf, R., Dykierek, P., Gattaz, W. F., Maras, A., Kohnen, R., Dittmann, R. W., Geuppert, M., Riemann, D., and Berger, M., Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry 2001 Mar;34[2]:60-65
Meythaler, J. M., Depalma, L., Devivo, M. J., Guin-Renfroe, S., and Novack, T. A., Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj 2001 Apr;15[4]:321-331
Kaye, W. H., Nagata, T., Weltzin, T. E., Hsu, L. K., Sokol, M. S., McConaha, C., Plotnicov, K. H., Weise, J., and Deep, D., Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001Apr1;49[7]:644-652
Krishnan, K. R., Doraiswamy, P. M., and Clary, C. M., Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 2001 Feb;25[2]:347-361
Dalery, J. and Aubin, V., [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence]. Encephale 2001 Jan;27[1]:71-81
Rush, A. J., Batey, S. R., Donahue, R. M., Ascher, J. A., Carmody, T. J., and Metz, A., Does pretreatment anxiety predict response to either bupropion SR or sertraline?. J Affect Disord 2001 Apr;64[1]:81-87
Zitman, F. G. and Couvee, J. E., Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry 2001 Apr;178:317-324
Hochstrasser, B., Isaksen, P. M., Koponen, H., Lauritzen, L., Mahnert, F. A., Rouillon, F., Wade, A. G., Andersen, M., Pedersen, S. F., Swart, J. C., and Nil, R., Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001 Apr;178:304-310
d’Amato, C. C., Pizza, V., Marmolo, T., Giordano, E., Alfano, V., and Nasta, A., Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999 Nov;39[10]:716-719
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., and Miller, A. H., Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001Mar29;344[13]:961-966
Zaninelli, R., Bauer, M., Jobert, M., and Muller-Oerlinghausen, B., Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. J Clin Psychopharmacol 2001 Apr;21[2]:190-198
Ekselius, L. and von Knorring, L., Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care. J Clin Psychopharmacol 2001 Apr;21[2]:154-160
Pettinati, H. M., Volpicelli, J. R., Luck, G., Kranzler, H. R., Rukstalis, M. R., and Cnaan, A., Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001 Apr;21[2]:143-153
Hellerstein, D. J., Little, S. A., Samstag, L. W., Batchelder, S., Muran, J. C., Fedak, M., Kreditor, D., Rosenthal, R. N., and Winston, A., Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study. J Psychother Pract Res 2001;10[2]:93-103
Shores, M. M., Pascualy, M., Lewis, N. L., Flatness, D., and Veith, R. C., Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 2001 May;26[4]:433-439
Kusumoto, M., Ueno, K., Oda, A., Takeda, K., Mashimo, K., Takaya, K., Fujimura, Y., Nishihori, T., and Tanaka, K., Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. Clin Pharmacol Ther 2001 Mar;69[3]:104-107
Humble, M., Bejerot, S., Bergqvist, P. B., and Bengtsson, F., Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder. Biol Psychiatry 2001Feb15;49[4]:360-368
Stain-Malmgren, R., Khoury, A. E., Aberg-Wistedt, A., and Tham, A., Serotonergic function in major depression and effect of sertraline and paroxetine treatment. Int Clin Psychopharmacol 2001 Mar;16[2]:93-101
Montgomery, S. A., Kasper, S., Stein, D. J., Bang, Hedegaard K., and Lemming, O. M., Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001 Mar;16[2]:75-86
Ferguson, J. M., Shrivastava, R. K., Stahl, S. M., Hartford, J. T., Borian, F., Ieni, J., McQuade, R. D., and Jody, D., Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. J Clin Psychiatry 2001 Jan;62[1]:24-29
Bump, G. M., Mulsant, B. H., Pollock, B. G., Mazumdar, S., Begley, A. E., Dew, M. A., and Reynolds, C. F., III., Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety 2001;13[1]:38-44
Russell, J. M., Koran, L. M., Rush, J., Hirschfeld, R. M., Harrison, W., Friedman, E. S., Davis, S., and Keller, M., Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001;13[1]:18-27
Levkovitz, Y., Bloch, Y., Kaplan, D., Diskin, A., and Abramovitchi, I., Fluvoxamine for psychosis in Alzheimer’s disease. J Nerv Ment Dis 2001 Feb;189[2]:126-129
Graff, D. W., Williamson, K. M., Pieper, J. A., Carson, S. W., Adams, K. F., Jr., Cascio, W. E., and Patterson, J. H., Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol 2001 Jan;41[1]:97-106
Azhar, M. Z., Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan--implications for management by family doctors. Med J Malaysia 2000 Dec;55[4]:402-408
Gutierrez, M. and Abramowitz, W., Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy 2001 Feb;21[2]:163-168
Riddle, M. A., Reeve, E. A., Yaryura-Tobias, J. A., Yang, H. M., Claghorn, J. L., Gaffney, G., Greist, J. H., Holland, D., McConville, B. J., Pigott, T., and Walkup, J. T., Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001 Feb;40[2]:222-229
Fleishaker, J. C., Ryan, K. K., Carel, B. J., and Azie, N. E., Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001 Feb;41[2]:217-223
Suri, R. A., Altshuler, L. L., Rasgon, N. L., Calcagno, J. L., Frye, M. A., Gitlin, M. J., Hwang, S., and Zuckerbrow-Miller, J., Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 2000 Dec;61[12]:942-946
Claxton, A., de Klerk, E., Parry, M., Robinson, J. M., and Schmidt, M. E., Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2000 Dec;61[12]:928-932
Ferreri, M., Lavergne, F., Berlin, I., Payan, C., and Puech, A. J., Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001 Jan;103[1]:66-72
Romano, S., Goodman, W., Tamura, R., and Gonzales, J., Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 2001 Feb;21[1]:46-52
Perez, V., Puiigdemont, D., Gilaberte, I., Alvarez, E., and Artigas, F., Augmentation of fluoxetine’s antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 2001 Feb;21[1]:36-45
Rapaport, M. H., Pollack, M. H., Clary, C. M., Mardekian, J., and Wolkow, R., Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines. J Clin Psychopharmacol 2001 Feb;21[1]:104-107
Wilson, S. J., Bailey, J. E., Alford, C., and Nutt, D. J., Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. J Psychopharmacol 2000;14[4]:378-386
Atan, A., Basar, M. M., and Aydoganli, L., Comparison of the efficacy of fluoxetine alone vs. fluoxetine plus local lidocaine ointment in the treatment of premature ejaculation. Arch Esp Urol 2000 Nov;53[9]:856-858
Draganich, L. F., Zacny, J., Klafta, J., and Karrison, T., The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J Gerontol A Biol Sci Med Sci 2001 Jan;56[1]:M36-M41
Oxman, T. E. and Hull, J. G., Social support and treatment response in older depressed primary care patients. J Gerontol B Psychol Sci Soc Sci 2001 Jan;56[1]:35-45
Gutierrez, M. M. and Abramowitz, W., Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. Clin Ther 2000 Dec;22[12]:1525-1532
Neziroglu, F., Yaryura-Tobias, J. A., Walz, J., and McKay, D., The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2000;10[4]:295-306
Madsen, H., Enggaard, T. P., Hansen, L. L., Klitgaard, N. A., and Brosen, K., Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001 Jan;69[1]:41-47
van Ameringen, M. A., Lane, R. M., Walker, J. R., Bowen, R. C., Chokka, P. R., Goldner, E. M., Johnston, D. G., Lavallee, Y. J., Nandy, S., Pecknold, J. C., Hadrava, V., and Swinson, R. P., Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001 Feb;158[2]:275-281
Moller, H. J., Glaser, K., Leverkus, F., and Gobel, C., Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry 2000 Nov;33[6]:206-212
Black, D. W., Gabel, J., Hansen, J., and Schlosser, S., A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 2000 Dec;12[4]:205-211
Strik, J. J., Honig, A., Lousberg, R., Lousberg, A. H., Cheriex, E. C., Tuynman-Qua, H. G., Kuijpers, P. M., Wellens, H. J., and Van Praag, H. M., Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000 Nov;62[6]:783-789
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., Feldman, P. D., and Meltzer, H. Y., A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001 Jan;158[1]:131-134
Marsland, T. W. and Newton, W., Are there differences by gender in response to pharmacotherapy for depression?. J Fam Pract 2000 Dec;49[12]:1149
Gutierrez, M. and Abramowitz, W., Steady-state pharmacokinetics of citalopram in young and elderly subjects. Pharmacotherapy 2000 Dec;20[12]:1441-1447
Bird, H. and Broggini, M., Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study. J Rheumatol 2000 Dec;27[12]:2791-2797
Dickens, C., Jayson, M., Sutton, C., and Creed, F., The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics 2000 Nov;41[6]:490-499
Sheikh, J. I., Londborg, P., Clary, C. M., and Fayyad, R., The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacol 2000 Nov;15[6]:335-342
Markowitz, J. S., DeVane, C. L., Liston, H. L., and Montgomery, S. A., An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000 Nov;15[6]:329-333
Gendall, K. A., Joyce, P. R., Mulder, R. T., and Sullivan, P. F., The effects of fluoxetine versus nortriptyline on body weight in depression. J Clin Psychopharmacol 2000 Dec;20[6]:714-715
Ackerman, D. L., Greenland, S., Bystritsky, A., and Small, G. W., Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. J Clin Psychopharmacol 2000 Dec;20[6]:658-665
Aberg-Wistedt, A., Agren, H., Ekselius, L., Bengtsson, F., and Akerblad, A. C., Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000 Dec;20[6]:645-652
Walker, J. R., van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y. J., Nandy, S., Pecknold, J. C., Hadrava, V., and Lane, R. M., Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000 Dec;20[6]:636-644
Uhlenhuth, E. H., Matuzas, W., Warner, T. D., Paine, S., Lydiard, R. B., and Pollack, M. H., Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication. J Clin Psychopharmacol 2000 Dec;20[6]:622-627
Fava, M., Judge, R., Hoog, S. L., Nilsson, M. E., and Koke, S. C., Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000 Nov;61[11]:863-867
Schmidt, M. E., Fava, M., Robinson, J. M., and Judge, R., The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000 Nov;61[11]:851-857
Ravindran, A. V., Guelfi, J. D., Lane, R. M., and Cassano, G. B., Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry 2000 Nov;61[11]:821-827
Londborg, P. D., Smith, W. T., Glaudin, V., and Painter, J. R., Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. J Affect Disord 2000 Dec;61[1-2]:73-79
Vallee, J. P., [What is the "best" treatment of depression in general practice?]. Presse Med 2000Oct28;29[32]:1765-1766
Butters, M. A., Becker, J. T., Nebes, R. D., Zmuda, M. D., Mulsant, B. H., Pollock, B. G., and Reynolds, C. F., III., Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 2000 Dec;157[12]:1949-1954
Bendtsen, L. and Jensen, R., Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache. Cephalalgia 2000 Jul;20[6]:603-610
Stahl, S. M., Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000Nov1;48[9]:894-901
Killen, J. D., Fortmann, S. P., Schatzberg, A. F., Hayward, C., Sussman, L., Rothman, M., Strausberg, L., and Varady, A., Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol 2000 Oct;68[5]:883-889
Hergovich, N., Aigner, M., Eichler, H. G., Entlicher, J., Drucker, C., and Jilma, B., Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000 Oct;68[4]:435-442
Warnock, J. K., Bundren, J. C., and Morris, D. W., Depressive mood symptoms associated with ovarian suppression. Fertil Steril 2000 Nov;74[5]:984-986
Jokinen, M. J., Ahonen, J., Neuvonen, P. J., and Olkkola, K. T., The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. Anesth Analg 2000 Nov;91[5]:1207-1212
Benkert, O., Szegedi, A., and Kohnen, R., Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000 Sep;61[9]:656-663
Hughes, C. W., Emslie, G., Kowatch, R., Weinberg, W., Rintelmann, J., and Rush, A. J., Clinician, parent, and child prediction of medication or placebo in double-blind depression study. Neuropsychopharmacology 2000 Nov;23[5]:591-594
Pollock, B. G., Ferrell, R. E., Mulsant, B. H., Mazumdar, S., Miller, M., Sweet, R. A., Davis, S., Kirshner, M. A., Houck, P. R., Stack, J. A., Reynolds, C. F., and Kupfer, D. J., Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000 Nov;23[5]:587-590
Levitan, R. D., Shen, J. H., Jindal, R., Driver, H. S., Kennedy, S. H., and Shapiro, C. M., Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. J Psychiatry Neurosci 2000 Sep;25[4]:337-346
Babyak, M., Blumenthal, J. A., Herman, S., Khatri, P., Doraiswamy, M., Moore, K., Craighead, W. E., Baldewicz, T. T., and Krishnan, K. R., Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med 2000 Sep;62[5]:633-638
Lyketsos, C. G., Sheppard, J. M., Steele, C. D., Kopunek, S., Steinberg, M., Baker, A. S., Brandt, J., and Rabins, P. V., Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer’s disease: initial results from the Depression in Alzheimer’s Disease study. Am J Psychiatry 2000 Oct;157[10]:1686-1689
Hirschmann, S., Dannon, P. N., Iancu, I., Dolberg, O. T., Zohar, J., and Grunhaus, L., Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000 Oct;20[5]:556-559
Williams, J. W., Jr., Barrett, J., Oxman, T., Frank, E., Katon, W., Sullivan, M., Cornell, J., and Sengupta, A., Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA 2000 Sep27;284[12]:1519-1526
Baldwin, D. S., Clinical experience with paroxetine in social anxiety disorder. Int Clin Psychopharmacol 2000 Jul;15 Suppl 1:S19-S24
Lepine, J. P., Goger, J., Blashko, C., Probst, C., Moles, M. F., Kosolowski, J., Scharfetter, B., and Lane, R. M., A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. Int Clin Psychopharmacol 2000 Sep;15[5]:263-271
Silver, H., Barash, I., Aharon, N., Kaplan, A., and Poyurovsky, M., Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 2000 Sep;15[5]:257-261
Sunderram, J., Parisi, R. A., and Strobel, R. J., Serotonergic stimulation of the genioglossus and the response to nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000 Sep;162[3 Pt 1]:925-929
Freeman, E. W., Sondheimer, S. J., Polansky, M., and Garcia-Espagna, B., Predictors of response to sertraline treatment of severe premenstrual syndromes. J Clin Psychiatry 2000 Aug;61[8]:579-584
Newhouse, P. A., Krishnan, K. R., Doraiswamy, P. M., Richter, E. M., Batzar, E. D., and Clary, C. M., A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000 Aug;61[8]:559-568
Coppen, A. and Bailey, J., Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000 Nov;60[2]:121-130
Varia, I., Logue, E., O’connor, C., Newby, K., Wagner, H. R., Davenport, C., Rathey, K., and Krishnan, K. R., Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000 Sep;140[3]:367-372
Bakker, A., Spinhoven, P., van Balkom, A. J., Vleugel, L., and van Dyck, R., Cognitive therapy by allocation versus cognitive therapy by preference in the treatment of panic disorder. Psychother Psychosom 2000 Sep;69[5]:240-243
Henry, M. E., Moore, C. M., Kaufman, M. J., Michelson, D., Schmidt, M. E., Stoddard, E., Vuckevic, A. J., Berreira, P. J., Cohen, B. M., and Renshaw, P. F., Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 2000 Sep;157[9]:1506-1508
Kornstein, S. G., Schatzberg, A. F., Thase, M. E., Yonkers, K. A., McCullough, J. P., Keitner, G. I., Gelenberg, A. J., Davis, S. M., Harrison, W. M., and Keller, M. B., Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000 Sep;157[9]:1445-1452
Hellerstein, D. J., Kocsis, J. H., Chapman, D., Stewart, J. W., and Harrison, W., Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality. Am J Psychiatry 2000 Sep;157[9]:1436-1444
Toni, C., Perugi, G., Frare, F., Mata, B., Vitale, B., Mengali, F., Recchia, M., Serra, G., and Akiskal, H. S., A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry 2000 Jul;33[4]:121-131
Bertani, A., Perna, G., Arancio, C., Caldirola, D., and Bellodi, L., Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol 1997 Apr;17[2]:97-101
Dunkin, J. J., Leuchter, A. F., Cook, I. A., Kasl-Godley, J. E., Abrams, M., and Rosenberg-Thompson, S., Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 2000 Oct;60[1]:13-23
McGrath, P. J., Stewart, J. W., Petkova, E., Quitkin, F. M., Amsterdam, J. D., Fawcett, J., Reimherr, F. W., Rosenbaum, J. F., and Beasley, C. M., Jr., Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry 2000 Jul;61[7]:518-524
Wiart, L., Petit, H., Joseph, P. A., Mazaux, J. M., and Barat, M., Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000 Aug;31[8]:1829-1832
Burke, W. J., Hendricks, S. E., McArthur-Miller, D., Jacques, D., Bessette, D., McKillup, T., Stull, T., and Wilson, J., Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. J Clin Psychopharmacol 2000 Aug;20[4]:423-427
Reznik, I. and Sirota, P., Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 2000 Aug;20[4]:410-416
Pettinati, H. M., Volpicelli, J. R., Kranzler, H. R., Luck, G., Rukstalis, M. R., and Cnaan, A., Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000 Jul;24[7]:1041-1049
Hamilton, S. P., Nunes, E. V., Janal, M., and Weber, L., The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000;9[1]:63-69
Batki, S. L., Moon, J., Delucchi, K., Bradley, M., Hersh, D., Smolar, S., Mengis, M., Lefkowitz, E., Sexe, D., Morello, L., Everhart, T., Jones, R. T., and Jacob, P., III., Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann N Y Acad Sci 2000;909:260-263
Walsh, B. T., Agras, W. S., Devlin, M. J., Fairburn, C. G., Wilson, G. T., Kahn, C., and Chally, M. K., Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am J Psychiatry 2000 Aug;157[8]:1332-1334
Weber, E., Stack, J., Pollock, B. G., Mulsant, B., Begley, A., Mazumdar, S., and Reynolds, C. F., Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: a double-blind randomized trial. Am J Geriatr Psychiatry 2000;8[3]:245-250
Mamo, D. C., Sweet, R. A., Mulsant, B. H., Pollock, B. G., Miller, M. D., Stack, J. A., Begley, A. E., and Reynolds, C. F., III., Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients. Am J Geriatr Psychiatry 2000;8[3]:226-231
Hertzberg, M. A., Feldman, M. E., Beckham, J. C., Kudler, H. S., and Davidson, J. R., Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry 2000 Jun;12[2]:101-105
Peter, H., Tabrizian, S., and Hand, I., Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo. Int J Psychiatry Med 2000;30[1]:27-39
Healy, E. and McKeon, P., Dopaminergic sensitivity and prediction of antidepressant response. J Psychopharmacol 2000 Jun;14[2]:152-156
Stein, M. B., Ron, Norton G., Walker, J. R., Chartier, M. J., and Graham, R., Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Psychiatry Res 2000Jul17;94[3]:191-200
Forlenza, O. V., Stoppe, Junior A., Hirata, E. S., and Ferreira, R. C., Antidepressant efficacy of sertraline and imipramine for the treatment of major depression in elderly outpatients. Sao Paulo Med J 2000Jul6;118[4]:99-104
Bondi, M., Menozzi, R., Bertolini, M., Venneri, M. G., and Del Rio, G., Metabolic effects of fluoxetine in obese menopausal women. J Endocrinol Invest 2000 May;23[5]:280-286
von Bahr, C., Ursing, C., Yasui, N., Tybring, G., Bertilsson, L., and Rojdmark, S., Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000 May;56[2]:123-127
Frank, E., Shear, M. K., Rucci, P., Cyranowski, J. M., Endicott, J., Fagiolini, A., Grochocinski, V. J., Houck, P., Kupfer, D. J., Maser, J. D., and Cassano, G. B., Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression. Am J Psychiatry 2000 Jul;157[7]:1101-1107
Hackmann, A., Clark, D. M., and McManus, F., Recurrent images and early memories in social phobia. Behav Res Ther 2000 Jun;38[6]:601-610
Fava, M., Rosenbaum, J. F., Hoog, S. L., Tepner, R. G., Kopp, J. B., and Nilsson, M. E., Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000 Aug;59[2]:119-126
Barak, Y., Kimhi, R., and Weizman, R., Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients?. Int Clin Psychopharmacol 2000 Jan;15[1]:53-56
Ballus, C., Quiros, G., De Flores, T., de la, Torre J., Palao, D., Rojo, L., Gutierrez, M., Casais, L., and Riesgo, Y., The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000 Jan;15[1]:43-48
Tzanakaki, M., Guazzelli, M., Nimatoudis, I., Zissis, N. P., Smeraldi, E., and Rizzo, F., Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000 Jan;15[1]:29-34
Lustman, P. J., Freedland, K. E., Griffith, L. S., and Clouse, R. E., Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000 May;23[5]:618-623
Anderberg, U. M., Marteinsdottir, I., and von Knorring, L., Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4[1]:27-35
Rapaport, M. H., Pollack, M., Wolkow, R., Mardekian, J., and Clary, C., Is placebo response the same as drug response in panic disorder?. Am J Psychiatry 2000 Jun;157[6]:1014-1016
McElroy, S. L., Casuto, L. S., Nelson, E. B., Lake, K. A., Soutullo, C. A., Keck, P. E., Jr., and Hudson, J. I., Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000 Jun;157[6]:1004-1006
Berndt, E. R., Koran, L. M., Finkelstein, S. N., Gelenberg, A. J., Kornstein, S. G., Miller, I. M., Thase, M. E., Trapp, G. A., and Keller, M. B., Lost human capital from early-onset chronic depression. Am J Psychiatry 2000 Jun;157[6]:940-947
Ninan, P. T., McElroy, S. L., Kane, C. P., Knight, B. T., Casuto, L. S., Rose, S. E., Marsteller, F. A., and Nemeroff, C. B., Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol 2000 Jun;20[3]:362-366
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., and Tepner, R. G., Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000 Apr;176:363-368
Brenner, R., Azbel, V., Madhusoodanan, S., and Pawlowska, M., Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 2000 Apr;22[4]:411-419
Weihs, K. L., Settle, E. C., Jr., Batey, S. R., Houser, T. L., Donahue, R. M., and Ascher, J. A., Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000 Mar;61[3]:196-202
Corrigan, M. H., Denahan, A. Q., Wright, C. E., Ragual, R. J., and Evans, D. L., Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11[2]:58-65
Hollander, E., DeCaria, C. M., Finkell, J. N., Begaz, T., Wong, C. M., and Cartwright, C., A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000May1;47[9]:813-817
Benjamin, J., Ben Zion, I. Z., Karbofsky, E., and Dannon, P., Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berl) 2000 Apr;149[2]:194-196
Oslin, D. W., Streim, J. E., Katz, I. R., Smith, B. D., DiFilippo, S. D., Ten Have, T. R., and Cooper, T., Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. Am J Geriatr Psychiatry 2000;8[2]:141-149
Guelfi, J. D., Strub, N., and Loft, H., Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord 2000 Jun;58[3]:201-209
Cornelius, J. R., Salloum, I. M., Haskett, R. F., Daley, D. C., Cornelius, M. D., Thase, M. E., and Perel, J. M., Fluoxetine versus placebo in depressed alcoholics: a 1-year follow-up study. Addict Behav 2000 Mar;25[2]:307-310
Moslinger-Gehmayr, R., Zaninelli, R., Contu, A., Oberhoff, C., Gutschow, K., Schindler, A. E., and Staab, H. J., [A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression]. Zentralbl Gynakol 2000;122[4]:195-202
Bondareff, W., Alpert, M., Friedhoff, A. J., Richter, E. M., Clary, C. M., and Batzar, E., Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000 May;157[5]:729-736
Todorov, C., Freeston, M. H., and Borgeat, F., On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?. Can J Psychiatry 2000 Apr;45[3]:257-262
Katzelnick, D. J., Simon, G. E., Pearson, S. D., Manning, W. G., Helstad, C. P., Henk, H. J., Cole, S. M., Lin, E. H., Taylor, L. H., and Kobak, K. A., Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med 2000 Apr;9[4]:345-351
Wilner, K. D., Demattos, S. B., Anziano, R. J., Apseloff, G., and Gerber, N., Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol 2000;49 Suppl 1:43S-47S
Hassan, P. C., Sproule, B. A., Naranjo, C. A., and Herrmann, N., Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. J Clin Psychopharmacol 2000 Apr;20[2]:150-158
Pollock, B. G., Laghrissi-Thode, F., and Wagner, W. R., Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000 Apr;20[2]:137-140
Segraves, R. T., Kavoussi, R., Hughes, A. R., Batey, S. R., Johnston, J. A., Donahue, R., and Ascher, J. A., Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000 Apr;20[2]:122-128
Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., and Farfel, G. M., Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000Apr12;283[14]:1837-1844
Karlsson, I., Godderis, J., Augusto De Mendonca, Lima C., Nygaard, H., Simanyi, M., Taal, M., and Eglin, M., A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int J Geriatr Psychiatry 2000 Apr;15[4]:295-305
Zaharia, M. D., Ravindran, A. V., Griffiths, J., Merali, Z., and Anisman, H., Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features. J Affect Disord 2000 Apr;58[1]:1-10
Sacristan, J. A., Gilaberte, I., Boto, B., Buesching, D. P., Obenchain, R. L., Demitrack, M., Perez, Sola, V, Alvarez, E., and Artigas, F., Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial. Int Clin Psychopharmacol 2000 Mar;15[2]:107-113
Mundo, E., Maina, G., and Uslenghi, C., Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2000 Mar;15[2]:69-76
Schrader, E., Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000 Mar;15[2]:61-68
Haug, T. T., Hellstrom, K., Blomhoff, S., Humble, M., Madsbu, H. P., and Wold, J. E., The treatment of social phobia in general practice. is exposure therapy feasible?. Fam Pract 2000 Apr;17[2]:114-118
Green, J. F., King, D. J., and Trimble, K. M., Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. J Psychopharmacol 2000 Mar;14[1]:30-36
Phillips, M. A., Langley, R. W., Bradshaw, C. M., and Szabadi, E., The effects of some antidepressant drugs on prepulse inhibition of the acoustic startle (eyeblink) response and the N1/P2 auditory evoked response in man. J Psychopharmacol 2000 Mar;14[1]:40-45
Ciaramella, A., Grosso, S., and Poli, P., [Fluoxetine versus fluvoxamine for treatment of chronic pain]. Minerva Anestesiol 2000 Jan;66[1-2]:55-61
Pearlstein, T. B., Halbreich, U., Batzar, E. D., Brown, C. S., Endicott, J., Frank, E., Freeman, E. W., Harrison, W. M., Haskett, R. F., Stout, A. L., and Yonkers, K. A., Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000 Feb;61[2]:101-109
Mehtonen, O. P., Sogaard, J., Roponen, P., and Behnke, K., Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 2000 Feb;61[2]:95-100
Ricca, V., Mannucci, E., Paionni, A., Di Bernardo, M., Cellini, M., Cabras, P. L., and Rotella, C. M., Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. Eat Weight Disord 1999 Mar;4[1]:10-14
Leinonen, E., Lepola, U., Koponen, H., Turtonen, J., Wade, A., and Lehto, H., Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 2000 Jan;25[1]:25-32
Blondal, T., Gudmundsson, L. J., Tomasson, K., Jonsdottir, D., Hilmarsdottir, H., Kristjansson, F., Nilsson, F., and Bjornsdottir, U. S., The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial. Addiction 1999 Jul;94[7]:1007-1015
Rudolph, R. L. and Feiger, A. D., A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999 Dec;56[2-3]:171-181
Loo, H., Saiz-Ruiz, J., Costa e Silva JACE, Ansseau, M., Herrington, R., Vaz-Serra, A., Dilling, H., and de Risio, S., Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord 1999 Dec;56[2-3]:109-118
Robinson, R. G., Schultz, S. K., Castillo, C., Kopel, T., Kosier, J. T., Newman, R. M., Curdue, K., Petracca, G., and Starkstein, S. E., Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000 Mar;157[3]:351-359
McGrath, P. J., Stewart, J. W., Janal, M. N., Petkova, E., Quitkin, F. M., and Klein, D. F., A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000 Mar;157[3]:344-350
Thompson, C., Peveler, R. C., Stephenson, D., and McKendrick, J., Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry 2000 Mar;157[3]:338-343
Faries, D., Herrera, J., Rayamajhi, J., DeBrota, D., Demitrack, M., and Potter, W. Z., The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000 Jan;34[1]:3-10
Zanardi, R., Franchini, L., Serretti, A., Perez, J., and Smeraldi, E., Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000 Jan;61[1]:26-29
Di Girolamo, E., Di Iorio, C., Leonzio, L., Sabatini, P., Ranalli, G., and Barsotti, A., [Effectiveness of paroxetine in the treatment of refractory vasovagal syncope in young patients]. G Ital Cardiol 1999 Dec;29[12]:1472-1477
Michelson, D., Amsterdam, J., Apter, J., Fava, M., Londborg, P., Tamura, R., and Pagh, L., Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology 2000 Feb;25[2]:169-177
Michelson, D., Bancroft, J., Targum, S., Kim, Y., and Tepner, R., Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000 Feb;157[2]:239-243
Sogaard, J., Lane, R., Latimer, P., Behnke, K., Christiansen, P. E., Nielsen, B., Ravindran, A. V., Reesal, R. T., and Goodwin, D. P., A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999 Dec;13[4]:406-414
Bakker, A., van Dyck, R., Spinhoven, P., and van Balkom, A. J., Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry 1999 Dec;60[12]:831-838
Feighner, J. P. and Overo, K., Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999 Dec;60[12]:824-830
Arango, C., Kirkpatrick, B., and Buchanan, R. W., Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J Nerv Ment Dis 2000 Jan;188[1]:50-53
Bonate, P. L., Kroboth, P. D., Smith, R. B., Suarez, E., and Oo, C, Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. J Clin Psychopharmacol 2000 Feb;20[1]:19-27
Magai, C., Kennedy, G., Cohen, C. I., and Gomberg, D., A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease. Am J Geriatr Psychiatry 2000;8[1]:66-74
Murat, Basar M., Atan, A., Yildiz, M., Baykam, M., and Aydoganli, L., Comparison of sertraline to fluoxetine with regard to their efficacy and side effects in the treatment of premature ejaculation. Arch Esp Urol 1999 Nov;52[9]:1008-1011
Alfaro, C. L., Lam, Y. W., Simpson, J., and Ereshefsky, L., CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000 Jan;40[1]:58-66
Hoehn-Saric, R., Ninan, P., Black, D. W., Stahl, S., Greist, J. H., Lydiard, B., McElroy, S., Zajecka, J., Chapman, D., Clary, C., and Harrison, W., Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 2000 Jan;57[1]:76-82
Baldwin, D., Bobes, J., Stein, D. J., Scharwachter, I., and Faure, M., Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999 Aug;175:120-126
Anisman, H., Ravindran, A. V., Griffiths, J., and Merali, Z., Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiatry 1999 Dec15;46[12]:1649-1655
Poirier, M. F. and Boyer, P., Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 1999 Jul;175:12-16
New, A. S., Woo-Ming, A., Mitropoulou, V., Silverman, J., Reynolds, D., Schopick, F., Trestman, R. L., and Siever, L. J., Serotonin and the prediction of response time to fluoxetine in patients with mild depression. Psychiatry Res 1999 Nov8;88[2]:89-93
Marazziti, D., Rossi, A., Dell’Osso, L., Palego, L., Placidi, G. P., Giannaccini, G., Lucacchini, A., and Cassano, G. B., Decreased platelet 3H-paroxetine binding in untreated panic disorder patients. Life Sci 1999;65[25]:2735-2741
Connor, K. M., Sutherland, S. M., Tupler, L. A., Malik, M. L., and Davidson, J. R., Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry 1999 Jul;175:17-22
Ekselius, L. and von Knorring, L., Changes in personality traits during treatment with sertraline or citalopram. Br J Psychiatry 1999 May;174:444-448
Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. The ENRICHD investigators. Am Heart J 2000 Jan;139[1 Pt 1]:1-9
Young, L. T., Joffe, R. T., Robb, J. C., MacQueen, G. M., Marriott, M., and Patelis-Siotis, I., Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000 Jan;157[1]:124-126
Mynors-Wallis, L. M., Gath, D. H., Day, A., and Baker, F., Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 2000 Jan1;320[7226]:26-30
Berry, R. B., Yamaura, E. M., Gill, K., and Reist, C., Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep 1999 Dec15;22[8]:1087-1092
Coleman, C. C., Cunningham, L. A., Foster, V. J., Batey, S. R., Donahue, R. M., Houser, T. L., and Ascher, J. A., Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999 Dec;11[4]:205-215
Mirghani, R. A., Hellgren, U., Westerberg, P. A., Ericsson, O., Bertilsson, L., and Gustafsson, L. L., The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther 1999 Nov;66[5]:454-460
Brown, M. C., Nimmerrichter, A. A., and Guest, J. F., Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria. Eur Psychiatry 1999 Jul;14[4]:230-244
Pallanti, S., Quercioli, L., Paiva, R. S., and Koran, L. M., Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 1999 Apr;14[2]:101-106
Sechter, D., Troy, S., Paternetti, S., and Boyer, P., A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 1999 Mar;14[1]:41-48
Bridler, R., [Optimal duration of fluoxetine administration for the successful treatment of depression]. Schweiz Rundsch Med Prax 1999 Oct21;88[43]:1777-1778
DeVane, C. L., Ware, M. R., Emmanuel, N. P., Brawman-Mintzer, O., Morton, W. A., Villarreal, G., and Lydiard, R. B., Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. Int Clin Psychopharmacol 1999 Nov;14[6]:345-351
Leinonen, E., Skarstein, J., Behnke, K., Agren, H., and Helsdingen, J. T., Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999 Nov;14[6]:329-337
Versiani, M., Ontiveros, A., Mazzotti, G., Ospina, J., Davila, J., Mata, S., Pacheco, A., Plewes, J., Tamura, R., and Palacios, M., Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. Int Clin Psychopharmacol 1999 Nov;14[6]:321-327
d’Ardhuy, X. L., Boeijinga, P. H., Renault, B., Luthringer, R., Rinaudo, G., Soufflet, L., Toussaint, M., and Macher, J., Effects of serotonin-selective and classical antidepressants on the auditory P300 cognitive potential. Neuropsychobiology 1999 Nov;40[4]:207-213
Atkinson, J. H., Slater, M. A., Wahlgren, D. R., Williams, R. A., Zisook, S., Pruitt, S. D., Epping-Jordan, J. E., Patterson, T. L., Grant, I., Abramson, I., and Garfin, S. R., Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999 Nov;83[2]:137-145
Freeman, E. W., Rickels, K., Sondheimer, S. J., and Polansky, M., Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999 Oct;56[10]:932-939
Flament, M. F., Lane, R. M., Zhu, R., and Ying, Z., Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 1999 Sep;14[5]:259-275
Ravindran, A. V., Anisman, H., Merali, Z., Charbonneau, Y., Telner, J., Bialik, R. J., Wiens, A., Ellis, J., and Griffiths, J., Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Am J Psychiatry 1999 Oct;156[10]:1608-1617
Moraes, M. O., Lerner, F. E., Corso, G., Bezerra, F. A., Moraes, M. E., and De Nucci, G., Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. J Clin Pharmacol 1999 Oct;39[10]:1053-1061
Barrett, J. E., Williams, J. W., Jr., Oxman, T. E., Katon, W., Frank, E., Hegel, M. T., Sullivan, M., and Schulberg, H. C., The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. Gen Hosp Psychiatry 1999 Jul;21[4]:260-273
Nebes, R. D., Pollock, B. G., Mulsant, B. H., Butters, M. A., Zmuda, M. D., and Reynolds, C. F., III., Cognitive effects of paroxetine in older depressed patients. J Clin Psychiatry 1999;60 Suppl 20:26-29
Walters, G., Reynolds, C. F., III, Mulsant, B. H., and Pollock, B. G., Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. J Clin Psychiatry 1999;60 Suppl 20:21-25
Mulsant, B. H., Pollock, B. G., Nebes, R. D., Miller, M. D., Little, J. T., Stack, J., Houck, P. R., Bensasi, S., Mazumdar, S., and Reynolds, C. F., III., A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999;60 Suppl 20:16-20
Abdelmawla, A. H., Langley, R. W., Szabadi, E., and Bradshaw, C. M., Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 1999 Sep;48[3]:345-354
Ackerman, D. L., Greenland, S., and Bystritsky, A., Side effects as predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 1999 Oct;19[5]:459-465
Rasmussen, S. L., Overo, K. F., and Tanghoj, P., Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999 Oct;19[5]:407-415
Allgulander, C., Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999 Sep;100[3]:193-198
Burns, A., Russell, E., Stratton-Powell, H., Tyrell, P., O’Neill, P., and Baldwin, R., Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999 Aug;14[8]:681-685
Green, T. D., Reynolds, C. F., III, Mulsant, B. H., Pollock, B. G., Miller, M. D., Houck, P. R., Mazumdar, S., Dew, M. A., and Kupfer, D. J., Accelerating antidepressant response in geriatric depression: a post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetine, nortriptyline, or placebo. J Geriatr Psychiatry Neurol 1999;12[2]:67-71
Hellewell, J. S., Guimaraes, F. S., Wang, M., and Deakin, J. F., Comparison of buspirone with diazepam and fluvoxamine on aversive classical conditioning in humans. J Psychopharmacol 1999;13[2]:122-127
Thorell, L. H., Kjellman, B., Arned, M., Lindwall-Sundel, K., Walinder, J., and Wetterberg, L., Light treatment of seasonal affective disorder in combination with citalopram or placebo with 1-year follow-up. Int Clin Psychopharmacol 1999 May;14 Suppl 2:S7-11
Kowatch, R. A., Carmody, T. J., Emslie, G. J., Rintelmann, J. W., Hughes, C. W., and Rush, A. J., Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study. J Affect Disord 1999 Aug;54[3]:269-276
Larsen, J. T., Hansen, L. L., Spigset, O., and Brosen, K., Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Eur J Clin Pharmacol 1999 Jul;55[5]:375-382
Michelson, D., Amsterdam, J. D., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Zajecka, J., Sundell, K. L., Kim, Y., and Beasley, C. M., Jr., Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999 Aug;156[8]:1170-1176
Hitsman, B., Pingitore, R., Spring, B., Mahableshwarkar, A., Mizes, J. S., Segraves, K. A., Kristeller, J. L., and Xu, W., Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol 1999 Aug;67[4]:547-554
Wilson, G. T., Loeb, K. L., Walsh, B. T., Labouvie, E., Petkova, E., Liu, X., and Waternaux, C., Psychological versus pharmacological treatments of bulimia nervosa: predictors and processes of change. J Consult Clin Psychol 1999 Aug;67[4]:451-459
Michelson, D., Pollack, M., Lydiard, R. B., Tamura, R., Tepner, R., and Tollefson, G., Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry 1999 Mar;174:213-218
Freed, E., Goldney, R., Lambert, T., Tiller, J., and Johnston, R., A double-blind, multicentre study to assess the tolerability and efficacy of paroxetine compared with amitriptyline in the treatment of depressed patients in Australian general practice. Aust N Z J Psychiatry 1999 Jun;33[3]:416-421
Finkel, S. I., Richter, E. M., Clary, C. M., and Batzar, E., Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry 1999;7[3]:221-227
Guelfi, J. D., Bouhassira, M., Bonett-Perrin, E., and Lancrenon, S., [The study of the efficacy of fluoxetine versus tianeptine in the treatment of elderly depressed patients followed in general practice]. Encephale 1999 May;25[3]:265-270
Zitterl, W., Meszaros, K., Hornik, K., Twaroch, T., Dossenbach, M., Zitterl-Eglseer, K., and Zapotoczky, H. G., Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. Wien Klin Wochenschr 1999 Jun4;111[11]:439-442
Delgado, P. L., Miller, H. L., Salomon, R. M., Licinio, J., Krystal, J. H., Moreno, F. A., Heninger, G. R., and Charney, D. S., Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999Jul15;46[2]:212-220
Jermain, D. M., Preece, C. K., Sykes, R. L., Kuehl, T. J., and Sulak, P. J., Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999 Jul;8[4]:328-332
Simon, G. E., Heiligenstein, J., Revicki, D., VonKorff, M., Katon, W. J., Ludman, E., Grothaus, L., and Wagner, E., Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. Arch Fam Med 1999 Jul;8[4]:319-325
Lapatto-Reiniluoto, O., Kivisto, K. T., and Neuvonen, P. J., Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram. Br J Clin Pharmacol 1999 Aug;48[2]:148-153
Steiner, M., Streiner, D. L., Steinberg, S., Stewart, D., Carter, D., Berger, C., Reid, R., and Grover, D., The measurement of premenstrual mood symptoms. J Affect Disord 1999 Jun;53[3]:269-273
Bakker, A., Spinhoven, P., van Balkom, A. J., Matser, D., and van Dyck, R., Double-blindness procedure did not mask giving of medication in panic disorder. J Affect Disord 1999 Jul;54[1-2]:189-192
Agosti, V., One year clinical and psychosocial outcomes of early-onset chronic depression. J Affect Disord 1999 Jul;54[1-2]:171-175
Chouinard, G., Saxena, B., Belanger, M. C., Ravindran, A., Bakish, D., Beauclair, L., Morris, P., Vasavan Nair, N. P., Manchanda, R., Reesal, R., Remick, R., and O’Neill, M. C., A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999 Jul;54[1-2]:39-48
Oguzhanoglu, A., Sahiner, T., Kurt, T., and Akalin, O., Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches. Cephalalgia 1999 Jun;19[5]:531-532
Zajecka, J., Amsterdam, J. D., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Tamura, R. N., Sundell, K. L., Michelson, D., and Beasley, C. M., Jr., Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999 Jun;60[6]:389-394
Nelson, J. C., Kennedy, J. S., Pollock, B. G., Laghrissi-Thode, F., Narayan, M., Nobler, M. S., Robin, D. W., Gergel, I., McCafferty, J., and Roose, S., Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999 Jul;156[7]:1024-1028
Blaha, J., Svobodova, K., and Kapounkova, Z., Therapeutical aspects of using citalopram in burns. Acta Chir Plast 1999;41[1]:25-32
Stomati, M., Rubino, S., Spinetti, A., Parrini, D., Luisi, S., Casarosa, E., Petraglia, F., and Genazzani, A. R., Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecol Endocrinol 1999 Feb;13[1]:15-25
Croft, H., Settle E Jr, Houser, T., Batey, S. R., Donahue, R. M., and Ascher, J. A., A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr;21[4]:643-658
Tiller, J. W., Bouwer, C., and Behnke, K., Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 1999;249 Suppl 1:S7-10
Klein, D. N., Schatzberg, A. F., McCullough, J. P., Keller, M. B., Dowling, F., Goodman, D., Howland, R. H., Markowitz, J. C., Smith, C., Miceli, R., and Harrison, W. M., Early- versus late-onset dythymic disorder: comparison in out-patients with superimposed major depressive episodes. J Affect Disord 1999 Jan;52[1-3]:187-196
Bitsios, P., Szabadi, E., and Bradshaw, C. M., Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berl) 1999 Apr;143[3]:286-292
Landen, M., Eriksson, E., Agren, H., and Fahlen, T., Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999 Jun;19[3]:268-271
Stein, D. J., Berk, M., Els, C., Emsley, R. A., Gittelson, L., Wilson, D., Oakes, R., and Hunter, B., A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J 1999 Apr;89[4]:402-406
Harrer, G., Schmidt, U., Kuhn, U., and Biller,, A. Comparison of equivalence between the St. John’s wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999 Apr;49[4]:289-296
Cook, I. A., Leuchter, A. F., Witte, E., Abrams, M., Uijtdehaage, S. H., Stubbeman, W., Rosenberg-Thompson, S., Anderson-Hanley, C., and Dunkin, J. J., Neurophysiologic predictors of treatment response to fluoxetine in major depression. Psychiatry Res 1999 Mar22;85[3]:263-273
Stassen, H. H., Angst, J., and Delini-Stula, A., Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry 1999 Mar;32[2]:56-60
McMahon, C. G. and Touma, K., Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol 1999 Jun;161[6]:1826-1830
Berman, R. M., Anand, A., Cappiello, A., Miller, H. L., Hu, X. S., Oren, D. A., and Charney, D. S., The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999 May1;45[9]:1170-1177
Stein, M. B., Fyer, A. J., Davidson, J. R., Pollack, M. H., and Wiita, B., Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999 May;156[5]:756-760
Rihet, P., Hasbroucq, T., Blin, O., and Possamai, C. A., Serotonin and human information processing: an electromyographic study of the effects of fluvoxamine on choice reaction time. Neurosci Lett 1999 Apr16;265[2]:143-146
Wilens, T. E., Biederman, J., March, J. S., Wolkow, R., Fine, C. S., Millstein, R. B., Faraone, S. V., Geller, D., and Spencer, T. J., Absence of cardiovascular adverse effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999 May;38[5]:573-577
Malt, U. F., Robak, O. H., Madsbu, H. P., Bakke, O., and Loeb, M., The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study. BMJ 1999 May1;318[7192]:1180-1184
Massana, J., Moller, H. J., Burrows, G. D., and Montenegro, R. M., Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999 Mar;14[2]:73-80
Cornelius, J. R., Perkins, K. A., Salloum, I. M., Thase, M. E., and Moss, H. B., Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients. J Clin Psychopharmacol 1999 Apr;19[2]:183-184
Maes, M., Libbrecht, I., van Hunsel, F., Campens, D., and Meltzer, H. Y., Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999 Apr;19[2]:177-182
Kronig, M. H., Apter, J., Asnis, G., Bystritsky, A., Curtis, G., Ferguson, J., Landbloom, R., Munjack, D., Riesenberg, R., Robinson, D., Roy-Byrne, P., Phillips, K., and Du, Pont, I., Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 1999 Apr;19[2]:172-176
Bauer, M., Zaninelli, R., Muller-Oerlinghausen, B., and Meister, W., Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol 1999 Apr;19[2]:164-171
Alfaro, C. L., Lam, Y. W., Simpson, J., and Ereshefsky, L., CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999 Apr;19[2]:155-163
Schwartz, J. A. and McDaniel, J. S., Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety 1999;9[2]:70-74
Mendels, J., Kiev, A., and Fabre, L. F., Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety 1999;9[2]:54-60
Perez, V., Soler, J., Puigdemont, D., Alvarez, E., and Artigas, F., A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 1999 Apr;56[4]:375-379
Di Girolamo, E., Di Iorio, C., Sabatini, P., Leonzio, L., Barbone, C., and Barsotti, A., Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999 Apr;33[5]:1227-1230
Spigset, O., Hagg, S., Soderstrom, E., and Dahlqvist, R., Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Eur J Clin Pharmacol 1999 Feb;54[12]:943-946
Finkel, S. I., Richter, E. M., and Clary, C. M., Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Int Psychogeriatr 1999 Mar;11[1]:85-99
Zhu, C. J., Wu, J. F., Qu, Z. W., Chen, L. M., and Zhang, J. T., Bioequivalence evaluation of two sertraline tablet formulations in healthy male volunteers after a single dose administration. Int J Clin Pharmacol Ther 1999 Mar;37[3]:120-124
Cornelius, J. R., Salloum, I. M., Haskett, R. F., Ehler, J. G., Jarrett, P. J., Thase, M. E., and Perel, J. M., Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 1999 Jan;24[1]:111-114
Bajo, S., Battaglia, M., Pegna, C., and Bellodi, L., Citalopram and fluvoxamine in Tourette’s disorder. J Am Acad Child Adolesc Psychiatry 1999 Mar;38[3]:230-231
Postolache, T. T., Rosenthal, R. N., Hellerstein, D. J., Aromin, R., Kelton, G. M., Muran, J. C., and Londono, J. H., Early augmentation of sertraline with methylphenidate. J Clin Psychiatry 1999 Feb;60[2]:123-124
Vallee, J. P., [Generalized social phobias, are they sufficiently recognised and treated?]. Presse Med 1999Feb20;28[7]:340-341
Silverstone, P. H. and Ravindran, A., Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999 Jan;60[1]:22-28
de Beurs, E., van Balkom, A. J., van Dyck, R., and Lange, A., Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatr Scand 1999 Jan;99[1]:59-67
Yilmaz, U., Tatlisen, A., Turan, H., Arman, F., and Ekmekcioglu, O., The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. J Urol 1999 Jan;161[1]:107-111
Borrelli, B., Spring, B., Niaura, R., Kristeller, J., Ockene, J. K., and Keuthen, N. J., Weight suppression and weight rebound in ex-smokers treated with fluoxetine. J Consult Clin Psychol 1999 Feb;67[1]:124-131
Kavoussi, R. J., Hauger, R. L., and Coccaro, E. F., Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors. Biol Psychiatry 1999 Feb1;45[3]:295-299
Mundo, E., Bareggi, S. R., Pirola, R., and Bellodi, L., Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?. Biol Psychiatry 1999 Feb1;45[3]:290-294
Kraiczi, H., Hedner, J., Dahlof, P., Ejnell, H., and Carlson, J., Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999 Feb1;22[1]:61-67
Fava, M., Amsterdam, J. D., Deltito, J. A., Salzman, C., Schwaller, M., and Dunner, D. L., A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998 Dec;10[4]:145-150
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., and Beasley, C., Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999 Feb;19[1]:9-14
Freeman, E. W., Rickels, K., Arredondo, F., Kao, L. C., Pollack, S. E., and Sondheimer, S. J., Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999 Feb;19[1]:3-8
Biri, H., Isen, K., Sinik, Z., Onaran, M., Kupeli, B., and Bozkirli, I., Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. Int Urol Nephrol 1998;30[5]:611-615
Marchesi, C., Ceccherininelli, A., Rossi, A., and Maggini, C., Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline. Pharmacopsychiatry 1998 Nov;31[6]:216-221
Schlosser, R., Roschke, J., Rossbach, W., and Benkert, O., Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 1998 Dec;8[4]:273-278
Goldstein, D. J., Wilson, M. G., Ascroft, R. C., and Al Banna, M., Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord 1999 Jan;25[1]:19-27
Lamberg, T. S., Kivisto, K. T., Laitila, J., Martensson, K., and Neuvonen, P. J., The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur J Clin Pharmacol 1998 Nov;54[9-10]:761-766
Hirschfeld, R. M., Russell, J. M., Delgado, P. L., Fawcett, J., Friedman, R. A., Harrison, W. M., Koran, L. M., Miller, I. W., Thase, M. E., Howland, R. H., Connolly, M. A., and Miceli, R. J., Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998 Dec;59[12]:669-675
Landen, M., Bjorling, G., Agren, H., and Fahlen, T., A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998 Dec;59[12]:664-668
Stanley, N., Fairweather, D. B., and Hindmarch, I., Effects of fluoxetine and dothiepin on 24-hour activity in depressed patients. Neuropsychobiology 1999;39[1]:44-48
Rabkin, J. G., Wagner, G. J., and Rabkin, R., Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999 Jan;156[1]:101-107
Greenberg, B. D., Benjamin, J., Martin, J. D., Keuler, D., Huang, S. J., Altemus, M., and Murphy, D. L., Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology (Berl) 1998 Dec;140[4]:434-444
Brown, K. W., Sloan, R. L., and Pentland, B., Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatr Scand 1998 Dec;98[6]:455-458
Moraes, M. E., Lerner, F. E., Perozin, M., Moraes, M. O., Frota Bezerra, F. A., Sucupira, M., Corso, G., and De Nucci, G., Comparative bioavailability of two sertraline tablet formulations in healthy human volunteers after a single dose administration. Int J Clin Pharmacol Ther 1998 Dec;36[12]:661-665
Kyle, C. J., Petersen, H. E., and Overo, K. F., Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998;8[4]:147-153
Zanardi, R., Franchini, L., Gasperini, M., Lucca, A., Smeraldi, E., and Perez, J., Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol 1998 Dec;18[6]:441-446
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Schweizer, E., and Beasley, C., Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998 Dec;18[6]:435-440
Miller, I. W., Keitner, G. I., Schatzberg, A. F., Klein, D. N., Thase, M. E., Rush, A. J., Markowitz, J. C., Schlager, D. S., Kornstein, S. G., Davis, S. M., Harrison, W. M., and Keller, M. B., The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998 Nov;59[11]:608-619
Keller, M. B., Gelenberg, A. J., Hirschfeld, R. M., Rush, A. J., Thase, M. E., Kocsis, J. H., Markowitz, J. C., Fawcett, J. A., Koran, L. M., Klein, D. N., Russell, J. M., Kornstein, S. G., McCullough, J. P., Davis, S. M., and Harrison, W. M., The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998 Nov;59[11]:598-607
Rush, A. J., Koran, L. M., Keller, M. B., Markowitz, J. C., Harrison, W. M., Miceli, R. J., Fawcett, J. A., Gelenberg, A. J., Hirschfeld, R. M., Klein, D. N., Kocsis, J. H., McCullough, J. P., Schatzberg, A. F., and Thase, M. E., The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 1998 Nov;59[11]:589-597
Strik, J. J., Honig, A., Lousberg, R., Cheriex, E. C., and Van Praag, H. M., Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients. Int Clin Psychopharmacol 1998 Nov;13[6]:263-267
Smeraldi, E., Zanardi, R., Benedetti, F., Di Bella, D., Perez, J., and Catalano, M., Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998 Nov;3[6]:508-511
Montgomery, S. A., Implications of the severity of social phobia. J Affect Disord 1998 Sep;50 Suppl 1:S17-S22
Londborg, P. D., Wolkow, R., Smith, W. T., DuBoff, E., England, D., Ferguson, J., Rosenthal, M., and Weise, C., Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998 Jul;173:54-60
March, J. S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E. H., Cutler, N. R., Dominguez, R., Ferguson, J., Muller, B., Riesenberg, R., Rosenthal, M., Sallee, F. R., Wagner, K. D., and Steiner, H., Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998Nov25;280[20]:1752-1756
Hudson, J. I., McElroy, S. L., Raymond, N. C., Crow, S., Keck, P. E., Jr., Carter, W. P., Mitchell, J. E., Strakowski, S. M., Pope, H. G., Jr., Coleman, B. S., and Jonas, J. M., Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998 Dec;155[12]:1756-1762
Arlander, E., Ekstrom, G., Alm, C., Carrillo, J. A., Bielenstein, M., Bottiger, Y., Bertilsson, L., and Gustafsson, L. L., Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 1998 Nov;64[5]:484-491
Keller, M. B., Kocsis, J. H., Thase, M. E., Gelenberg, A. J., Rush, A. J., Koran, L., Schatzberg, A., Russell, J., Hirschfeld, R., Klein, D., McCullough, J. P., Fawcett, J. A., Kornstein, S., LaVange, L., and Harrison, W., Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998 Nov18;280[19]:1665-1672
Moller, H. J., Gallinat, J., Hegerl, U., Arato, M., Janka, Z., Pflug, B., and Bauer, H., Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry 1998 Sep;31[5]:170-177
Hohagen, F., Winkelmann, G., Rasche-Ruchle, H., Hand, I., Konig, A., Munchau, N., Hiss, H., Geiger-Kabisch, C., Kappler, C., Schramm, P., Rey, E., Aldenhoff, J., and Berger, M., Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl 1998;[35]:71-78
Wearden, A. J., Morriss, R. K., Mullis, R., Strickland, P. L., Pearson, D. J., Appleby, L., Campbell, I. T., and Morris, J. A., Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 1998 Jun;172:485-490
Pollack, M. H., Otto, M. W., Worthington, J. J., Manfro, G. G., and Wolkow, R., Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998 Nov;55[11]:1010-1016
Lepola, U. M., Wade, A. G., Leinonen, E. V., Koponen, H. J., Frazer, J., Sjodin, I., Penttinen, J. T., Pedersen, T., and Lehto, H. J., A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998 Oct;59[10]:528-534
Massana, J., Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59 Suppl 14:8-10
Mundo, E., Guglielmo, E., and Bellodi, L., Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998 Sep;13[5]:219-224
Ekselius, L. and von Knorring, L., Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. Int Clin Psychopharmacol 1998 Sep;13[5]:205-211
Michelson, D., Lydiard, R. B., Pollack, M. H., Tamura, R. N., Hoog, S. L., Tepner, R., Demitrack, M. A., and Tollefson, G. D., Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998 Nov;155[11]:1570-1577
Emslie, G. J., Weinberg, W. A., and Mayes, T. L., Treatment of children with antidepressants: focus on selective serotonin reuptake inhibitors. Depress Anxiety 1998;8 Suppl 1:13-17
Lee, M. S., Kim, Y. K., Lee, S. K., and Suh, K. Y., A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998 Oct;18[5]:399-403.. 9790158
Wikander, I., Sundblad, C., Andersch, B., Dagnell, I., Zylberstein, D., Bengtsson, F., and Eriksson, E., Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?. J Clin Psychopharmacol 1998 Oct;18[5]:390-398
Roy, A., Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry 1998 Oct1;44[7]:633-637
Kirli, S. and Caliskan, M., A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 1998 Sep7;33[1-2]:103-111
Bordet, R., Thomas, P., and Dupuis, B., Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d’Experimentation Psychopharmacologique. Am J Psychiatry 1998 Oct;155[10]:1346-1351
Smith, W. T., Londborg, P. D., Glaudin, V., and Painter, J. R., Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry 1998 Oct;155[10]:1339-1345
Sandmann, J., Lorch, B., Bandelow, B., Hartter, S., Winter, P., Hiemke, C., and Benkert, O., Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 1998 Jul;31[4]:117-121
Wynchank, D. and Berk, M., Fluoxetine treatment of acral lick dermatitis in dogs: a placebo-controlled randomized double blind trial. Depress Anxiety 1998;8[1]:21-23
Letizia, C., Kapik, B., and Flanders, W. D., Suicidal risk during controlled clinical investigations of fluvoxamine. J Clin Psychiatry 1996 Sep;57[9]:415-421
Holland, J. C., Romano, S. J., Heiligenstein, J. H., Tepner, R. G., and Wilson, M. G., A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998 Jul;7[4]:291-300
Reimherr, F. W., Amsterdam, J. D., Quitkin, F. M., Rosenbaum, J. F., Fava, M., Zajecka, J., Beasley, C. M., Jr., Michelson, D., Roback, P., and Sundell, K., Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998 Sep;155[9]:1247-1253
Pohl, R. B., Wolkow, R. M., and Clary, C. M., Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998 Sep;155[9]:1189-1195
Kramer, M. S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J. J., Reines, S. A., Liu, G., Snavely, D., Wyatt-Knowles, E., Hale, J. J., Mills, S. G., MacCoss, M., Swain, C. J., Harrison, T., Hill, R. G., Hefti, F., Scolnick, E. M., Casci, Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998 Sep11;281[5383]:1640-1645
Stein, M. B., Liebowitz, M. R., Lydiard, R. B., Pitts, C. D., Bushnell, W., and Gergel, I., Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998 Aug26;280[8]:708-713
Tome, M. B. and Isaac, M. T., Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo. Int Clin Psychopharmacol 1998 Jul;13[4]:175-182
Tome, M. B. and Isaac, M. T., One year real world prospective follow-up study of a major depressive episode of patients treated with paroxetine and pindolol or paroxetine for 6 weeks. Int Clin Psychopharmacol 1998 Jul;13[4]:169-174
Ruhrmann, S., Kasper, S., Hawellek, B., Martinez, B., Hoflich, G., Nickelsen, T., and Moller, H. J., Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 1998 Jul;28[4]:923-933
Diegoli, M. S., da Fonseca, A. M., Diegoli, C. A., and Pinotti, J. A., A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998 Jul;62[1]:63-67
Black, D. W., Monahan, P., Gable, J., Blum, N., Clancy, G., and Baker, P., Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry 1998 Aug;59[8]:420-425
Costa e Silva., Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998 Jul;59[7]:352-357
van Balkom, A. J., de Haan, E., van Oppen, P., Spinhoven, P., Hoogduin, K. A., and van Dyck, R., Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998 Aug;186[8]:492-499
Pollock, B. G., Mulsant, B. H., Nebes, R., Kirshner, M. A., Begley, A. E., Mazumdar, S., and Reynolds, C. F., III., Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 1998 Aug;155[8]:1110-1112
Dolberg, O. T., Hirschmann, S., and Grunhaus, L., Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998 Aug;155[8]:1119-1121
Landabaso, M. A., Iraurgi, I., Jimenez-Lerma, J. M., Sanz, J., Fernadez, de Corres, Araluce, K., Calle, R., and Gutierrez-Fraile, M., A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction 1998 May;93[5]:739-744
Guelfi, J. D., Ansseau, M., Corruble, E., Samuelian, J. C., Tonelli, I., Tournoux, A., and Pletan, Y., A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 1998 May;13[3]:121-128
Waldinger, M. D., Hengeveld, M. W., Zwinderman, A. H., and Olivier, B., Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998 Aug;18[4]:274-281
Joffe, P., Larsen, F. S., Pedersen, V., Ring-Larsen, H., Aaes-Jorgensen, T., and Sidhu, J., Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998 May;54[3]:237-242
Steiner, T. J., Ahmed, F., Findley, L. J., MacGregor, E. A., and Wilkinson, M., S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998 Jun;18[5]:283-286
Wheatley, D. P., van Moffaert, M., Timmerman, L., and Kremer, C. M., Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 1998 Jun;59[6]:306-312
Terra, J. L. and Montgomery, S. A., Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998 Mar;13[2]:55-62
Diaz-Martinez, A., Benassinni, O., Ontiveros, A., Gonzalez, S., Salin, R., Basquedano, G., and Martinez, R. A., A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 1998 May;20[3]:467-476
Smith, D. A., Cleary, E. W., Watkins, S., Huffman, C. S., and Polvino, W. J., Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. Int J Clin Pharmacol Ther 1998 Jun;36[6]:301-305
Petrakis, I., Carroll, K. M., Nich, C., Gordon, L., Kosten, T., and Rounsaville, B., Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend 1998 May1;50[3]:221-226
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., and Krebs, W. B., Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998 Jul15;44[2]:77-87
Rush, A. J., Armitage, R., Gillin, J. C., Yonkers, K. A., Winokur, A., Moldofsky, H., Vogel, G. W., Kaplita, S. B., Fleming, J. B., Montplaisir, J., Erman, M. K., Albala, B. J., and McQuade, R. D., Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998Jul1;44[1]:3-14
Franchini, L., Gasperini, M., Perez, J., Smeraldi, E., and Zanardi, R., Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry 1998 May;59[5]:229-232
Zisook, S., Peterkin, J., Goggin, K. J., Sledge, P., Atkinson, J. H., and Grant, I., Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 1998 May;59[5]:217-224
Baumann, P., Nil, R., Bertschy, G., Jecker, A., Brandli, H., Morand, J., Kasas, A., Vuagniaux, O., and Ramseier, F., A double-blind double-dummy study of citalopram comparing infusion versus oral administration. J Affect Disord 1998 Jun;49[3]:203-210
Zajecka, J., Fawcett, J., Amsterdam, J., Quitkin, F., Reimherr, F., Rosenbaum, J., Michelson, D., and Beasley, C., Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 1998 Jun;18[3]:193-197
Sandor, P., Baker, B., Irvine, J., Dorian, P., McKessok, D., and Mendlowitz, S., Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients. Depress Anxiety 1998;7[2]:69-72
Aberg-Wistedt, A., Hasselmark, L., Stain-Malmgren, R., Aperia, B., Kjellman, B. F., and Mathe, A. A., Serotonergic ’vulnerability’ in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand 1998 May;97[5]:374-380
Schmitz, J. M., Rhoades, H. M., Elk, R., Creson, D., Hussein, I., and Grabowski, J., Medication take-home doses and contingency management. Exp Clin Psychopharmacol 1998 May;6[2]:162-168
Huang, C. C., Chian, C. Y., and Lin, J. D., Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. Changgeng Yi Xue Za Zhi 1998 Mar;21[1]:50-56
McMahon, C. G., Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998 Jun;159[6]:1935-1938
Emslie, G. J., Rush, A. J., Weinberg, W. A., Kowatch, R. A., Carmody, T., and Mayes, T. L., Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 1998;7[1]:32-39
Berlin, I., Warot, D., Legout, V., Guillemant, S., Schollnhammer, G., and Puech, A. J., Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther 1998 Apr;63[4]:428-436
Dingemanse, J., Wallnofer, A., Gieschke, R., Guentert, T., and Amrein, R., Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome". Clin Pharmacol Ther 1998 Apr;63[4]:403-413
Wagner, G. J., Maguen, S., and Rabkin, J. G., Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv 1998 Feb;49[2]:239-240
Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A., and Scharpe, S., Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998 Apr;97[4]:302-308
Blumenfield, M., Levy, N. B., Spinowitz, B., Charytan, C., Beasley, C. M., Jr., Dubey, A. K., Solomon, R. J., Todd, R., Goodman, A., and Bergstrom, R. F., Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med 1997;27[1]:71-80
Angelone, S. M., Bellini, L., Di Bella, D., and Catalano, M., Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics. Alcohol Alcohol 1998 Mar;33[2]:151-156
Cornelius, J. R., Salloum, I. M., Thase, M. E., Haskett, R. F., Daley, D. C., Jones-Barlock, A., Upsher, C., and Perel, J. M., Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull 1998;34[1]:117-121
Dam, J., Ryde, L., Svejso, J., Lauge, N., Lauritsen, B., and Bech, P., Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998 Mar;31[2]:48-54
Stewart, J. W., Quitkin, F. M., McGrath, P. J., Amsterdam, J., Fava, M., Fawcett, J., Reimherr, F., Rosenbaum, J., Beasley, C., and Roback, P., Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998 Apr;55[4]:334-343
Ekselius, L., von Knorring, L., and Eberhard, G., A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997 Nov;12[6]:323-331
Attia, E., Haiman, C., Walsh, B. T., and Flater, S. R., Does fluoxetine augment the inpatient treatment of anorexia nervosa?. Am J Psychiatry 1998 Apr;155[4]:548-551
Verkes, R. J., Van der Mast, R. C., Hengeveld, M. W., Tuyl, J. P., Zwinderman, A. H., and Van Kempen, G. M., Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 1998 Apr;155[4]:543-547
Sargent, P. A., Williamson, D. J., and Cowen, P. J., Brain 5-HT neurotransmission during paroxetine treatment. Br J Psychiatry 1998 Jan;172:49-52
Khaykin, Y., Dorian, P., Baker, B., Shapiro, C., Sandor, P., Mironov, D., Irvine, J., and Newman, D., Autonomic correlates of antidepressant treatment using heart-rate variability analysis. Can J Psychiatry 1998 Mar;43[2]:183-186
Engel, C. C., Jr., Walker, E. A., Engel, A. L., Bullis, J., and Armstrong, A., A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain. J Psychosom Res 1998 Feb;44[2]:203-207
Katona, C. L., Hunter, B. N., and Bray, J., A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998 Feb;13[2]:100-108
Simeon, D., Stein, D. J., Gross, S., Islam, N., Schmeidler, J., and Hollander, E., A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry 1997 Aug;58[8]:341-347
Young, S. A., Hurt, P. H., Benedek, D. M., and Howard, R. S., Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998 Feb;59[2]:76-80
Simon, G. E., Heiligenstein, J. H., Grothaus, L., Katon, W., and Revicki, D., Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. J Clin Psychiatry 1998 Feb;59[2]:49-55
Knutson, B., Wolkowitz, O. M., Cole, S. W., Chan, T., Moore, E. A., Johnson, R. C., Terpstra, J., Turner, R. A., and Reus, V. I., Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998 Mar;155[3]:373-379
Elliott, A. J., Uldall, K. K., Bergam, K., Russo, J., Claypoole, K., and Roy-Byrne, P. P., Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998 Mar;155[3]:367-372
Bonaccorso, S., Lin, A. H., Verkerk, R., van Hunsel, F., Libbrecht, I., Scharpe, S., DeClerck, L., Biondi, M., Janca, A., and Maes, M., Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers. J Affect Disord 1998 Feb;48[1]:75-82
Smeraldi, E., Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord 1998 Feb;48[1]:47-56
Ackerman, D. L., Greenland, S., Bystritsky, A., and Small, G. W., Characteristics of fluoxetine versus placebo responders in a randomized trial of geriatric depression. Psychopharmacol Bull 1997;33[4]:707-714
Bienert, S. E., Use of SSRIs in children. J Fam Pract 1998 Feb;46[2]:118
Skarstein, J., [A "trouble-blind" placebo-controlled comparative study between two new antidepressive agents]. Tidsskr Nor Laegeforen 1998Jan20;118[2]:265-266
Pidrman, V. and Tuma, I., Fenfluramine challenge test in obsessive-compulsive disorder--first results. Acta Medica (Hradec Kralove) 1997;40[4]:99-102
Tiller, J. W., Bouwer, C., and Behnke, K., Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. Int Clin Psychopharmacol 1997 Oct;12 Suppl 6:S27-S30
Roose, S. P., Laghrissi-Thode, F., Kennedy, J. S., Nelson, J. C., Bigger, J. T., Jr., Pollock, B. G., Gaffney, A., Narayan, M., Finkel, M. S., McCafferty, J., and Gergel, I., Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998Jan28;279[4]:287-291
Kavoussi, R. J., Segraves, R. T., Hughes, A. R., Ascher, J. A., and Johnston, J. A., Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997 Dec;58[12]:532-537
Auchus, A. P. and Bissey-Black, C., Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1997;9[4]:591-593
Guthrie, S. K., Hariharan, M., Kumar, A. A., Bader, G., and Tandon, R., The effect of paroxetine on thiothixene pharmacokinetics. J Clin Pharm Ther 1997 Jun;22[3]:221-226
Evans, M., Hammond, M., Wilson, K., Lye, M., and Copeland, J., Treatment of depression in the elderly: effect of physical illness on response. Int J Geriatr Psychiatry 1997 Dec;12[12]:1189-1194
Dubini, A., Bosc, M., and Polin, V., Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997;11[4 Suppl]:S17-S23
Ballenger, J. C., Wheadon, D. E., Steiner, M., Bushnell, W., and Gergel, I. P., Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998 Jan;155[1]:36-42
Lydiard, R. B., Stahl, S. M., Hertzman, M., and Harrison, W. M., A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997 Nov;58[11]:484-491
Baraczka, K., Janko, Z., Vargha, K., and Markus, H., [Clinical experiences with the analgesic effects of citalopram]. Orv Hetil 1997 Oct12;138[41]:2605-2607
Martin, D. E., Zussman, B. D., Everitt, D. E., Benincosa, L. J., Etheredge, R. C., and Jorkasky, D. K., Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Psychopharmacol 1997 Dec;17[6]:451-459
Zanardi, R., Artigas, F., Franchini, L., Sforzini, L., Gasperini, M., Smeraldi, E., and Perez, J., How long should pindolol be associated with paroxetine to improve the antidepressant response?. J Clin Psychopharmacol 1997 Dec;17[6]:446-450
[Chronic depression in the year 2000: therapeutic hopes. 10th World Congress for Psychiatry. Madrid, 24 August 1996]. Fortschr Neurol Psychiatr 1996 Dec;64[12 Suppl Chronische]:1-4
Coccaro, E. F. and Kavoussi, R. J., Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997 Dec;54[12]:1081-1088
Flint, A., The impact of treatment resistance on depressive relapse following electroconvulsive therapy. Acta Psychiatr Scand 1997 Nov;96[5]:405-406
de Haan, E., van Oppen, P., van Balkom, A. J., Spinhoven, P., Hoogduin, K. A., and van Dyck, R., Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand 1997 Nov;96[5]:354-361
Folkerts, H. W., Michael, N., Tolle, R., Schonauer, K., Mucke, S., and Schulze-Monking, H., Electroconvulsive therapy vs. paroxetine in treatment-resistant depression -- a randomized study. Acta Psychiatr Scand 1997 Nov;96[5]:334-342
Boyer, P., Danion, J. M., Bisserbe, J. C., Hotton, J. M., and Troy, S., Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998 Jan;13[1 Pt 2]:157-169
Emslie, G. J., Rush, A. J., Weinberg, W. A., Kowatch, R. A., Hughes, C. W., Carmody, T., and Rintelmann, J., A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997 Nov;54[11]:1031-1037
Quested, D. J., Sargent, P. A., and Cowen, P. J., SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology (Berl) 1997 Oct;133[3]:305-308
Steiner, M., Lamont, J., Steinberg, S., Stewart, D., Reid, R., and Streiner, D., Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. Obstet Gynecol 1997 Oct;90[4 Pt 1]:590-595
Dalery, J., Rochat, C., Peyron, E., and Bernard, G., The efficacy and acceptability of amineptine versus fluoxetine in major depression. Int Clin Psychopharmacol 1997 Jul;12 Suppl 3:S35-S38
Yonkers, K. A., Halbreich, U., Freeman, E., Brown, C., Endicott, J., Frank, E., Parry, B., Pearlstein, T., Severino, S., Stout, A., Stone, A., and Harrison, W., Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997 Sep24;278[12]:983-988
Halbreich, U. and Smoller, J. W., Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997 Sep;58[9]:399-402
Scahill, L., Riddle, M. A., King, R. A., Hardin, M. T., Rasmusson, A., Makuch, R. W., and Leckman, J. F., Fluoxetine has no marked effect on tic symptoms in patients with Tourette’s syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1997;7[2]:75-85
Ozdemir, V., Naranjo, C. A., Herrmann, N., Reed, K., Sellers, E. M., and Kalow, W., Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997 Sep;62[3]:334-347
Jeppesen, U., Rasmussen, B. B., and Brosen, K., Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997 Sep;62[3]:279-286
Laine, K., Anttila, M., Heinonen, E., Helminen, A., Huupponen, R., Maki-Ikola, O., Reinikainen, K., and Scheinin, M., Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997 Oct;20[5]:419-433
Monteleone, P., Catapano, F., Di Martino, S., Ferraro, C., and Maj, M., Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment. Br J Psychiatry 1997 Jun;170:554-557
Wade, A. G., Lepola, U., Koponen, H. J., Pedersen, V., and Pedersen, T., The effect of citalopram in panic disorder. Br J Psychiatry 1997 Jun;170:549-553
Goldstein, D. J., Hamilton, S. H., Masica, D. N., and Beasley, C. M., Jr., Fluoxetine in medically stable, depressed geriatric patients: effects on weight. J Clin Psychopharmacol 1997 Oct;17[5]:365-369
Maes, M., Westenberg, H., Vandoolaeghe, E., Demedts, P., Wauters, A., Neels, H., and Meltzer, H. Y., Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 1997 Oct;17[5]:358-364
Coccaro, E. F., Kavoussi, R. J., and Hauger, R. L., Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol Psychiatry 1997 Oct1;42[7]:546-552
Oakley, F. and Sunderland, T., Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer’s disease: a pilot study. Int Psychogeriatr 1997 Jun;9[2]:197-206
Goldbloom, D. S., Olmsted, M., Davis, R., Clewes, J., Heinmaa, M., Rockert, W., and Shaw, B., A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. Behav Res Ther 1997 Sep;35[9]:803-811
Szegedi, A., Wetzel, H., Angersbach, D., Philipp, M., and Benkert, O., Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline. J Affect Disord 1997 Sep;45[3]:167-178
Sargent, P., Williamson, D. J., Pearson, G., Odontiadis, J., and Cowen, P. J., Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity. Psychopharmacology (Berl) 1997 Aug;132[3]:296-302
Barr, L. C., Goodman, W. K., Anand, A., McDougle, C. J., and Price, L. H., Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 1997 Sep;154[9]:1293-1295
Jenike, M. A., Baer, L., Minichiello, W. E., Rauch, S. L., and Buttolph, M. L., Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997 Sep;154[9]:1261-1264
Naranjo, C. A., Bremner, K. E., Bazoon, M., and Turksen, I. B., Using fuzzy logic to predict response to citalopram in alcohol dependence. Clin Pharmacol Ther 1997 Aug;62[2]:209-224
Kurtz, D. L., Bergstrom, R. F., Goldberg, M. J., and Cerimele, B. J., The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997 Aug;62[2]:145-156
Evans, M., Hammond, M., Wilson, K., Lye, M., and Copeland, J., Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry 1997 Aug;12[8]:817-824
Cornelius, J. R., Salloum, I. M., Ehler, J. G., Jarrett, P. J., Cornelius, M. D., Perel, J. M., Thase, M. E., and Black, A., Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997 Aug;54[8]:700-705
Priskorn, M., Sidhu, J. S., Larsen, F., Davis, J. D., Khan, A. Z., and Rolan, P. E., Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997 Aug;44[2]:199-202
Beumont, P. J., Russell, J. D., Touyz, S. W., Buckley, C., Lowinger, K., Talbot, P., and Johnson, G. F., Intensive nutritional counselling in bulimia nervosa: a role for supplementation with fluoxetine?. Aust N Z J Psychiatry 1997 Aug;31[4]:514-524
Alderman, J., Preskorn, S. H., Greenblatt, D. J., Harrison, W., Penenberg, D., Allison, J., and Chung, M., Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997 Aug;17[4]:284-291
Mundo, E., Bianchi, L., and Bellodi, L., Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997 Aug;17[4]:267-271
Pearlstein, T. B., Stone, A. B., Lund, S. A., Scheft, H., Zlotnick, C., and Brown, W. A., Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997 Aug;17[4]:261-266
Isaac, M. T. and Tome, M. B, Selective serotonin reuptake inhibitors plus pindolol. Lancet 1997 Jul26;350[9073]:288-289
Hasbroucq, T., Rihet, P., Blin, O., and Possamai, C. A., Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neurosci Lett 1997Jul4;229[3]:204-208
Tome, M. B., Cloninger, C. R., Watson, J. P., and Isaac, M. T., Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. J Affect Disord 1997 Jul;44[2-3]:101-109
Serzone superior to Prozac. Ir Med J 1997 Jun;90[4]:156
Becquemont, L., Ragueneau, I., Le Bot, M. A., Riche, C., Funck-Brentano, C., and Jaillon, P., Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997 Jun;61[6]:619-627
Lewis-Hall, F. C., Wilson, M. G., Tepner, R. G., and Koke, S. C., Fluoxetine vs. tricyclic antidepressants in women with major depressive disorder. J Womens Health 1997 Jun;6[3]:337-343
Buni, T. M., Treatment of dysthymia. J Fam Pract 1997 Jun;44[6]:528-529
Torpy, D. J., Grice, J. E., Hockings, G. I., Walters, M. M., Crosbie, G. V., and Jackson, R. V., Diurnal effects of fluoxetine and naloxone on the human hypothalamic-pituitary-adrenal axis. Clin Exp Pharmacol Physiol 1997 Jun;24[6]:421-423
Perna, G., Bertani, A., Gabriele, A., Politi, E., and Bellodi, L., Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 1997 Jun;17[3]:173-178
Armitage, R., Yonkers, K., Cole, D., and Rush, A. J., A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 1997 Jun;17[3]:161-168
Perez, V., Gilaberte, I., Faries, D., Alvarez, E., and Artigas, F., Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997May31;349[9065]:1594-1597
Foglia, J. P., Sorisio, D., Kirshner, M., and Pollock, B. G., Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997May23;693[1]:147-151
Ramaekers, J. G., Ansseau, M., Muntjewerff, N. D., Sweens, J. P., and O’Hanlon, J. F., Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. Int Clin Psychopharmacol 1997 May;12[3]:159-169
Szegedi, A., Wetzel, H., Angersbach, D., Dunbar, G. C., Schwarze, H., Philipp, M., and Benkert, O., A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry 1997 May;30[3]:97-105
Fichter, M. M., Leibl, C., Kruger, R., and Rief, W., Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry 1997 May;30[3]:85-92
Rocca, P., Fonzo, V., Scotta, M., Zanalda, E., and Ravizza, L., Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997 May;95[5]:444-450
Gillin, J. C., Rapaport, M., Erman, M. K., Winokur, A., and Albala, B. J., A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 1997 May;58[5]:185-192
Como, P. G., Rubin, A. J., O’Brien, C. F., Lawler, K., Hickey, C., Rubin, A. E., Henderson, R., McDermott, M. P., McDermott, M., Steinberg, K., and Shoulson, I., A controlled trial of fluoxetine in nondepressed patients with Huntington’s disease. Mov Disord 1997 May;12[3]:397-401
Taragano, F. E., Lyketsos, C. G., Mangone, C. A., Allegri, R. F., and Comesana-Diaz, E., A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics 1997 May;38[3]:246-252
Barr, L. C., Heninger, G. R., Goodman, W., Charney, D. S., and Price, L. H., Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 1997May1;41[9]:949-954
Su, T. P., Schmidt, P. J., Danaceau, M. A., Tobin, M. B., Rosenstein, D. L., Murphy, D. L., and Rubinow, D. R., Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997 May;16[5]:346-356
Vanelle, J. M., Attar-Levy, D., Poirier, M. F., Bouhassira, M., Blin, P., and Olie, J. P., Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry 1997 Apr;170:345-350
Bosc, M., Dubini, A., and Polin, V., Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S57-S70
Dubini, A., Bosc, M., and Polin, V., Do noradrenaline and serotonin differentially affect social motivation and behaviour?. Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S49-S55
Kiev, A. and Feiger, A., A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997 Apr;58[4]:146-152
Benkert, O., Szegedi, A., Wetzel, H., Staab, H. J., Meister, W., and Philipp, M., Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 1997 Apr;95[4]:288-296
Waldinger, M. D., Hengeveld, M. W., and Zwinderman, A. H., Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. Br J Urol 1997 Apr;79[4]:592-595
Schneider, L. S., Small, G. W., Hamilton, S. H., Bystritsky, A., Nemeroff, C. B., and Meyers, B. S., Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry 1997;5[2]:97-106
Walsh, B. T., Wilson, G. T., Loeb, K. L., Devlin, M. J., Pike, K. M., Roose, S. P., Fleiss, J., and Waternaux, C., Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry 1997 Apr;154[4]:523-531
Ko, H. C., Lu, R. B., Shiah, I. S., and Hwang, C. C., Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine. Biol Psychiatry 1997Apr1;41[7]:774-781
Appleby, L., Warner, R., Whitton, A., and Faragher, B., A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997Mar29;314[7085]:932-936
Tome, M. B., Isaac, M. T., Harte, R., and Holland, C., Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997 Mar;12[2]:81-89
Sharp, D. M., Power, K. G., Simpson, R. J., Swanson, V., and Anstee, J. A., Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract 1997 Mar;47[416]:150-155
Ravindran, A. V., Judge, R., Hunter, B. N., Bray, J., and Morton, N. H., A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 1997 Mar;58[3]:112-118
Franchini, L., Gasperini, M., Perez, J., Smeraldi, E., and Zanardi, R., A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 1997 Mar;58[3]:104-107
Lapierre, Y. D., Joffe, R., McKenna, K., Bland, R., Kennedy, S., Ingram, P., Reesal, R., Rickhi, B. G., Beauclair, L., Chouinard, G., and Annable, L., Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci 1997 Mar;22[2]:118-126
Kocsis, J. H., Zisook, S., Davidson, J., Shelton, R., Yonkers, K., Hellerstein, D. J., Rosenbaum, J., and Halbreich, U., Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 1997 Mar;154[3]:390-395
Livingston, M. G. and Clark, A., Curvaceous model of recovery from depression. Lancet 1997Feb15;349[9050]:447
Giammusso, B., Morgia, G., Spampinato, A., and Motta, M., [Paroxetine in the treatment of premature ejaculation]. Arch Ital Urol Androl 1997 Feb;69[1]:11-13
Lecrubier, Y. and Judge, R., Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997 Feb;95[2]:153-160
Lecrubier, Y., Bakker, A., Dunbar, G., and Judge, R., A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997 Feb;95[2]:145-152
Shelton, R. C., Davidson, J., Yonkers, K. A., Koran, L., Thase, M. E., Pearlstein, T., and Halbreich, U., The undertreatment of dysthymia. J Clin Psychiatry 1997 Feb;58[2]:59-65
Maheux, P., Ducros, F., Bourque, J., Garon, J., and Chiasson, J. L., Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997 Feb;21[2]:97-102
Rasmussen, B. B., Jeppesen, U., Gaist, D., and Brosen, K., Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Ther Drug Monit 1997 Feb;19[1]:56-62
Baker, B., Dorian, P., Sandor, P., Shapiro, C., Schell, C., Mitchell, J., and Irvine, M. J., Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997 Feb;17[1]:15-21
Mundo, E., Bareggi, S. R., Pirola, R., Bellodi, L., and Smeraldi, E., Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol 1997 Feb;17[1]:4-10
Salokangas, R. K., Saarijarvi, S., Taiminen, T., Lehto, H., Niemi, H., Ahola, V., and Syvalahti, E., Effect of smoking on neuroleptics in schizophrenia. Schizophr Res 1997 Jan17;23[1]:55-60
Bakish, D., Cavazzoni, P., Chudzik, J., Ravindran, A., and Hrdina, P. D., Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 1997Jan15;41[2]:184-190
Taiminen, T. J., Syvalahti, E., Saarijarvi, S., Niemi, H., Lehto, H., Ahola, V., and Salokangas, R. K., Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol 1997 Jan;12[1]:31-35
Mendonca Lima, C. A., Vandel, S., Bonin, B., Bechtel, P., and Carron, R., [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis]. Encephale 1997 Jan;23[1]:48-55
Cornelius, J. R., Salloum, I. M., Ehler, J. G., Jarrett, P. J., Cornelius, M. D., Black, A., Perel, J. M., and Thase, M. E., Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacol Bull 1997;33[1]:165-170
Fava, M., Nierenberg, A. A., Quitkin, F. M., Zisook, S., Pearlstein, T., Stone, A., and Rosenbaum, J. F., A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull 1997;33[1]:101-103
Ronfeld, R. A., Wilner, K. D., and Baris, B. A., Sertraline. Chronopharmacokinetics and the effect of coadministration with food. Clin Pharmacokinet 1997;32 Suppl 1:50-55
Gardner, M. J., Baris, B. A., Wilner, K. D., and Preskorn, S. H., Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997;32 Suppl 1:43-49
Apseloff, G., Wilner, K. D., Gerber, N., and Tremaine, L. M., Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997;32 Suppl 1:37-42
Tremaine, L. M., Wilner, K. D., and Preskorn, S. H., A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997;32 Suppl 1:31-36
Syvalahti, E. K., Taiminen, T., Saarijarvi, S., Lehto, H., Niemi, H., Ahola, V., Dahl, M. L., and Salokangas, R. K., Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997 Jan;25[1]:24-32
Berman, R. M., Darnell, A. M., Miller, H. L., Anand, A., and Charney, D. S., Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997 Jan;154[1]:37-43
Buchsbaum, M. S., Wu, J., Siegel, B. V., Hackett, E., Trenary, M., Abel, L., and Reynolds, C., Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997 Jan1;41[1]:15-22
Maes, M., Vandoolaeghe, E., and Desnyder, R., Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996 Dec16;41[3]:201-210
Zanardi, R., Franchini, L., Gasperini, M., Perez, J., and Smeraldi, E., Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996 Dec;153[12]:1631-1633
Buchanan, R. W., Kirkpatrick, B., Bryant, N., Ball, P., and Breier, A., Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996 Dec;153[12]:1625-1627
Rintelmann, J. W., Emslie, G. J., Rush, A. J., Varghese, T., Gullion, C. M., Kowatch, R. A., and Hughes, C. W., The effects of extended evaluation on depressive symptoms in children and adolescents. J Affect Disord 1996 Nov25;41[2]:149-156
Partonen, T. and Lonnqvist, J., Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996 Nov25;41[2]:93-99
Pande, A. C., Birkett, M., Fechner-Bates, S., Haskett, R. F., and Greden, J. F., Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996 Nov15;40[10]:1017-1020
Duarte, A., Mikkelsen, H., and Delini-Stula, A., Moclobemide versus fluoxetine for double depression: a randomized double-blind study. J Psychiatr Res 1996 Nov;30[6]:453-458
Borrelli, B., Niaura, R., Keuthen, N. J., Goldstein, M. G., DePue, J. D., Murphy, C., and Abrams, D. B., Development of major depressive disorder during smoking-cessation treatment. J Clin Psychiatry 1996 Nov;57[11]:534-538
Del Boca, F. K., Kranzler, H. R., Brown, J., and Korner, P. F., Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 1996 Nov;20[8]:1412-1417
Pedrinola, F., Sztejnsznajd, C., Lima, N., Halpern, A., and Medeiros-Neto, G., The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obes Res 1996 Nov;4[6]:549-554
Laine, K., Kivisto, K. T., Pelttari, S., and Neuvonen, P. J., The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration. Pharmacol Toxicol 1996 Nov;79[5]:270-273
Goldenberg, D., Mayskiy, M., Mossey, C., Ruthazer, R., and Schmid, C., A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996 Nov;39[11]:1852-1859
McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., and Price, L. H., A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996 Nov;53[11]:1001-1008
Koran, L. M., Cain, J. W., Dominguez, R. A., Rush, A. J., and Thiemann, S., Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?. Am J Psychiatry 1996 Nov;153[11]:1450-1454
Reynolds, C. F., III, Frank, E., Perel, J. M., Mazumdar, S., Dew, M. A., Begley, A., Houck, P. R., Hall, M., Mulsant, B., Shear, M. K., Miller, M. D., Cornes, C., and Kupfer, D. J., High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Am J Psychiatry 1996 Nov;153[11]:1418-1422
Kara, H., Aydin, S., Yucel, M., Agargun, M. Y., Odabas, O., and Yilmaz, Y., The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 1996 Nov;156[5]:1631-1632
Kwon, J. S., Youn, T., and Jung, H. Y., Right hemisphere abnormalities in major depression: quantitative electroencephalographic findings before and after treatment. J Affect Disord 1996Oct14;40[3]:169-173
Bendtsen, L., Jensen, R., and Olesen, J., Amitriptyline, a combined serotonin and noradrenaline re-uptake inhibitor, reduces exteroceptive suppression of temporal muscle activity in patients with chronic tension-type headache. Electroencephalogr Clin Neurophysiol 1996 Oct;101[5]:418-422
Lauritzen, L., Odgaard, K., Clemmesen, L., Lunde, M., Ohrstrom, J., Black, C., and Bech, P., Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand 1996 Oct;94[4]:241-251
Zohar, J. and Judge, R., Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996 Oct;169[4]:468-474
Rapaport, M., Coccaro, E., Sheline, Y., Perse, T., Holland, P., Fabre, L., and Bradford, D., A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996 Oct;16[5]:373-378
Small, G. W., Birkett, M., Meyers, B. S., Koran, L. M., Bystritsky, A., and Nemeroff, C. B., Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group. J Am Geriatr Soc 1996 Oct;44[10]:1220-1225
Haffmans, P. M., Timmerman, L., and Hoogduin, C. A., Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Int Clin Psychopharmacol 1996 Sep;11[3]:157-164
Nathan, P. J., Norman, T. R., and Burrows, G. D., Nocturnal plasma melatonin concentrations in healthy volunteers: effect of single doses of d-fenfluramine, paroxetine, and ipsapirone. J Pineal Res 1996 Sep;21[2]:55-58
Walczak, D. D., Apter, J. T., Halikas, J. A., Borison, R. L., Carman, J. S., Post, G. L., Patrick, R., Cohn, J. B., Cunningham, L. A., Rittberg, B., Preskorn, S. H., Kang, J. S., and Wilcox, C. S., The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996 Sep;8[3]:139-151
Razavi, D., Allilaire, J. F., Smith, M., Salimpour, A., Verra, M., Desclaux, B., Saltel, P., Piollet, I., Gauvain-Piquard, A., Trichard, C., Cordier, B., Fresco, R., Guillibert, E., Sechter, D., Orth, J. P., Bouhassira, M., Mesters, P., and Blin, P., The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 1996 Sep;94[3]:205-210
Salokangas, R. K., Saarijarvi, S., Taiminen, T., Kallioniemi, H., Lehto, H., Niemi, H., Tuominen, J., Ahola, V., and Syvalahti, E., Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996 Sep;94[3]:175-180
Bendtsen, L., Jensen, R., and Olesen, J., A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996 Sep;61[3]:285-290
Thase, M. E., Fava, M., Halbreich, U., Kocsis, J. H., Koran, L., Davidson, J., Rosenbaum, J., and Harrison, W., A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996 Sep;53[9]:777-784
Greeno, C. G. and Wing, R. R., A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am J Clin Nutr 1996 Sep;64[3]:267-273
Linnet, K. and Olesen, O. V., [Citalopram and desmethylcitalopram for psychiatric patients]. Ugeskr Laeger 1996Aug26;158[35]:4920-4923
Baumann, P., Nil, R., Souche, A., Montaldi, S., Baettig, D., Lambert, S., Uehlinger, C., Kasas, A., Amey, M., and Jonzier-Perey, M., A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996 Aug;16[4]:307-314
de Zwaan, M. and Nutzinger, D. O., Effect of fluvoxamine on total serum cholesterol levels during weight reduction. J Clin Psychiatry 1996 Aug;57[8]:346-348
Rani, P. U., Naidu, M. U., Prasad, V. B., Rao, T. R., and Shobha, J. C., An evaluation of antidepressants in rheumatic pain conditions. Anesth Analg 1996 Aug;83[2]:371-375
Sharpley, A. L., Williamson, D. J., Attenburrow, M. E., Pearson, G., Sargent, P., and Cowen, P. J., The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996 Jul;126[1]:50-54
Daubresse, J. C., Kolanowski, J., Krzentowski, G., Kutnowski, M., Scheen, A., and Van Gaal, L., Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996 Jul;4[4]:391-396
Moon, C. A. and Vince, M., Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Br J Clin Pract 1996 Jul;50[5]:240-244
Dam, M., Tonin, P., De Boni, A., Pizzolato, G., Casson, S., Ermani, M., Freo, U., Piron, L., and Battistin, L., Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996 Jul;27[7]:1211-1214
Simon, G. E., VonKorff, M., Heiligenstein, J. H., Revicki, D. A., Grothaus, L., Katon, W., and Wagner, E. H, Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996 Jun26;275[24]:1897-1902
Slaap, B. R., van Vliet, I. M., Westenberg, H. G., and Den Boer, J. A., Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. J Affect Disord 1996 Jun20;39[1]:13-19
Amsterdam, J. D., Fava, M., Maislin, G., Rosenbaum, J., and Hornig-Rohan, M., TRH stimulation test as a predictor of acute and long-term antidepressant response in major depression. J Affect Disord 1996Jun5;38[2-3]:165-172.
Batki, S. L., Washburn, A. M., Delucchi, K., and Jones, R. T., A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 1996 Jun;41[2]:137-142
Jeppesen, U., Loft, S., Poulsen, H. E., and Brsen, K., A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996 Jun;6[3]:213-222
Patris, M., Bouchard, J. M., Bougerol, T., Charbonnier, J. F., Chevalier, J. F., Clerc, G., Cyran, C., Van Amerongen, P., Lemming, O., and Hopfner Petersen, H. E., Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996 Jun;11[2]:129-136
Fabre, L., Birkhimer, L. J., Zaborny, B. A., Wong, L. F., and Kapik, B. M., Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int Clin Psychopharmacol 1996 Jun;11[2]:119-127
Chiu, H. J., Hong, C. J., and Chan, C. H., Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine. Zhonghua Yi Xue Za Zhi (Taipei) 1996 Jun;57[6]:418-423
Kabel, D. I. and Petty, F., A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 1996 Jun;20[4]:780-784
Stein, M. B., Chartier, M. J., Hazen, A. L., Kroft, C. D., Chale, R. A., Cote, D., and Walker, J. R., Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996 Jun;16[3]:218-222
Schnyder, U. and Koller-Leiser, A., A double-blind, multicentre study of paroxetine and maprotiline in major depression. Can J Psychiatry 1996 May;41[4]:239-244
Seifritz, E., Baumann, P., Muller, M. J., Annen, O., Amey, M., Hemmeter, U., Hatzinger, M., Chardon, F., and Holsboer-Trachsler, E., Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996 Apr;14[4]:253-263
Koran, L. M., McElroy, S. L., Davidson, J. R., Rasmussen, S. A., Hollander, E., and Jenike, M. A., Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996 Apr;16[2]:121-129
Claghorn, J. L., Earl, C. Q., Walczak, D. D., Stoner, K. A., Wong, L. F., Kanter, D., and Houser, V. P., Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996 Apr;16[2]:113-120
Vercoulen, J. H., Swanink, C. M., Zitman, F. G., Vreden, S. G., Hoofs, M. P., Fennis, J. F., Galama, J. M., van der Meer, J. W., and Bleijenberg, G., Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996 Mar30;347[9005]:858-861
Reist, C., Helmeste, D., Albers, L., Chhay, H., and Tang, S. W., Serotonin indices and impulsivity in normal volunteers. Psychiatry Res 1996 Mar29;60[2-3]:177-184
Christiansen, P. E., Behnke, K., Black, C. H., Ohrstrom, J. K., Bork-Rasmussen, H., and Nilsson, J., Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatr Scand 1996 Mar;93[3]:158-163
Goodman, W. K., Kozak, M. J., Liebowitz, M., and White, K. L., Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996 Mar;11[1]:21-29
Meszaros, K., Willinger, U., Fischer, G., Schonbeck, G., and Aschauer, H. N., The tridimensional personality model: influencing variables in a sample of detoxified alcohol dependents. European Fluvoxamine in Alcoholism Study Group. Compr Psychiatry 1996 Mar;37[2]:109-114
Fichter, M. M., Kruger, R., Rief, W., Holland, R., and Dohne, J., Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol 1996 Feb;16[1]:9-18
Yonkers, K. A., Gullion, C., Williams, A., Novak, K., and Rush, A. J., Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol 1996 Feb;16[1]:3-8
Fairweather, D. B., Ashford, J., and Hindmarch, I., Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers. Pharmacol Biochem Behav 1996 Feb;53[2]:265-269
van Balkom, A. J., de Beurs, E., Koele, P., Lange, A., and van Dyck, R., Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia. J Nerv Ment Dis 1996 Feb;184[2]:133-135
Dunner, D. L., Schmaling, K. B., Hendrickson, H., Becker, J., Lehman, A., and Bea, C., Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depression 1996;4[1]:34-41
Agosti, V. and Stewart, J. W., Six month follow-up of early-onset chronic depression. Depression 1996;4[2]:63-67
Nair, N. P., Bakish, D., Saxena, B., Amin, M., Schwartz, G., and West, T. E., Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996;2[4]:192-198
Auer, S. R., Monteiro, I. M., and Reisberg, B., Behavioral symptoms in dementia: community-based research. Int Psychogeriatr 1996;8 Suppl 3:363-366
Saletu, B., Grunberger, J., Anderer, P., Linzmayer, L., and Zyhlarz, G., Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry. J Neural Transm 1996;103[1-2]:191-216
Yonkers, K. A., Halbreich, U., Freeman, E., Brown, C., and Pearlstein, T., Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacol Bull 1996;32[1]:41-46
Finkelstein, S. N., Berndt, E. R., Greenberg, P. E., Parsley, R. A., Russell, J. M., and Keller, M. B., Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group. Psychopharmacol Bull 1996;32[1]:33-40
Burke, W. J., Hendricks, S. E., McArthur-Campbell, D., Jacques, D., and Stull, T., Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. Psychopharmacol Bull 1996;32[1]:27-32
Ravizza, L., Barzega, G., Bellino, S., Bogetto, F., and Maina, G., Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996;32[1]:167-173
Bakish, D., Hooper, C. L., Filteau, M. J., Charbonneau, Y., Fraser, G., West, D. L., Thibaudeau, C., and Raine, D., A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996;32[1]:135-141
Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., and Brosen, K., Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51[1]:73-78
Dierick, M., Ravizza, L., Realini, R., and Martin, A., A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996 Jan;20[1]:57-71
Tiihonen, J., Ryynanen, O. P., Kauhanen, J., Hakola, H. P., and Salaspuro, M., Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 1996 Jan;29[1]:27-29
Chien, A. J. and Dunner, D. L., The Tridimensional Personality Questionnaire in depression: state versus trait issues. J Psychiatr Res 1996 Jan;30[1]:21-27
Tollefson, G. D., Heiligenstein, J. H., Tollefson, S. L., Birkett, M. A., Knight, D. L., and Nemeroff, C. B., Is there a relationship between baseline and treatment-associated changes in [3H]-IMI platelet binding and clinical response in major depression?. Neuropsychopharmacology 1996 Jan;14[1]:47-53
Beusterien, K. M., Steinwald, B., and Ware, J. E., Jr., Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly. J Geriatr Psychiatry Neurol 1996 Jan;9[1]:13-21
Feiger, A., Kiev, A., Shrivastava, R. K., Wisselink, P. G., and Wilcox, C. S., Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57 Suppl 2:53-62
Baldwin, D. S., Hawley, C. J., Abed, R. T., Maragakis, B. P., Cox, J., Buckingham, S. A., Pover, G. H., and Ascher, A., A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996;57 Suppl 2:46-52
Williams, S. A., Wesnes, K., Oliver, S. D., and Rapeport, W. G., Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. J Clin Psychiatry 1996;57 Suppl 1:7-11
Rapeport, W. G., Muirhead, D. C., Williams, S. A., Cross, M., and Wesnes, K., Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996;57 Suppl 1:24-28
Rapeport, W. G., Williams, S. A., Muirhead, D. C., Dewland, P. M., Tanner, T., and Wesnes, K., Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57 Suppl 1:20-23
Rapeport, W. G., Coates, P. E., Dewland, P. M., and Forster, P. L., Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. J Clin Psychiatry 1996;57 Suppl 1:16-19
Ziegler, M. G. and Wilner, K. D., Sertraline does not alter the beta-adrenergic blocking activity of atenolol in healthy male volunteers. J Clin Psychiatry 1996;57 Suppl 1:12-15
Burns, R. A., Lock, T., Edwards, D. R., Katona, C. L., Harrison, D. A., Robertson, M. M., Nairac, B., and Abou-Saleh, M. T., Predictors of response to amine-specific antidepressants. J Affect Disord 1995Dec13;35[3]:97-106
Breum, L., Bjerre, U., Bak, J. F., Jacobsen, S., and Astrup, A., Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 1995 Dec;44[12]:1570-1576
Costa, A. D. and Kroll, R. M., Sertraline in stuttering. J Clin Psychopharmacol 1995 Dec;15[6]:443-444
Koran, L. M., Hamilton, S. H., Hertzman, M., Meyers, B. S., Halaris, A. E., Tollefson, G. D., Downs, J. M., Folks, D. G., Jeste, D. V., Lazarus, L. W., Predicting response to fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1995 Dec;15[6]:421-427
Black, D. W., Wesner, R., Bowers, W., Monahan, P., and Gabel, J., Acute treatment response in outpatients with panic disorder: high versus low depressive symptoms. Ann Clin Psychiatry 1995 Dec;7[4]:181-188
Cappiello, A., McDougle, C. J., Malison, R. T., Heninger, G. R., and Price, L. H., Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol Psychiatry 1995Dec1;38[11]:765-767
Lam, R. W., Gorman, C. P., Michalon, M., Steiner, M., Levitt, A. J., Corral, M. R., Watson, G. D., Morehouse, R. L., Tam, W., and Joffe, R. T., Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995 Dec;152[12]:1765-1770
Spring, B., Wurtman, J., Wurtman, R., el Khoury, A., Goldberg, H., McDermott, J., and Pingitore, R., Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. Am J Clin Nutr 1995 Dec;62[6]:1181-1187
Brambilla, F., Brunetta, M., Peirone, A., Perna, G., Sacerdote, P., Manfredi, B., and Panerai, A. E., T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa. Psychiatry Res 1995 Nov29;59[1-2]:43-50
Pijl, H., Cohen, A. F., Verkes, R. J., Koppeschaar, H. P., Iestra, J. A., Schoemaker, H. C., Frolich, M., Onkenhout, W., and Meinders, A. E., Plasma amino acid ratios related to brain serotonin synthesis in response to food intake in bulimia nervosa. Biol Psychiatry 1995 Nov15;38[10]:659-668
Hochberg, H. M., Kanter, D., and Houser, V. P., Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience. Pharmacopsychiatry 1995 Nov;28[6]:253-256
Oliveto, A., Kosten, T. R., Schottenfeld, R., Falcioni, J., and Ziedonis, D., Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J Subst Abuse Treat 1995 Nov;12[6]:423-428
Goldstein, D. J., Rampey, A. H., Jr., Roback, P. J., Wilson, M. G., Hamilton, S. H., Sayler, M. E., and Tollefson, G. D., Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success. Obes Res 1995 Nov;3 Suppl 4:481S-490S
Wadden, T. A., Bartlett, S. J., Foster, G. D., Greenstein, R. A., Wingate, B. J., Stunkard, A. J., and Letizia, K. A., Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res 1995 Nov;3[6]:549-557
Fabre, L. F., Abuzzahab, F. S., Amin, M., Claghorn, J. L., Mendels, J., Petrie, W. M., Dube, S., and Small, J. G., Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995 Nov1;38[9]:592-602
Mendoza, Espejo R., Diaz Perez, de Madrid, and Buitrago, F., [Effectiveness of serotonergic agonists in the treatment of obese patients]. Aten Primaria 1995 Oct15;16[6]:364-366
Mendels, J., Camera, A., and Sikes, C., Sertraline treatment for premature ejaculation. J Clin Psychopharmacol 1995 Oct;15[5]:341-346
Brauer, L. H., Rukstalis, M. R., and de Wit, H., Acute subjective responses to paroxetine in normal volunteers. Drug Alcohol Depend 1995 Oct;39[3]:223-230
Lapierre, Y., Bentkover, J., Schainbaum, S., and Manners, S., Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Can J Psychiatry 1995 Sep;40[7]:370-377
Katzelnick, D. J., Kobak, K. A., Greist, J. H., Jefferson, J. W., Mantle, J. M., and Serlin, R. C., Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995 Sep;152[9]:1368-1371
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., and Manniche, P. M., Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995 Sep;167[3]:374-379
Ravizza, L., Barzega, G., Bellino, S., Bogetto, F., and Maina, G., Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 1995 Aug;56[8]:368-373
Streichenwein, S. M. and Thornby, J. I., A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 1995 Aug;152[8]:1192-1196
Gattaz, W. F., Vogel, P., Kick, H., and Kohnen, R., Moclobemide versus fluoxetine in the treatment of inpatients with major depression. J Clin Psychopharmacol 1995 Aug;15[4 Suppl 2]:35S-40S
Covi, L., Hess, J. M., Kreiter, N. A., and Haertzen, C. A., Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Am J Drug Alcohol Abuse 1995 Aug;21[3]:327-344
Lawton, C. L., Wales, J. K., Hill, A. J., and Blundell, J. E., Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obes Res 1995 Jul;3[4]:345-356
Ottevanger, E. A., Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Encephale 1995 Jul;21[4]:317-321
Staner, L., Kerkhofs, M., Detroux, D., Leyman, S., Linkowski, P., and Mendlewicz, J., Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995 Jul;18[6]:470-477
Haider, A., Miller, D. R., Christenson, J. L., Cushing, A. G., and Station, R. D., Clinical effect of converting antidepressant therapy from fluoxetine to sertraline. Am J Health Syst Pharm 1995 Jun15;52[12]:1317-1319
Steiner, M., Steinberg, S., Stewart, D., Carter, D., Berger, C., Reid, R., Grover, D., and Streiner, D., Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995 Jun8;332[23]:1529-1534
Bennie, E. H., Mullin, J. M., and Martindale, J. J., A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995 Jun;56[6]:229-237
Geretsegger, C., Stuppaeck, C. H., Mair, M., Platz, T., Fartacek, R., and Heim, M., Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology (Berl) 1995 Jun;119[3]:277-281
Greist, J. H., Jefferson, J. W., Kobak, K. A., Chouinard, G., DuBoff, E., Halaris, A., Kim, S. W., Koran, L., Liebowtiz, M. R., Lydiard, B., A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995 Jun;10[2]:57-65
Grabowski, J., Rhoades, H., Elk, R., Schmitz, J., Davis, C., Creson, D., and Kirby, K., Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 1995 Jun;15[3]:163-174
Reynaert, C., Janne, P., Vause, M., Zdanowicz, N., and Lejeune, D., Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome. Psychopharmacology (Berl) 1995 Jun;119[4]:449-454
Norregaard, J., Volkmann, H., and Danneskiold-Samsoe, B., A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995 Jun;61[3]:445-449
Nierenberg, A. A., Grossbard, S. J., Fava, M., and Rosenbaum, J. F., Social adjustment does not predict depressive relapse during continuation fluoxetine therapy. J Affect Disord 1995 May17;34[2]:73-77
Barge-Schaapveld, D. Q., Nicolson, N. A., van der Hoop, R. G., and De Vries, M. W., Changes in daily life experience associated with clinical improvement in depression. J Affect Disord 1995 May17;34[2]:139-154
Orsel, Donbak S., Turkcapar, M. H., Ozturk Kilic, E. Z., Demirergi, N., Akdemir, A., Sirin, A., and Ozbay, M. H., Moclobemide and sertraline in the treatment of depressive disorders: a comparative study. Acta Psychiatr Belg 1995 May;95[3]:139-151
van Oppen, P., de Haan, E., van Balkom, A. J., Spinhoven, P., Hoogduin, K., and van Dyck, R., Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behav Res Ther 1995 May;33[4]:379-390
Bross, R. and Hoffer, L. J., Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am J Clin Nutr 1995 May;61[5]:1020-1025
de Beurs, E., van Balkom, A. J., Lange, A., Koele, P., and van Dyck, R., Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995 May;152[5]:683-691
Connolly, V. M., Gallagher, A., and Kesson, C. M., A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med 1995 May;12[5]:416-418
Vartiainen, H., Tiihonen, J., Putkonen, A., Koponen, H., Virkkunen, M., Hakola, P., and Lehto, H., Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995 May;91[5]:348-351
Goldstein, D. J., Wilson, M. G., Thompson, V. L., Potvin, J. H., and Rampey, A. H., Jr., Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry 1995 May;166[5]:660-666
Mehta, V. K. and Blume, G. B., A randomized trial of fluoxetine in a patient with persistent fatigue. J Am Board Fam Pract 1995 May;8[3]:230-232
Andersen, G., Vestergaard, K., and Lauritzen, L. U., [Effective treatment of depression following apoplexy with citalopram]. Ugeskr Laeger 1995 Apr3;157[14]:2000-2003
Piccinelli, M., Pini, S., Bellantuono, C., and Wilkinson, G., Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995 Apr;166[4]:424-443
Zawertailo, L. A., Busto, U., Kaplan, H. L., and Sellers, E. M, Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. J Clin Psychopharmacol 1995 Apr;15[2]:117-124
Eriksson, E., Hedberg, M. A., Andersch, B., and Sundblad, C., The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995 Apr;12[2]:167-176
Kreider, M. S., Bushnell, W. D., Oakes, R., and Wheadon, D. E., A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. J Clin Psychiatry 1995 Apr;56[4]:142-145
Greist, J., Chouinard, G., DuBoff, E., Halaris, A., Kim, S. W., Koran, L., Liebowitz, M., Lydiard, R. B., Rasmussen, S., White, K., Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995 Apr;52[4]:289-295
Thakore, J. H. and Dinan, T. G., Effect of fluoxetine on dexamethasone-induced growth hormone release in depression: a double-blind, placebo-controlled study. Am J Psychiatry 1995 Apr;152[4]:616-618
Ramaekers, J. G., Muntjewerff, N. D., and O’Hanlon, J. F., A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995 Apr;39[4]:397-404
Simon, G., Wagner, E., and VonKorff, M., Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995 Mar;48[3]:363-373
Dalack, G. W., Glassman, A. H., Rivelli, S., Covey, L., and Stetner, F., Mood, major depression, and fluoxetine response in cigarette smokers. Am J Psychiatry 1995 Mar;152[3]:398-403
Kranzler, H. R., Burleson, J. A., Korner, P., Del Boca, F. K., Bohn, M. J., Brown, J., and Liebowitz, N., Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995 Mar;152[3]:391-397
Lonnqvist, J., Sihvo, S., Syvalahti, E., Sintonen, H., Kiviruusu, O., and Pitkanen, H., Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression. Acta Psychiatr Scand 1995 Mar;91[3]:189-194
Robert, P. and Montgomery, S. A., Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995 Mar;10 Suppl 1:29-35
Reynaert, C., Parent, M., Mirel, J., Janne, P., and Haazen, L., Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology (Berl) 1995 Mar;118[2]:183-187
Robbe, H. W. and O’Hanlon, J. F., Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995 Mar;5[1]:35-42
Martin, P. R., Adinoff, B., Lane, E., Stapleton, J. M., Bone, G. A., Weingartner, H., Linnoila, M., and Eckardt, M. J., Fluvoxamine treatment of alcoholic amnestic disorder. Eur Neuropsychopharmacol 1995 Mar;5[1]:27-33
Fava, M., Rappe, S. M., Pava, J. A., Nierenberg, A. A., Alpert, J. E., and Rosenbaum, J. F., Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995 Feb;56[2]:52-55
Nofzinger, E. A., Reynolds, C. F., III, Thase, M. E., Frank, E., Jennings, J. R., Fasiczka, A. L., Sullivan, L. R., and Kupfer, D. J., REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 1995 Feb;152[2]:274-276
Salzman, C., Wolfson, A. N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., Schwartz, J., and Miyawaki, E., Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995 Feb;15[1]:23-29
Goff, D. C., Midha, K. K., Sarid-Segal, O., Hubbard, J. W., and Amico, E., A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995 Feb;117[4]:417-423
Slaap, B. R., van Vliet, I. M., Westenberg, H. G., and Den Boer, J. A., Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report). J Affect Disord 1995Jan11;33[1]:31-38
Laghrissi-Thode, F., Pollock, B. G., Miller, M. C., Mulsant, B. H., Altieri, L., and Finkel, M. S., Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients. Psychopharmacol Bull 1995;31[4]:659-663
Hewer, W., Rost, W., and Gattaz, W. F., Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 1995;246[1]:1-6
Small, G. W., Hamilton, S. H., Bystritsky, A., Meyers, B. S., and Nemeroff, C. B., Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995;7 Suppl:41-53
Heiligenstein, J. H., Ware, J. E., Jr., Beusterien, K. M., Roback, P. J., Andrejasich, C., and Tollefson, G. D., Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychogeriatr 1995;7 Suppl:125-137
Katona, C. L., Abou-Saleh, M. T., Harrison, D. A., Nairac, B. A., Edwards, D. R., Lock, T., Burns, R. A., and Robertson, M. M., Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995 Jan;166[1]:80-86
Naranjo, C. A., Bremner, K. E., and Lanctot, K. L., Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 1995 Jan;90[1]:87-99
el Yazigi, A., Chaleby, K., Gad, A., and Raines, D. A., Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol 1995 Jan;35[1]:17-21
Thienemann, M. and Koran, L. M., Do soft signs predict treatment outcome in obsessive-compulsive disorder?. J Neuropsychiatry Clin Neurosci 1995;7[2]:218-222
Alpert, J. E., Uebelacker, L. A., McLean, N. E., Abraham, M., Rosenbaum, J. F., and Fava, M., The Mini-Mental State Examination among adult outpatients with major depressive disorder. Psychother Psychosom 1995;63[3-4]:207-211
Kasper, S., Moller, H. J., Montgomery, S. A., and Zondag, E., Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol 1995 Jan;9 Suppl 4:3-12
Tollefson, G. D., Bosomworth, J. C., Heiligenstein, J. H., Potvin, J. H., and Holman, S., A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995;7[1]:89-104
Cornelius, J. R., Salloum, I. M., Cornelius, M. D., Perel, J. M., Ehler, J. G., Jarrett, P. J., Levin, R. L., Black, A., and Mann, J. J., Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull 1995;31[2]:297-303
Satterlee, W. G. and Faries, D., The effects of fluoxetine on symptoms of insomnia in depressed patients. Psychopharmacol Bull 1995;31[2]:227-237
Keller, M. B., Harrison, W., Fawcett, J. A., Gelenberg, A., Hirschfeld, R. M., Klein, D., Kocsis, J. H., McCullough, J. P., Rush, A. J., Schatzberg, A., Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull 1995;31[2]:205-212
Fernandez-Soto, M. L., Gonzalez-Jimenez, A., Barredo-Acedo, F., Luna del Castillo, J. D., and Escobar-Jimenez, F., Comparison of fluoxetine and placebo in the treatment of obesity. Ann Nutr Metab 1995;39[3]:159-163
Roose, S. P., Glassman, A. H., Attia, E., and Woodring, S., Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994 Dec;151[12]:1735-1739
Franchini, L., Gasperini, M., and Smeraldi, E., A 24-month follow-up study of unipolar subjects: a comparison between lithium and fluvoxamine. J Affect Disord 1994 Dec;32[4]:225-231
Walsh, S. L., Preston, K. L., Sullivan, J. T., Fromme, R., and Bigelow, G. E., Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 1994 Dec;14[6]:396-407
Rechlin, T., The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability. J Clin Psychopharmacol 1994 Dec;14[6]:392-395
Tollefson, G. D., Greist, J. H., Jefferson, J. W., Heiligenstein, J. H., Sayler, M. E., Tollefson, S. L., and Koback, K., Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 1994 Dec;14[6]:385-391
Brady, K. T., Lydiard, R. B., Kellner, C. H., Joffe, R., Laird, L. K., Morton, W. A., and Steele, T. E., A comparison of the effects of imipramine and fluvoxamine on the thyroid axis. Biol Psychiatry 1994 Dec1;36[11]:778-779
van der Kolk, B. A., Dreyfuss, D., Michaels, M., Shera, D., Berkowitz, R., Fisler, R., and Saxe, G., Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994 Dec;55[12]:517-522
Sayler, M. E., Goldstein, D. J., Roback, P. J., and Atkinson, R. L., Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. Int J Obes Relat Metab Disord 1994 Nov;18[11]:742-751
Lonnqvist, J., Sihvo, S., Syvalahti, E., and Kiviruusu, O., Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord 1994 Nov;32[3]:169-177
Saper, J. R., Silberstein, S. D., Lake, A. E., III, and Winters, M. E., Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994 Oct;34[9]:497-502
Tollefson, G. D., Birkett, M., Koran, L., and Genduso, L., Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 1994 Oct;55 Suppl:69-76
Eick, T. J. and Kofoed, L., An unusual indication for a single-subject clinical trial. J Nerv Ment Dis 1994 Oct;182[10]:587-590
Huyse, F. J., Zwaan, W. A., and Kupka, R., The applicability of antidepressants in the depressed medically ill: an open clinical trial with fluoxetine. J Psychosom Res 1994 Oct;38[7]:695-703
Balldin, J., Berggren, U., Engel, J., Eriksson, M., Hard, E., and Soderpalm, B., Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res 1994 Oct;18[5]:1133-1136
Daniel, D. G., Randolph, C., Jaskiw, G., Handel, S., Williams, T., Abi-Dargham, A., Shoaf, S., Egan, M., Elkashef, A., Liboff, S., Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994 Oct;14[5]:340-343
Cook, E. H., Jr., Metz, J., Leventhal, B. L., Lebovitz, M., Nathan, M., Semerdjian, S. A., Brown, T., and Cooper, M. D., Fluoxetine effects on cerebral glucose metabolism. Neuroreport 1994 Sep8;5[14]:1745-1748
Waldinger, M. D., Hengeveld, M. W., and Zwinderman, A. H., Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994 Sep;151[9]:1377-1379
Fava, M., Rosenbaum, J. F., McGrath, P. J., Stewart, J. W., Amsterdam, J. D., and Quitkin, F. M., Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994 Sep;151[9]:1372-1374
Black, B. and Uhde, T. W., Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1994 Sep;33[7]:1000-1006
Bank, J., A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994 Sep;34[8]:476-478
Herberg, K. W., [Antidepressives and traffic safety]. Fortschr Neurol Psychiatr 1994 Sep;62 Suppl 1:24-28
Schone, W. and Ludwig, M., [Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine]. Fortschr Neurol Psychiatr 1994 Sep;62 Suppl 1:16-18
O’Carroll, R. E., Moffoot, A. P., Ebmeier, K. P., and Goodwin, G. M., Effects of fluvoxamine treatment on cognitive functioning in the alcoholic Korsakoff syndrome. Psychopharmacology (Berl) 1994 Sep;116[1]:85-88
Vasar, V., Appelberg, B., Rimon, R., and Selvaratnam, J., The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers. Int Clin Psychopharmacol 1994 Sep;9[3]:203-206
Naranjo, C. A., Poulos, C. X., Bremner, K. E., and Lanctot, K. L., Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol 1994 Sep;9[3]:163-172
Clerc, G. E., Ruimy, P., and Verdeau-Palles, J., A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994 Sep;9[3]:139-143
Menkes, D. B., Coates, D. C., and Fawcett, J. P., Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994 Sep;32[1]:37-44
Bach, F. W., Langemark, M., Ekman, R., Rehfeld, J. F., Schifter, S., and Olesen, J., Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache. Neuropeptides 1994 Aug;27[2]:129-136
Gorard, D. A., Healy, J. C., O’Donnell, L. J., and Farthing, M. J., Inhibition of 5-hydroxytryptamine re-uptake impairs human gall-bladder emptying. Aliment Pharmacol Ther 1994 Aug;8[4]:461-464
Balldin, J., Berggren, U., Engel, J., and Eriksson, M., Neuroendocrine evidence for reduced serotonergic neurotransmission during heavy drinking. Alcohol Clin Exp Res 1994 Aug;18[4]:822-825
Stuppaeck, C. H., Geretsegger, C., Whitworth, A. B., Schubert, H., Platz, T., Konig, P., Hinterhuber, H., and Fleischhacker, W. W., A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994 Aug;14[4]:241-246
Stewart, D. E., Fairman, M., Barbadoro, S., Zownir, P., and Steiner, M., Follicular and late luteal phase serum fluoxetine levels in women suffering from late luteal phase dysphoric disorder. Biol Psychiatry 1994Aug1;36[3]:201-202
Freeman, C. P., Trimble, M. R., Deakin, J. F., Stokes, T. M., and Ashford, J. J., Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994 Jul;55[7]:301-305
Tollefson, G. D., Rampey, A. H., Jr., Potvin, J. H., Jenike, M. A., Rush, A. J., kominguez, R. A., Koran, L. M., Shear, M. K., Goodman, W., and Genduso, L. A., A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994 Jul;51[7]:559-567
Nierenberg, A. A., Adler, L. A., Peselow, E., Zornberg, G., and Rosenthal, M., Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994 Jul;151[7]:1069-1072
Gordon, N. C., Heller, P. H., Gear, R. W., and Levine, J. D., Interactions between fluoxetine and opiate analgesia for postoperative dental pain. Pain 1994 Jul;58[1]:85-88
Alpert, J. E., Maddocks, A., Rosenbaum, J. F., and Fava, M., Childhood psychopathology retrospectively assessed among adults with early onset major depression. J Affect Disord 1994 Jul;31[3]:165-171
Ottevanger, E. A., The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 1994 Jul;18[4]:731-740
Andersen, G., Vestergaard, K., and Lauritzen, L., Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994 Jun;25[6]:1099-1104
Arminen, S. L., Ikonen, U., Pulkkinen, P., Leinonen, E., Mahlanen, A., Koponen, H., Kourula, K., Ryyppo, J., Korpela, V., Lehtonen, M. L., A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 1994 Jun;89[6]:382-389
Lonnqvist, J., Sintonen, H., Syvalahti, E., Appelberg, B., Koskinen, T., Mannikko, T., Mehtonen, O. P., Naarala, M., Sihvo, S., Auvinen, J., Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994 Jun;89[6]:363-369
Heiligenstein, J. H., Faries, D. E., Rush, A. J., Andersen, J. S., Pande, A. C., Roffwarg, H. P., Dunner, D., Gillin, J. C., James, S. P., Lahmeyer, H., Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. Psychiatry Res 1994 Jun;52[3]:327-339
Turner, R., Quality of life: experience with sertraline. Int Clin Psychopharmacol 1994 Jun;9 Suppl 3:27-31
Thompson, C., Management of depression in real-life settings: knowledge gained from large-scale clinical trials. Int Clin Psychopharmacol 1994 Jun;9 Suppl 3:21-25
Lawrence, K. M., Katona, C. L., Abou-Saleh, M. T., Robertson, M. M., Nairac, B. L., Edwards, D. R., Lock, T., Burns, R. A., Harrison, D. A., and Horton, R. W., Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine. Psychopharmacology (Berl) 1994 Jun;115[1-2]:261-264
van Vliet, I. M., Den Boer, J. A., and Westenberg, H. G., Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994 Jun;115[1-2]:128-134
Rechlin, T., Weis, M., and Claus, D., Heart rate variability in depressed patients and differential effects of paroxetine and amitriptyline on cardiovascular autonomic functions. Pharmacopsychiatry 1994 May;27[3]:124-128
Holman, S. L., Goldstein, D. J., and Enas, G. G., Pattern analysis method for assessing successful weight reduction. Int J Obes Relat Metab Disord 1994 May;18[5]:281-285
McCarthy, M. K., Goff, D. C., Baer, L., Cioffi, J., and Herzog, D. B., Dissociation, childhood trauma, and the response to fluoxetine in bulimic patients. Int J Eat Disord 1994 Apr;15[3]:219-226
Preskorn, S. H., Alderman, J., Chung, M., Harrison, W., Messig, M., and Harris, S., Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994 Apr;14[2]:90-98
Gorard, D. A., Libby, G. W., and Farthing, M. J., 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 1994 Apr;35[4]:496-500
McDougle, C. J., Goodman, W. K., Leckman, J. F., Lee, N. C., Heninger, G. R., and Price, L. H., Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994 Apr;51[4]:302-308
Black, D. W., Wesner, R. B., Gabel, J., Bowers, W., and Monahan, P., Predictors of short-term treatment response in 66 patients with panic disorder. J Affect Disord 1994 Apr;30[4]:233-241
Moller, H. J. and Steinmeyer, E. M., Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. Eur Neuropsychopharmacol 1994 Mar;4[1]:55-59
Cantini, F., Bellandi, F., Niccoli, L., and Di Munno, O., [Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia]. Minerva Med 1994 Mar;85[3]:97-100
Goldstein, D. J., Rampey, A. H., Jr., Enas, G. G., Potvin, J. H., Fludzinski, L. A., and Levine, L. R., Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994 Mar;18[3]:129-135
Targ, E. F., Karasic, D. H., Diefenbach, P. N., Anderson, D. A., Bystritsky, A., and Fawzy, F. I., Structured group therapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics 1994 Mar;35[2]:132-137
Rosenberg, C., Damsbo, N., Fuglum, E., Jacobsen, L. V., and Horsgard, S., Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol 1994 Mar;9 Suppl 1:41-48
Heiligenstein, J. H., Tollefson, G. D., and Faries, D. E., Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J Affect Disord 1994 Mar;30[3]:163-173
Skene, D. J., Bojkowski, C. J., and Arendt, J., Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 1994 Feb;37[2]:181-186
Ansseau, M., Papart, P., Troisfontaines, B., Bartholome, F., Bataille, M., Charles, G., Schittecatte, M., Darimont, P., Devoitille, J. M., De Wilde, J., Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 1994 Feb;114[1]:131-137
Bystritsky, A., Rosen, R. M., Murphy, K. J., Bohn, P., Keys, S. A., and Vapnik, T., Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994;1[6]:287-290
Centorrino, F., Baldessarini, R. J., Kando, J., Frankenburg, F. R., Volpicelli, S. A., Puopolo, P. R., and Flood, J. G., Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994 Jan;151[1]:123-125
Richardson, J. S., Keegan, D. L., Bowen, R. C., Blackshaw, S. L., Cebrian-Perez, S., Dayal, N., Saleh, S., and Shrikhande, S., Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. Int Clin Psychopharmacol 1994;9[1]:35-40
Geretsegger, C., Bohmer, F., and Ludwig, M., Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994;9[1]:25-29
O’Kane, M., Wiles, P. G., and Wales, J. K., Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994 Jan;11[1]:105-110
Manna, V., Bolino, F., and Di Cicco, L., Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine. Headache 1994 Jan;34[1]:44-49
Langemark, M. and Olesen, J., Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. Headache 1994 Jan;34[1]:20-24
Doogan, D. P. and Langdon, C. J., A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 1994;9[2]:95-100
Fleishaker, J. C. and Hulst, L. K., A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46[1]:35-39
Wolfe, F., Cathey, M. A., and Hawley, D. J., A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23[5]:255-259
Sommers, D. K., van Wyk, M., and Snyman, J. R., Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine. Eur J Clin Pharmacol 1994;46[5]:441-444
Geerts, S., Bruynooghe, F., De Cuyper, H., Demeulemeester, F., and Haazen, L., Moclobemide versus fluoxetine for major depressive episodes. Clin Neuropharmacol 1994;17 Suppl 1:S50-S57
Smulevich, A. B., Andriushchenko, A. V., Morkovkina, I. V., Tkhostov, A. S., and Koliutskaia, E. V., [The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)]. Zh Nevropatol Psikhiatr Im S S Korsakova 1994;94[5]:60-64
Montgomery, D. B., Roberts, A., Green, M., Bullock, T., Baldwin, D., and Montgomery, S. A., Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. Eur Arch Psychiatry Clin Neurosci 1994;244[4]:211-215
Leblhuber, F., [Citalopram in treatment of behavioral disorders in demented patients]. Acta Med Austriaca 1994;21[4]:104-106
Spina, E., De Domenico, P., Ruello, C., Longobardo, N., Gitto, C., Ancione, M., Di Rosa, A. E., and Caputi, A. P., Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994;9[4]:281-285
Linden, R. D., Wilcox, C. S., Heiser, J. F., Cavanaugh, E., and Wisselink, P. G., Are selective serotonin reuptake inhibitors well tolerated in somatizing depressives?. Psychopharmacol Bull 1994;30[2]:151-156
Szkudlarek, J. and Elsborg, L., Treatment of severe obesity with a highly selective serotonin re-uptake inhibitor as a supplement to a low calorie diet. Int J Obes Relat Metab Disord 1993 Dec;17[12]:681-683
Schone, W. and Ludwig, M., A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993 Dec;13[6 Suppl 2]:34S-39S
Duboff, E. A., Long-term treatment of major depressive disorder with paroxetine. J Clin Psychopharmacol 1993 Dec;13[6 Suppl 2]:28S-33S
Claghorn, J. L. and Feighner, J. P., A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol 1993 Dec;13[6 Suppl 2]:23S-27S
Tignol, J., A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993 Dec;13[6 Suppl 2]:18S-22S
Lafer, B., Fava, M., Hammerness, P., and Rosenbaum, J. F., The influence of DST and TRH test administration on depression assessments: a controlled study. Biol Psychiatry 1993 Nov1;34[9]:650-653
Bodfish, J. W. and Madison, J. T., Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation. Am J Ment Retard 1993 Nov;98[3]:360-367
Salzman, C., Jimerson, D., Vasile, R., Watsky, E., and Gerber, J., Response to SSRI antidepressants correlates with reduction in plasma HVA: pilot study. Biol Psychiatry 1993 Oct15;34[8]:569-571
Andersen, G., Vestergaard, K., and Riis, J. O., Citalopram for post-stroke pathological crying. Lancet 1993 Oct2;342[8875]:837-839
McDougle, C. J., Goodman, W. K., Leckman, J. F., Barr, L. C., Heninger, G. R., and Price, L. H., The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993 Oct;13[5]:354-358
Hoehn-Saric, R., McLeod, D. R., and Hipsley, P. A., Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993 Oct;13[5]:321-326
Bowden, C. L., Schatzberg, A. F., Rosenbaum, A., Contreras, S. A., Samson, J. A., Dessain, E., and Sayler, M., Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993 Oct;13[5]:305-311
Cottraux, J., Mollard, E., Bouvard, M., and Marks, I., Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Res 1993 Oct;49[1]:63-75
Coquoz, D., Porchet, H. C., and Dayer, P., Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers. Clin Pharmacol Ther 1993 Sep;54[3]:339-344
Beasley, C. M., Jr., Holman, S. L., and Potvin, J. H., Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 1993 Sep;5[3]:199-207
Tarn, M., Edwards, J. G., and Sedgwick, E. M., Fluoxetine, amitriptyline and the electroencephalogram. J Affect Disord 1993 Sep;29[1]:7-10
Pijl, H., Koppeschaar, H. P., Cohen, A. F., Iestra, J. A., Schoemaker, H. C., Frolich, M., Onkenhout, W., and Meinders, A. E., Evidence for brain serotonin-mediated control of carbohydrate consumption in normal weight and obese humans. Int J Obes Relat Metab Disord 1993 Sep;17[9]:513-520
Goddard, A. W., Woods, S. W., Sholomskas, D. E., Goodman, W. K., Charney, D. S., and Heninger, G. R., Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993 Aug;48[2]:119-133
Hellerstein, D. J., Yanowitch, P., Rosenthal, J., Samstag, L. W., Maurer, M., Kasch, K., Burrows, L., Poster, M., Cantillon, M., and Winston, A., A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993 Aug;150[8]:1169-1175
Goldstein, D. J., Rampey, A. H., Jr., Potvin, J. H., Masica, D. N., and Beasley, C. M., Jr., Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. J Clin Psychiatry 1993 Aug;54[8]:309-316
Waller, D. A., Gullion, C. M., Petty, F., Hardy, B. W., Murdock, M. V., and Rush, A. J., Tridimensional Personality Questionnaire and serotonin in bulimia nervosa. Psychiatry Res 1993 Jul;48[1]:9-15
Besancon, G., Cousin, R., Guitton, B., and Lavergne, F., [Double-blind study of mianserin and fluoxetine in ambulatory therapy of depressed patients]. Encephale 1993 Jul;19[4]:341-345
Montgomery, S. A., McIntyre, A., Osterheider, M., Sarteschi, P., Zitterl, W., Zohar, J., Birkett, M., and Wood, A. J., A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993 Jun;3[2]:143-152
Feighner, J. P., Cohn, J. B., Fabre, L. F., Jr., Fieve, R. R., Mendels, J., Shrivastava, R. K., and Dunbar, G. C., A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord 1993 Jun;28[2]:71-79
George, M. S. and Trimble, M. R., Dystonic reaction associated with fluvoxamine. J Clin Psychopharmacol 1993 Jun;13[3]:220-221
Linnoila, M., Stapleton, J. M., George, D. T., Lane, E., and Eckardt, M. J., Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. J Clin Psychopharmacol 1993 Jun;13[3]:175-180
Spina, E., Avenoso, A., Pollicino, A. M., Caputi, A. P., Fazio, A., and Pisani, F., Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993 Jun;15[3]:247-250
Hollander, E., Stein, D. J., DeCaria, C. M., Saoud, J. B., Klein, D. F., and Liebowitz, M. R., A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder. Biol Psychiatry 1993May15;33[10]:747-749
Buchholtz-Hansen, P. E., Wang, A. G., and Kragh-Sorensen, P., Mortality in major affective disorder: relationship to subtype of depression. The Danish University Antidepressant Group. Acta Psychiatr Scand 1993 May;87[5]:329-335
Dunbar, G. C., Claghorn, J. L., Kiev, A., Rickels, K., and Smith, W. T., A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand 1993 May;87[5]:302-305
De Vries, M. H., Van Harten, J., Van Bemmel, P., and Raghoebar, M., Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos 1993 May;14[4]:291-296
Grady, T. A., Pigott, T. A., L’Heureux, F., Hill, J. L., Bernstein, S. E., and Murphy, D. L., Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993 May;150[5]:819-821
Goldbloom, D. S. and Olmsted, M. P., Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Am J Psychiatry 1993 May;150[5]:770-774
Moller, H. J., Berzewski, H., Eckmann, F., Gonzalves, N., Kissling, W., Knorr, W., Ressler, P., Rudolf, G. A., Steinmeyer, E. M., Magyar, I., Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 1993 May;26[3]:75-78
Visser, M., Seidell, J. C., Koppeschaar, H. P., and Smits, P., The effect of fluoxetine on body weight, body composition and visceral fat accumulation. Int J Obes Relat Metab Disord 1993 May;17[5]:247-253
Kranzler, H. R., Del Boca, F., Korner, P., and Brown, J., Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism. J Subst Abuse Treat 1993 May;10[3]:283-287
Pelicier, Y. and Schaeffer, P., [Multicenter double-blind study comparing the efficacy and tolerance of paroxetine and clomipramine in reactive depression in the elderly patient]. Encephale 1993 May;19[3]:257-261
Pols, H., Zandergen, J., de Loof, C., Fernandez, I., and Griez, E., Clinical effects of fluvoxamine on panic symptomatology. Acta Psychiatr Belg 1993 May;93[3]:169-177
Nielsen, B. M., Behnke, K., Arup, P., Christiansen, P. E., Geisler, A., Ipsen, E., Maach-Moller, B., and Ohrberg, S. C., A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand 1993 Apr;87[4]:269-272
Kurlan, R., Como, P. G., Deeley, C., McDermott, M., and McDermott, M. P., A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette’s syndrome. Clin Neuropharmacol 1993 Apr;16[2]:167-172
McDougle, C. J., Goodman, W. K., Leckman, J. F., Holzer, J. C., Barr, L. C., McCance-Katz, E., Heninger, G. R., and Price, L. H., Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993 Apr;150[4]:647-649
Johnson, M. R., Lydiard, R. B., Morton, W. A., Laird, L. K., Steele, T. E., Kellner, C. H., and Ballenger, J. C., Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res 1993 Apr;27[2]:161-172
Greenes, D., Fava, M., Cioffi, J., and Herzog, D. B., The relationship of depression to dissociation in patients with bulimia nervosa. J Psychiatr Res 1993 Apr;27[2]:133-137
Judd, F. K., Moore, K., Norman, T. R., Burrows, G. D., Gupta, R. K., and Parker, G., A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Aust N Z J Psychiatry 1993 Mar;27[1]:49-55
Kasper, S., Dotsch, M., Kick, H., Vieira, A., and Moller, H. J., Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993 Mar;3[1]:13-21
Bretz, W. A., Krahn, D. D., Drury, M., Schork, N., and Loesche, W. J., Effects of fluoxetine on the oral environment of bulimics. Oral Microbiol Immunol 1993 Feb;8[1]:62-64
De Wilde, J., Spiers, R., Mertens, C., Bartholome, F., Schotte, G., and Leyman, S., A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993 Feb;87[2]:141-145
van Wyk, M., Sommers, D. K., and Moncrieff, J., Effects of enhancement and antagonism of 5-hydroxytryptamine activity on the influence of metoclopramide on gastric emptying. Digestion 1993;54[1]:40-43
Norman, T. R., Gupta, R. K., Burrows, G. D., Parker, G., and Judd, F. K., Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 1993;8[1]:25-29
Williams, R., Edwards, R. A., Newburn, G. M., Mullen, R., Menkes, D. B., and Segkar, C, A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol 1993 Jan;7[3-4]:155-158
Black, D. W., Wesner, R., Bowers, W., and Gabel, J., A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993 Jan;50[1]:44-50
Menkes, D. B., Taghavi, E., Mason, P. A., and Howard, R. C., Fluoxetine’s spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol 1993;8[2]:95-102
Kerr, J. S., Fairweather, D. B., and Hindmarch, I., Effects of fluoxetine on psychomotor performance, cognitive function and sleep in depressed patients. Int Clin Psychopharmacol 1993;8[4]:341-343
Ceccherini-Nelli, A. and Guidi, L., Fluoxetine: the relationship between response, adverse events, and plasma concentrations in the treatment of bulimia nervosa. Int Clin Psychopharmacol 1993;8[4]:311-313
Wood, A., Pharmacotherapy of bulimia nervosa--experience with fluoxetine. Int Clin Psychopharmacol 1993;8[4]:295-299
Tollefson, G. D. and Holman, S. L., Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol 1993;8[4]:253-259
Heiligenstein, J. H., Tollefson, G. D., and Faries, D. E., A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. Int Clin Psychopharmacol 1993;8[4]:247-251
Aguglia, E., Casacchia, M., Cassano, G. B., Faravelli, C., Ferrari, G., Giordano, P., Pancheri, P., Ravizza, L., Trabucchi, M., Bolino, F., Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993;8[3]:197-202
Montgomery, S. A. and Dunbar, G., Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8[3]:189-195
Montgomery, S. A., Rasmussen, J. G., and Tanghoj, P., A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8[3]:181-188
Beasley, C. M., Jr., Sayler, M. E., and Potvin, J. H., Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int Clin Psychopharmacol 1993;8[3]:143-149
van Bemmel, A. L., van den Hoofdakker, R. H., Beersma, D. G., and Bouhuys, A. L., Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology (Berl) 1993;113[2]:225-230
Claghorn, J. L., Kiev, A., Rickels, K., Smith, W. T., and Dunbar, G. C., Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry 1992 Dec;53[12]:434-438
Ohrberg, S., Christiansen, P. E., Severin, B., Calberg, H., Nilakantan, B., Borup, A., Sogaard, J., Larsen, S. B., Loldrup, D., Bahr, B., Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand 1992 Dec;86[6]:437-444
Gray, D. S., Fujioka, K., Devine, W., and Bray, G. A., A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord 1992 Dec;16 Suppl 4:S67-S72
Potter van Loon, B. J., Radder, J. K., Frolich, M., Krans, H. M., Zwinderman, A. H., and Meinders, A. E., Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992 Dec;16 Suppl 4:S55-S61
Kerr, J. S., Fairweather, D. B., Mahendran, R., and Hindmarch, I., The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol 1992 Nov;7[2]:101-108
Leibenluft, E., Noonan, B. M., and Wehr, T. A., Diurnal variation: reliability of measurement and relationship to typical and atypical symptoms of depression. J Affect Disord 1992 Nov;26[3]:199-204
O’Keane, V., McLoughlin, D., and Dinan, T. G., D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. J Affect Disord 1992 Nov;26[3]:143-150
Riddle, M. A., Scahill, L., King, R. A., Hardin, M. T., Anderson, G. M., Ort, S. I., Smith, J. C., Leckman, J. F., and Cohen, D. J., Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992 Nov;31[6]:1062-1069
Sindrup, S. H., Bjerre, U., Dejgaard, A., Brosen, K., Aaes-Jorgensen, T., and Gram, L. F., The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992 Nov;52[5]:547-552
Greenblatt, D. J., Preskorn, S. H., Cotreau, M. M., Horst, W. D., and Harmatz, J. S., Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992 Nov;52[5]:479-486
Raucoules, D., Levy, C., Azorin, J. M., Bruno, M., and Valli, M., [Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study]. Encephale 1992 Nov;18[6]:611-616
Beasley, C. M., Jr., Sayler, M. E., Weiss, A. M., and Potvin, J. H., Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol 1992 Oct;12[5]:328-333
Chouinard, G., Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992 Oct;7 Suppl 2:37-41
Thompson, C., Bridging the gap between psychiatric practice and primary care. Int Clin Psychopharmacol 1992 Oct;7 Suppl 2:31-36
Dominguez, R. A., Serotonergic antidepressants and their efficacy in obsessive compulsive disorder. J Clin Psychiatry 1992 Oct;53 Suppl:56-59
Van Harten, J., Stevens, L. A., Raghoebar, M., Holland, R. L., Wesnes, K., and Cournot,, A. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther 1992 Oct;52[4]:427-435
Kopelman, P. G., Elliott, M. W., Simonds, A., Cramer, D., Ward, S., and Wedzicha, J. A., Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation. Int J Obes Relat Metab Disord 1992 Oct;16[10]:825-830
Wood, S. H., Mortola, J. F., Chan, Y. F., Moossazadeh, F., and Yen, S. S., Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992 Sep;80[3 Pt 1]:339-344
Menkes, D. B., Taghavi, E., Mason, P. A., Spears, G. F., and Howard, R. C., Fluoxetine treatment of severe premenstrual syndrome. BMJ 1992Aug8;305[6849]:346-347
Nyth, A. L., Gottfries, C. G., Lyby, K., Smedegaard-Andersen, L., Gylding-Sabroe, J., Kristensen, M., Refsum, H. E., Ofsti, E., Eriksson, S., and Syversen, S., A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992 Aug;86[2]:138-145
Peselow, E. D., Robins, C. J., Sanfilipo, M. P., Block, P., and Fieve, R. R., Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. J Abnorm Psychol 1992 Aug;101[3]:479-486
Apseloff, G., Wilner, K. D., von Deutsch, D. A., Henry, E. B., Tremaine, L. M., Gerber, N., and Lazar, J. D., Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers. J Clin Pharmacol 1992 Jul;32[7]:643-646
Olafsson, K., Jorgensen, S., Jensen, H. V., Bille, A., Arup, P., and Andersen, J., Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 1992 Jun;85[6]:453-456
Naranjo, C. A., Poulos, C. X., Bremner, K. E., and Lanctot, K. L., Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 1992 Jun;51[6]:729-739
Montgomery, S. A. and Rasmussen, J. G., Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1992 Jun;6 Suppl 5:71-73
Montgomery, S. A., Rasmussen, J. G., Lyby, K., Connor, P., and Tanghoj, P., Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992 Jun;6 Suppl 5:65-70
Hindmarch, I., A review of the psychomotor effects of paroxetine. Int Clin Psychopharmacol 1992 Jun;6 Suppl 4:65-67
Warrington, S. J. and Lewis, Y., Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. Int Clin Psychopharmacol 1992 Jun;6 Suppl 4:59-64
Dorman, T., Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. Int Clin Psychopharmacol 1992 Jun;6 Suppl 4:53-58
Hutchinson, D. R., Tong, S., Moon, C. A., Vince, M., and Clarke, A., Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol 1992 Jun;6 Suppl 4:43-51
Bignamini, A. and Rapisarda, V., A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Italian Paroxetine Study Group. Int Clin Psychopharmacol 1992 Jun;6 Suppl 4:37-41
Feighner, J. P., A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. Int Clin Psychopharmacol 1992 Jun;6 Suppl 4:31-35
Claghorn, J., A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients. Int Clin Psychopharmacol 1992 Jun;6 Suppl 4:25-30
Sindrup, S. H., Bach, F. W., and Gram, L. F., Plasma beta-endorphin is not affected by treatment with imipramine or paroxetine in patients with diabetic neuropathy symptoms. Clin J Pain 1992 Jun;8[2]:145-148
Max, M. B., Lynch, S. A., Muir, J., Shoaf, S. E., Smoller, B., and Dubner, R., Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992May7;326[19]:1250-1256
Steinmeyer, E. M. and Moller, H. J., Facet theoretic analysis of the Hamilton-D scale. J Affect Disord 1992 May;25[1]:53-61
Stinson, J. C., Murphy, C. M., Andrews, J. F., and Tomkin, G. H., An assessment of the thermogenic effects of fluoxetine in obese subjects. Int J Obes Relat Metab Disord 1992 May;16[5]:391-395
Dalery, J., Rochat, C., Peyron, E., and Bernard, G., [Comparative study of the efficacy and acceptability of amineptine and fluoxetine in patients with major depression]. Encephale 1992 May;18[3]:257-262
Silver, H. and Nassar, A., Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992Apr1;31[7]:698-704
Gorelick, D. A. and Paredes, A., Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992 Apr;16[2]:261-265
Gray, D. S., Fujioka, K., Devine, W., and Bray, G. A., Fluoxetine treatment of the obese diabetic. Int J Obes Relat Metab Disord 1992 Mar;16[3]:193-198
Dunner, D. L., Cohn, J. B., Walshe, T., III, Cohn, C. K., Feighner, J. P., Fieve, R. R., Halikas, J. P., Hartford, J. T., Hearst, E. D., Settle, E. C., Jr., Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992 Feb;53 Suppl:57-60
Adly, C., Straumanis, J., and Chesson, A., Fluoxetine prophylaxis of migraine. Headache 1992 Feb;32[2]:101-104
Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psychiatry 1992 Feb;49[2]:139-147
Doogan, D. P. and Caillard, V., Sertraline in the prevention of depression. Br J Psychiatry 1992 Feb;160:217-222
Cohn, J. B. and Wilcox, C. S., Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992 Feb;53 Suppl:52-56
Shrivastava, R. K., Shrivastava, S. H., Overweg, N., and Blumhardt, C. L., A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry 1992 Feb;53 Suppl:48-51
Feighner, J. P. and Boyer, W. F., Paroxetine in the treatment of depression: a comparison with imipramine and placebo. J Clin Psychiatry 1992 Feb;53 Suppl:44-47
Fabre, L. F., A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 1992 Feb;53 Suppl:40-43
Smith, W. T. and Glaudin, V., A placebo-controlled trial of paroxetine in the treatment of major depression. J Clin Psychiatry 1992 Feb;53 Suppl:36-39
Claghorn, J. L., The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. J Clin Psychiatry 1992 Feb;53 Suppl:33-35
Rickels, K., Amsterdam, J., Clary, C., Fox, I., Schweizer, E., and Weise, C., The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. J Clin Psychiatry 1992 Feb;53 Suppl:30-32
Kiev, A., A double-blind, placebo-controlled study of paroxetine in depressed outpatients. J Clin Psychiatry 1992 Feb;53 Suppl:27-29
Potter van Loon, B. J., Radder, J. K., Frolich, M., Krans, H. M., Zwinderman, A. H., and Meinders, A. E., Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. Int J Obes Relat Metab Disord 1992 Feb;16[2]:79-85
Beasley, C. M., Jr., Potvin, J. H., Masica, D. N., Wheadon, D. E., Dornseif, B. E., and Genduso, L. A., Fluoxetine no association with suicidality in obsessive-compulsive disorder. J Affect Disord 1992 Jan;24[1]:1-10
Wise, S. D., Clinical studies with fluoxetine in obesity. Am J Clin Nutr 1992 Jan;55[1 Suppl]:181S-184S
Bougerol, T., Uchida, C., Gachoud, J. P., Kohler, M., and Mikkelsen, H., Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial. Psychopharmacology (Berl) 1992;106 Suppl:S102-S108
Brown, W. A. and Harrison, W., Are patients who are intolerant to one SSRI intolerant to another?. Psychopharmacol Bull 1992;28[3]:253-256
Sellers, E. M., Higgins, G. A., Tompkins, D. M., and Romach, M. K., Serotonin and alcohol drinking. NIDA Res Monogr 1992;119:141-145
Whitehead AM, Ashford JJ., Fluvoxamine in the treatment of depressive illness. A series of double-blind hospital based comparative studies carried out in the UK. Br J Clin Pract 1992;46[1]:21-23
Gasperini, M., Gatti, F., Bellini, L., Anniverno, R., and Smeraldi, E., Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine. A double-blind study in depressed inpatients. Neuropsychobiology 1992;26[4]:186-192
Lapierre, Y. D., Controlling acute episodes of depression. Int Clin Psychopharmacol 1991 Dec;6 Suppl 2:23-35
Christenson, G. A., Mackenzie, T. B., Mitchell, J. E., and Callies, A. L., A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 1991 Nov;148[11]:1566-1571
Andersen, B. B., Mikkelsen, M., Vesterager, A., Dam, M., Kristensen, H. B., Pedersen, B., Lund, J., and Mengel, H., No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991 Nov;10[2-3]:201-204
Faull, C. M., Rooke, P., and Baylis, P. H., The effect of a highly specific serotonin agonist on osmoregulated vasopressin secretion in healthy man. Clin Endocrinol (Oxf) 1991 Nov;35[5]:423-430
Van Harten, J., Van Bemmel, P., Dobrinska, M. R., Ferguson, R. K., and Raghoebar, M., Bioavailability of fluvoxamine given with and without food. Biopharm Drug Dispos 1991 Nov;12[8]:571-576
Davis, B. A., Boulton, A. A., Yu, P. H., Durden, D. A., Keegan, D. L., Bowen, R. C., Blackshaw, S., D’Arcy, C., Remillard, A. J., Dayal, N., et al., Longitudinal effect of amitriptyline and fluoxetine treatment on plasma phenylacetic acid concentrations in depression. Biol Psychiatry 1991Sep15;30[6]:600-608
Weddington, W. W., Haertzen, C. A., Hess, J. M., and Brown, B. S., Psychological reactions and retention by cocaine addicts during treatment according to HIV-serostatus: a matched-control study. Am J Drug Alcohol Abuse 1991 Sep;17[3]:355-368
Dunbar, G. C., Cohn, J. B., Fabre, L. F., Feighner, J. P., Fieve, R. R., Mendels, J., and Shrivastava, R. K., A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991 Sep;159:394-398
O’Flynn, K., O’Keane, V., Lucey, J. V., and Dinan, T. G., Effect of fluoxetine on noradrenergic mediated growth hormone release: a double blind, placebo-controlled study. Biol Psychiatry 1991Aug15;30[4]:377-382
Feighner, J. P., Gardner, E. A., Johnston, J. A., Batey, S. R., Khayrallah, M. A., Ascher, J. A., and Lineberry, C. G., Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991 Aug;52[8]:329-335
Darga, L. L., Carroll-Michals, L., Botsford, S. J., and Lucas, C. P., Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr 1991 Aug;54[2]:321-325
Beasley, C. M., Jr., Dornseif, B. E., Pultz, J. A., Bosomworth, J. C., and Sayler, M. E., Fluoxetine versus trazodone efficacy and activating-sedating effects. J Clin Psychiatry 1991 Jul;52[7]:294-299
Stone, A. B., Pearlstein, T. B., and Brown, W. A., Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991 Jul;52[7]:290-293
Noguera, R., Altuna, R., Alvarez, E., Ayuso, J. L., Casais, L., and Udina, C., Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial. J Affect Disord 1991 Jul;22[3]:119-124
Fabre, L. F., Scharf, M. B., and Itil, T. M., Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatry 1991 Jun;52 Suppl:62-67
McDougle, C. J., Price, L. H., Goodman, W. K., Charney, D. S., and Heninger, G. R., A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991 Jun;11[3]:175-184
Souche, A., Montaldi, S., Uehlinger, C., Kasas, A., Reymond, M. J., Reymond, P., Baumann, P., and Dufour, H., [Treatment of resistant depression with the citalopram-lithium combination. Methodology of a double-blind multicenter study and preliminary results]. Encephale 1991 May;17[3]:213-219
Ansseau, M., von Frenckell, R., Gerard, M. A., Mertens, C., De Wilde, J., Botte, L., Devoitille, J. M., Evrard, J. L., De Nayer, A., Darimont, P., et al., Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol 1991 May;1[2]:113-121
Kasper, S., Kick, H., Voll, G., and Vieira, A., Therapeutic sleep deprivation and antidepressant medication in patients with major depression. Eur Neuropsychopharmacol 1991 May;1[2]:107-111
Usher, R. W., Beasley, C. M., Jr., and Bosomworth, J. C., Efficacy and safety of morning versus evening fluoxetine administration. J Clin Psychiatry 1991 Mar;52[3]:134-136
de Jonghe, F., Ravelli, D. P., and Tuynman-Qua, H., A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991 Mar;24[2]:62-67
Pijl, H., Koppeschaar, H. P., Willekens, F. L., Op, de Kamp, I, Veldhuis, H. D., and Meinders, A. E., Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 1991 Mar;15[3]:237-242
Pakesch, G. and Dossenbach, M., [Efficacy and safety of fluoxetine versus clomipramine in ambulatory patients with a depressive syndrome in a clinical trial with private practitioners]. Wien Klin Wochenschr 1991;103[6]:176-182
Hollander, E., DeCaria, C., Gully, R., Nitescu, A., Suckow, R. F., Gorman, J. M., Klein, D. F., and Liebowitz, M. R., Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 1991 Jan;36[1]:1-17
Fichter, M. M., Leibl, K., Rief, W., Brunner, E., Schmidt-Auberger, S., and Engel, R. R., Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry 1991 Jan;24[1]:1-7
Keegan, D., Bowen, R. C., Blackshaw, S., Saleh, S., Dayal, N., Remillard, F., Shrikhande, S., Cebrian, Perez S., and Boulton, A., A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol 1991;6[2]:117-124
Lasher, T. A., Fleishaker, J. C., Steenwyk, R. C., and Antal, E. J., Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl) 1991;104[3]:323-327
Poldinger, W., Calanchini, B., and Schwarz, W., A functional-dimensional approach to depression serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology 1991;24[2]:53-81
de Jonghe, F., Swinkels, J., and Tuynman-Qua, H., Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry 1991 Jan;24[1]:21-27
Kupfer, D. J., Perel, J. M., Pollock, B. G., Nathan, R. S., Grochocinski, V. J., Wilson, M. J., and McEachran, A. B., Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry 1991Jan1;29[1]:23-40
George, M. S. and Lydiard, R. B., Speed of onset of action of the newer antidepressants--fluoxetine and bupropion. Int Clin Psychopharmacol 1991;6[4]:209-217
Moon, C. A. and Jesinger, D. K., The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Br J Clin Pract 1991;45[4]:259-262
Rahman, M. K., Akhtar, M. J., Savla, N. C., Sharma, R. R., Kellett, J. M., and Ashford, J. J., A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br J Clin Pract 1991;45[4]:255-258
Stratta, P., Bolino, F., Cupillari, M., and Casacchia, M., A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991;6[3]:193-196
Pomerleau, O. F., Pomerleau, C. S., Morrell, E. M., and Lowenbergh, J. M., Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. Psychoneuroendocrinology 1991;16[5]:433-440
Sommers, D. K., Meyer, E. C., and van Wyk, M., Effects of enhancement and antagonism of 5-hydroxytryptamine activity on metoclopramide-induced aldosterone secretion in man. Res Exp Med (Berl) 1991;191[6]:423-427
Fava, M., Rosenbaum, J. F., McCarthy, M., Pava, J., Steingard, R., and Bless, E., Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacol Bull 1991;27[3]:275-279
Lesch, K. P., Hoh, A., Schulte, H. M., Osterheider, M., and Muller, T., Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder. Psychopharmacology (Berl) 1991;105[3]:415-420
Cohn, C. K., Shrivastava, R., Mendels, J., Cohn, J. B., Fabre, L. F., Claghorn, J. L., Dessain, E. C., Itil, T. M., and Lautin, A., Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990 Dec;51 Suppl B:28-33
Reimherr, F. W., Chouinard, G., Cohn, C. K., Cole, J. O., Itil, T. M., Lapierre, Y. D., Masco, H. L., and Mendels, J., Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990 Dec;51 Suppl B:18-27
Nyth, A. L. and Gottfries, C. G., The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990 Dec;157:894-901
Bystritsky, A. and Pasnau, R. O., Initial reaction and subsequent response to antidepressants in panic patients. Am J Psychiatry 1990 Nov;147[11]:1575
Delgado, P. L., Goodman, W. K., Price, L. H., Heninger, G. R., and Charney, D. S., Fluvoxamine/pimozide treatment of concurrent Tourette’s and obsessive-compulsive disorder. Br J Psychiatry 1990 Nov;157:762-765
Pigott, T. A., Pato, M. T., Bernstein, S. E., Grover, G. N., Hill, J. L., Tolliver, T. J., and Murphy, D. L., Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 1990 Oct;47[10]:926-932
Kerkhofs, M., Rielaert, C., de, Maertelaer, V, Linkowski, P., Czarka, M., and Mendlewicz, J., Fluoxetine in major depression efficacy, safety and effects on sleep polygraphic variables. Int Clin Psychopharmacol 1990 Oct;5[4]:253-260
Nathan, R. S., Perel, J. M., Pollock, B. G., and Kupfer, D. J., The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry 1990 Sep;51[9]:367-372
Sindrup, S. H., Gram, L. F., Brosen, K., Eshoj, O., and Mogensen, E. F., The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990 Aug;42[2]:135-144
Marcus, M. D., Wing, R. R., Ewing, L., Kern, E., McDermott, M., and Gooding, W., A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry 1990 Jul;147[7]:876-881
Goodman, W. K., Price, L. H., Delgado, P. L., Palumbo, J., Krystal, J. H., Nagy, L. M., Rasmussen, S. A., Heninger, G. R., and Charney, D. S., Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990 Jun;47[6]:577-585
Kasper, S., Voll, G., Vieira, A., and Kick, H., Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression--results of a double-blind study. Pharmacopsychiatry 1990 May;23[3]:135-142
Naranjo, C. A., Kadlec, K. E., Sanhueza, P., Woodley-Remus, D., and Sellers, E. M., Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990 Apr;47[4]:490-498
Paroxetine a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 1990 Apr;18[4]:289-299
Fudge, J. L., Perry, P. J., Garvey, M. J., and Kelly, M. W., A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. J Affect Disord 1990 Apr;18[4]:275-280
Jenike, M. A., Baer, L., and Greist, J. H., Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 1990 Apr;10[2]:122-124
Vanelle, J. M., Poirier, M. F., Benkelfat, C., Galinowski, A., Sechter, D., Suzini, de Luca, and Loo, H., Diagnostic and therapeutic value of testing stimulation of thyroid-stimulating hormone by thyrotropin-releasing hormone in 100 depressed patients. Acta Psychiatr Scand 1990 Feb;81[2]:156-161
Schweizer, E., Rickels, K., Amsterdam, J. D., Fox, I., Puzzuoli, G., and Weise, C., Private Practice Research Group, University of Pennsylvania, Philadelphia. J Clin Psychiatry 1990 Jan;51[1]:8-11
Stone, A. B., Pearlstein, T. B., and Brown, W. A., Fluoxetine in the treatment of premenstrual syndrome. Psychopharmacol Bull 1990;26[3]:331-335
Orzack, M. H., Friedman, L. M., and Marby, D. W., Weight changes on fluoxetine as a function of baseline weight in depressed outpatients. Psychopharmacol Bull 1990;26[3]:327-330
Chouinard, G., Goodman, W., Greist, J., Jenike, M., Rasmussen, S., White, K., Hackett, E., Gaffney, M., and Bick, P. A., Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990;26[3]:279-284
Dunlop, S. R., Dornseif, B. E., Wernicke, J. F., and Potvin, J. H., Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 1990;26[2]:173-180
Beasley, C. M., Jr., Bosomworth, J. C., and Wernicke, J. F., Fluoxetine relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26[1]:18-24
Kuhs, H. and Rudolf, G. A., Cardiovascular effects of paroxetine. Psychopharmacology (Berl) 1990;102[3]:379-382
Cohn, J. B., Crowder, J. E., Wilcox, C. S., and Ryan, P. J., A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol Bull 1990;26[2]:185-189
Perez, A. and Ashford, J. J., A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. Curr Med Res Opin 1990;12[4]:234-241
Gonella, G., Baignoli, G., and Ecari, U., Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study. Curr Med Res Opin 1990;12[3]:177-184
Veeninga, A. T., Westenberg, H. G., and Weusten, J. T., Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacology (Berl) 1990;102[3]:414-416
Cottraux, J., Mollard, E., Bouvard, M., Marks, I., Sluys, M., Nury, A. M., Douge, R., and Cialdella, P., A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990 Jan;5[1]:17-30
Den Boer, J. A. and Westenberg, H. G., Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102[1]:85-94
Falk, W. E., Rosenbaum, J. F., Otto, M. W., Zusky, P. M., Weilburg, J. B., and Nixon, R. A., Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol 1989 Oct;2[4]:208-214
Cohn, J. B., Collins, G., Ashbrook, E., and Wernicke, J. F., A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989 Oct;4[4]:313-322
Corne, S. J. and Hall, J. R., A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice. Int Clin Psychopharmacol 1989 Jul;4[3]:245-254
Feighner, J. P., Boyer, W. F., Meredith, C. H., and Hendrickson, G. G., A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989 Jul;4[3]:239-244
Feighner, J. P., Boyer, W. F., Merideth, C. H., and Hendrickson, G. G., A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol 1989 Apr;4[2]:127-134
Loeb, C., Albano, C., and Gandolfo, C., Fluoxetine versus imipramine. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:75-79
Allen, D. and Lader, M., Interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:7-14
Bressa, G. M., Brugnoli, R., and Pancheri, P., A double-blind study of fluoxetine and imipramine in major depression. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:69-73
Taneri, Z. and Kohler, R., Fluoxetine versus nomifensine in outpatients with neurotic or reactive depressive disorder. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:57-61
Tamminen, T. T. and Lehtinen, V. V., A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:51-56
Altamura, A. C., Percudani, M., Guercetti, G., and Invernizzi, G., Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:103-106
Altamura, A. C., De Novellis, F., Guercetti, G., Invernizzi, G., Percudani, M., and Montgomery, S. A., Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989;9[6]:391-396
Amin, M., Lehmann, H., and Mirmiran, J., A double-blind, placebo-controlled dose-finding study with sertraline. Psychopharmacol Bull 1989;25[2]:164-167
Dornseif, B. E., Dunlop, S. R., Potvin, J. H., and Wernicke, J. F., Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989;25[1]:71-79
Ferreri, M., Fluoxetine versus amineptine in the treatment of outpatients with major depressive disorders. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:97-101
Ropert, R., Fluoxetine versus clomipramine in major depressive disorders. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:89-95
Poelinger, W. and Haber, H., Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:47-50
Levine, S., Deo, R., and Mahadevan, K., A comparative trial of a new antidepressant, fluoxetine. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:41-45
Ginestet, D., Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:37-40
Levine, L. R., Enas, G. G., Thompson, W. L., Byyny, R. L., Dauer, A. D., Kirby, R. W., Kreindler, T. G., Levy, B., Lucas, C. P., McIlwain, H. H., et al., Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). Int J Obes 1989;13[5]:635-645
von Bardeleben, U., Steiger, A., Gerken, A., and Holsboer, F., Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:1-5
Peselow, E. D., Filippi, A. M., Goodnick, P., Barouche, F., and Fieve, R. R., The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacol Bull 1989;25[2]:272-276
Peselow, E. D., Filippi, A. M., Goodnick, P., Barouche, F., and Fieve, R. R., The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacol Bull 1989;25[2]:267-271
Hebenstreit, G. F., Fellerer, K., Zochling, R., Zentz, A., and Dunbar, G. C., A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand Suppl 1989;350:81-84
Cooper, S. M., Jackson, D., Loudon, J. M., McClelland, G. R., and Raptopoulos, P., The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol. Acta Psychiatr Scand Suppl 1989;350:53-55
Hassan, S. M., Wainscott, G., and Turner, P., Paroxetine: lack of effect on the tyramine pressor response in man. Acta Psychiatr Scand Suppl 1989;350:49
Hindmarch, I. and Harrison, C., The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity related to car driving. Acta Psychiatr Scand Suppl 1989;350:45
Warrington, S. J., Dana-Haeri, J., and Sinclair, A. J., Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy men. Acta Psychiatr Scand Suppl 1989;350:42-44
Schlake, H. P., Kuhs, H., Rolf, L. H., Bosse, T., Schuhknecht, E., Rudolf, G. A., and Brune, G. G., Platelet 5-HT transport in depressed patients under double-blind treatment with paroxetine versus amitriptyline. Acta Psychiatr Scand Suppl 1989;350:149-151
Kuhs, H. and Rudolf, G. A., A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr Scand Suppl 1989;350:145-146
Miller, S. M., Naylor, G. J., Murtagh, M., and Winslow, G., A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. Acta Psychiatr Scand Suppl 1989;350:143-144
Bascara, L., A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr Scand Suppl 1989;350:141-142
Byrne, M. M., Meta-analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta Psychiatr Scand Suppl 1989;350:138-139
Guillibert, E., Pelicier, Y., Archambault, J. C., Chabannes, J. P., Clerc, G., Desvilles, M., Guibert, M., Pagot, R., Poisat, J. L., and Thobie, Y., A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl 1989;350:132-134
Gagiano, C. A., Muller, P. G., Fourie, J., and Le Roux, J. F., The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients. Acta Psychiatr Scand Suppl 1989;350:130-131
Feighner, J. P. and Boyer, W. F., Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand Suppl 1989;350:125-129
Rickels, K., Amsterdam, J., Clary, C., Fox, I., Schweizer, E., and Weise, C., A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatr Scand Suppl 1989;350:117-123
Lydiard, R. B., Laird, L. K., Morton, W. A., Jr., Steele, T. E., Kellner, C., Laraia, M. T., and Ballenger, J. C., Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull 1989;25[1]:68-70
Hamilton, B. A., Jones, P. G., Hoda, A. N., Keane, P. M., Majid, I., and Zaidi, S. I., Flupenthixol and fluvoxamine in mild to moderate depression: a comparison in general practice. Pharmatherapeutica 1989;5[5]:292-297
Westenberg, H. G. and Den Boer, J. A., Serotonin-influencing drugs in the treatment of panic disorder. Psychopathology 1989;22 Suppl 1:68-77
Netter, P. and Rammsayer, T., Serotoninergic effects on sensory and motor responses in extraverts and introverts. Int Clin Psychopharmacol 1989 Jan;4 Suppl 1:21-26
Goodman, W. K., Price, L. H., Rasmussen, S. A., Delgado, P. L., Heninger, G. R., and Charney, D. S., Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 1989 Jan;46[1]:36-44
Debus, J. R., Rush, A. J., Himmel, C., Tyler, D., Polatin, P., and Weissenburger, J., Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry 1988 Nov;49[11]:422-426
Rammsayer, T. and Netter, P., Effects of changes in brain 5-HT activity on indicators of cortical arousal. Int Clin Psychopharmacol 1988 Jul;3[3]:231-237
Byerley, W. F., Reimherr, F. W., Wood, D. R., and Grosser, B. I., Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988 Apr;8[2]:112-115
Mullin, J. M., Pandita-Gunawardena, V. R., and Whitehead, A. M., A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br J Clin Pract 1988 Feb;42[2]:51-55
Reimherr, F. W., Byerley, W. F., Ward, M. F., Lebegue, B. J., and Wender, P. H., Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull 1988;24[1]:200-205
Wernicke, J. F., Dunlop, S. R., Dornseif, B. E., Bosomworth, J. C., and Humbert, M., Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24[1]:183-188
A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness. South Wales Antidepressant Drug Trial Group. Int Clin Psychopharmacol 1988 Jan;3[1]:75-81
Harto, N. E., Spera, K. F., and Branconnier, R. J., Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull 1988;24[2]:220-223
Sullivan, J. T., Naranjo, C. A., and Sellers, E. M., Compliance among heavy alcohol users in clinical drug trials. J Subst Abuse 1988;1[2]:183-194
Den Boer, J. A. and Westenberg, H. G., Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988 Jan;3[1]:59-74
Sellers, E. M., Naranjo, C. A., and Kadlec, K., Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers. J Clin Psychopharmacol 1987 Dec;7[6]:417-420
Fabre, L. F. and Putman, H. P., III., A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 1987 Oct;48[10]:406-408
Timmerman, L., de Beurs, P., Tan, B. K., Leijnse-Ybema, H., Sanchez, C., Hopfner Petersen, H. E., and Cohen Stuart, M. H., A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. Int Clin Psychopharmacol 1987 Jul;2[3]:239-253
Benkelfat, C., Poirier, M. F., Leouffre, P., Gay, C., and Loo, H., Dexamethasone suppression test and the response to antidepressant depending on their central monoaminergic action in major depression. Can J Psychiatry 1987 Apr;32[3]:175-178
Guelfi, J. D., Dreyfus, J. F., and Pichot, P., Fluvoxamine and imipramine results of a long-term controlled trial. Int Clin Psychopharmacol 1987 Apr;2[2]:103-109
Naranjo, C. A., Sellers, E. M., Sullivan, J. T., Woodley, D. V., Kadlec, K., and Sykora, K., The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987 Mar;41[3]:266-274
Emrich, H. M., Berger, M., Riemann, D., and von Zerssen, D., Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry 1987 Mar;20[2]:60-63
Wernicke, J. F., Dunlop, S. R., Dornseif, B. E., and Zerbe, R. L., Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23[1]:164-168
Goodnick, P. J., Fieve, R. R., Peselow, E. D., Barouche, F., and Schlegel, A., Double-blind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGI change. Psychopharmacol Bull 1987;23[1]:162-163
Den Boer, J. A., Westenberg, H. G., Kamerbeek, W. D., Verhoeven, W. M., and Kahn, R. S., Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987 Jan;2[1]:21-32
Westenberg, H. G., Den Boer, J. A., and Kahn, R. S., Psychopharmacology of anxiety disorders: on the role of serotonin in the treatment of anxiety states and phobic disorders. Psychopharmacol Bull 1987;23[1]:145-149
Fieve, R. R., Goodnick, P. J., Peselow, E., and Schlegel, A., Fluoxetine response: endpoint vs pattern analysis. Int Clin Psychopharmacol 1986 Oct;1[4]:320-323
Peselow, E. D., Lautin, A., Wolkin, A., Rohrs, C., Novatt, A., Siekierski, J., and Rotrosen, J., The dexamethasone suppression test and response to placebo. J Clin Psychopharmacol 1986 Oct;6[5]:286-291
Wakelin, J. S., Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data. Int Clin Psychopharmacol 1986 Jul;1[3]:221-230
Abell, C. A., Farquhar, D. L., Galloway, S. M., Steven, F., Philip, A. E., and Munro, J. F., Placebo controlled double-blind trial of fluvoxamine maleate in the obese. J Psychosom Res 1986;30[2]:143-146
Saletu, B., Grunberger, J., and Linzmayer, L., On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimelidine. J Neural Transm 1986;67[3-4]:241-266
Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl) 1986;90[1]:131-138
Feighner, J. P., A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin Psychiatry 1985 Sep;46[9]:369-372
Saletu, B. and Grunberger, J., Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses. J Clin Psychiatry 1985 Mar;46[3 Pt 2]:45-52
Chouinard, G., A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 1985 Mar;46[3 Pt 2]:32-37
Cohn, J. B. and Wilcox, C., A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985 Mar;46[3 Pt 2]:26-31
Laursen, A. L., Mikkelsen, P. L., Rasmussen, S., and le Fevre, Honore P., Paroxetine in the treatment of depression--a randomized comparison with amitriptyline. Acta Psychiatr Scand 1985 Mar;71[3]:249-255
Bjerkenstedt, L., Edman, G., Flyckt, L., Hagenfeldt, L., Sedvall, G., and Wiesel, F. A., Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients. Psychopharmacology (Berl) 1985;87[3]:253-259
Siddiqui, U. A., Chakravarti, S. K., and Jesinger, D. K., The tolerance and antidepressive activity of fluvoxamine as a single dose compared to a twice daily dose. Curr Med Res Opin 1985;9[10]:681-690
Christensen, P., Thomsen, H. Y., Pedersen, O. L., Gram, L. F., and Kragh-Sorensen, P., Orthostatic side effects of clomipramine and citalopram during treatment for depression. Psychopharmacology (Berl) 1985;86[4]:383-385
Bjerkenstedt, L., Flyckt, L., Overo, K. F., and Lingjaerde, O., Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985;28[5]:553-557
Bremner, J. D., Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry 1984 Oct;45[10]:414-419
Guy, W., Wilson, W. H., Ban, T. A., King, D. L., Manov, G., and Fjetland, O. K., A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacol Bull 1984;20[1]:73-78
Reimherr, F. W., Wood, D. R., Byerley, B., Brainard, J., and Grosser, B. I., Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20[1]:70-72
McClelland, G. R. and Raptopoulos, P., EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers. Psychopharmacology (Berl) 1984;83[4]:327-329
Itil, T. M., Shrivastava, R. K., Mukherjee, S., Coleman, B. S., and Michael, S. T., A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 1983;15 Suppl 3:433S-438S
De Wilde, J. E., Mertens, C., and Wakelin, J. S., Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. Br J Clin Pharmacol 1983;15 Suppl 3:427S-431S
Dick, P. and Ferrero, E., A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine. Br J Clin Pharmacol 1983;15 Suppl 3:419S-425S
Guelfi, J. D., Dreyfus, J. F., and Pichot, P., A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 1983;15 Suppl 3:411S-417S
De Wilde, J. E. and Doogan, D. P., Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 1982 Sep;4[3]:249-259
Coleman, B. S. and Block, B. A., Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine. Prog Neuropsychopharmacol Biol Psychiatry 1982;6[4-6]:475-478
Saletu, B., Grunberger, J., Rajna, P., and Karobath, M., Clovoxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting antidepressants: quantitative EEG, psychometric and pharmacokinetic studies in man. J Neural Transm 1980;49[1-2]:63-86
Tallova, J., Bicikova, M., Hill, M., Tomandl, J., and Valentova, D., Homocysteine during the menstrual cycle in depressive women. Eur J Clin Invest 2003 Mar;33[3]:268-273
Deuschle, M., Hamann, B., Meichel, C., Krumm, B., Lederbogen, F., Kniest, A., Colla, M., and Heuser, I., Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. J Clin Psychopharmacol 2003 Apr;23[2]:201-205
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A., Murck, H., Ising, M., Yassouridis, A., Steiger, A., Zihl, J., and Holsboer, F., Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 2003 Apr;23[2]:155-168
Berlanga, C., Mendieta, D., Alva, G., and Del Carmen, Lara M., Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression. J Womens Health (Larchmt ) 2003 Jan;12[1]:33-39
Fruehwald, S., Gatterbauer, E., Rehak, P., and Baumhackl, U., Early fluoxetine treatment of post-stroke depression A three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003 Mar;250[3]:347-351
Hajos, M., Hoffmann, W. E., Robinson, D. D., Yu, J. H., and Hajos-Korcsok, E., Norepinephrine but not Serotonin Reuptake Inhibitors Enhance Theta and Gamma Activity of the Septo-Hippocampal System. Neuropsychopharmacology 2002Nov22
Monaca, C., Boutrel, B., Hen, R., Hamon, M., and Adrien, J., 5-HT(1A/1B) Receptor-Mediated Effects of the Selective Serotonin Reuptake Inhibitor, Citalopram, on Sleep: Studies in 5-HT(1A) and 5-HT(1B) Knockout Mice. Neuropsychopharmacology 2002Nov6
Estrada-Camarena, E., Fernandez-Guasti, A., and Lopez-Rubalcava, C., Antidepressant-Like Effect of Different Estrogenic Compounds in the Forced Swimming Test. Neuropsychopharmacology 2002Oct22
Hendrick, V., Smith, L. M., Suri, R., Hwang, S., Haynes, D., and Altshuler, L., Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003 Mar;188[3]:812-815
Yoshitake, T., Reenila, I., I, Ogren, S. O., Hokfelt, T., and Kehr, J., Galanin attenuates basal and antidepressant drug-induced increase of extracellular serotonin and noradrenaline levels in the rat hippocampus. Neurosci Lett 2003Mar27;339[3]:239-242
Messa, C., Colombo, C., Moresco, R. M., Gobbo, C., Galli, L., Lucignani, G., Gilardi, M. C., Rizzo, G., Smeraldi, E., Zanardi, R., Artigas, F., and Fazio, F., 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl) 2003Mar11
Magyar, J., Rusznak, Z., Harasztosi, C., Kortvely, A., Pacher, P., Banyasz, T., Pankucsi, C., Kovacs, L., Szucs, G., Nanasi, P. P., and Kecskemeti, V., Differential effects of fluoxetine enantiomers in mammalian neural and cardiac tissues. Int J Mol Med 2003 Apr;11[4]:535-542
Wu, C. Y., Chou, L. T., Chen, H. P., Chang, C. S., Wong, P. G., and Chen, G. H., Effect of fluoxetine on symptoms and gastric dysrhythmia in patients with functional dyspepsia. Hepatogastroenterology 2003 Jan;50[49]:278-283
Denes, V., Lazar, Z., Bartho, L., and Gabriel, R., Serotonin in the rabbit ileum: Localization, uptake, and effect on motility. Anat Rec 2003 Apr;271A[2]:368-376
Bustillo, J. R., Lauriello, J., Parker, K., Hammond, R., Rowland, L., Bogenschutz, M., and Keith, S., Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 2003 Mar;28[3]:527-529
Tack, J., Broekaert, D., Coulie, B., Fischler, B., and Janssens, J., Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003 Feb;17[4]:603-608
Perna, G., Alpini, D., Caldirola, D., Raponi, G., Cesarani, A., and Bellodi, L., Serotonergic modulation of the balance system in panic disorder: An open study. Depress Anxiety 2003;17[2]:101-106
Skinner, M. H., Kuan, H. Y., Pan, A., Sathirakul, K., Knadler, M. P., Gonzales, C. R., Yeo, K. P., Reddy, S., Lim, M., Ayan-Oshodi, M., and Wise, S. D., Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003 Mar;73[3]:170-177
Goodman, M. M., Chen, P., Plisson, C., Martarello, L., Galt, J., Votaw, J. R., Kilts, C. D., Malveaux, G., Camp, V. M., Shi, B., Ely, T. D., Howell, L., McConathy, J., and Nemeroff, C. B., Synthesis and Characterization of Iodine-123 Labeled 2beta-Carbomethoxy-3beta-(4’-((Z)-2-iodoethenyl)phenyl)nortropane. A Ligand for in Vivo Imaging of Serotonin Transporters by Single-Photon-Emission Tomography. J Med Chem 2003Mar13;46[6]:925-935
Clements, S., Moore, F. L., and Schreck, C. B., Evidence that acute serotonergic activation potentiates the locomotor-stimulating effects of corticotropin-releasing hormone in juvenile chinook salmon (Oncorhynchus tshawytscha)( small star, filled ). Horm Behav 2003 Jan;43[1]:214-221
Monte, T. L., Rieder, C. R., Tort, A. B., Rockenback, I., Pereira, M. L., Silveira, I., Ferro, A., Sequeiros, J., and Jardim, L. B., Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 2003 Mar;107[3]:207-210
Bayes, M., Rabasseda, X., and Prous, J. R., Gateways to Clinical Trials. Methods Find Exp Clin Pharmacol 2002 Dec;24[10]:703-729
Kostiukova EG, Granenov GM Andreichik LA Serditov OV Mosolov SN., [Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital]. Zh Nevrol Psikhiatr Im S S Korsakova 2003;103[1]:24-29
Bayes, M., Rabasseda, X., and Prous, J. R., Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2002 Nov;24[9]:615-643
Ohara, K., Tanabu, S., Ishibashi, K., Ikemoto, K., Yoshida, K., and Shibuya, H., CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003 Feb;58[10]:659-661
Urbina, M., Pineda, S., Pinango, L., Carreira, I., and Lima, L., [(3)H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine. Int J Immunopharmacol 1999 Oct;21[10]:631-646
Kanner, A. M., Kozak, A. M., and Frey, M., The Use of Sertraline in Patients with Epilepsy: Is It Safe?. Epilepsy Behav. 2000 Apr;1[2]:100-105
Halpern, A. and Mancini, M. C., Treatment of obesity: an update on anti-obesity medications. Obes Rev 2003 Feb;4[1]:25-42
Sugie, Y., Sugie, H., Fukuda, T., Ito, M., and Ohzeki, T., [Serotonin 2A receptor gene polymorphism and clinical efficacy of fluvoxamine in children with autistic disorder]. No To Hattatsu 2003 Jan;35[1]:23-28
Versiani, M., A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia). World J Biol Psychiatry 2000 Jan;1[1]:27-33
Romeo, E., Pompili, E., di Michele, F., Pace, M., Rupprecht, R., Bernardi, G., and Pasinib, A., Effects of fluoxetine, indomethacine and placebo on 3 alpha, 5 alpha tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. World J Biol Psychiatry 2000 Apr;1[2]:101-104
Zohar, J., Chopra, M., Sasson, Y., Amiaz, R., and Amital, D., Obsessive compulsive disorder: serotonin and beyond. World J Biol Psychiatry 2000 Apr;1[2]:92-100
Marazziti, D., Rucci, P., Di Nasso, E., Masala, I., Baroni, S., Rossi, A., Giannaccini, G., Mengali, F., and Lucacchini, A., Jealousy and subthreshold psychopathology: a serotonergic link. Neuropsychobiology 2003;47[1]:12-16
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., and Carlezon, W. A., Antidepressant-like effects of {kappa} opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003Jan21
Weiss, J., Dormann, S. M., Martin-Facklam, M., Kerpen, C. J., Ketabi-Kiyanvash, N., and Haefeli, W. E., Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003Jan21
Harmer, C. J., Bhagwagar, Z., Shelley, N., and Cowen, P. J., Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology (Berl) 2003Feb26
Bubar, M. J., McMahon, L. R., De Deurwaerdere, P., Spampinato, U., and Cunningham, K. A., Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens. Neuropharmacology 2003 Mar;44[3]:342-353
Porras, G., De Deurwaerdere, P., Moison, D., and Spampinato, U., Conditional involvement of striatal serotonin3 receptors in the control of in vivo dopamine outflow in the rat striatum. Eur J Neurosci 2003 Feb;17[4]:771-781
Kojima, H., Terao, T., Iwakawa, M., Soya, A., Inoue, N., Shiraishi, Y., Son, Y., Soeda, S., Ueda, N., Yoshimura, R., and Nakamura, J., Paroxetine as a 5-HT neuroendocrine probe. Psychopharmacology (Berl) 2003 Feb25
David, D. J., Renard, C. E., Jolliet, P., Hascoet, M., and Bourin, M., Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology (Berl) 2003 Feb25
Sanchez, C., Stress-induced vocalisation in adult animals. A valid model of anxiety?. Eur J Pharmacol 2003 Feb28;463[1-3]:133-143
Silver, H., Nassar, A., Aharon, N., and Kaplan, A., The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int Clin Psychopharmacol 2003 Mar;18[2]:87-92
Bonnet, U., Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003;9[1]:97-140
Zohar, J., Keegstra, H., and Barrelet, L., Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Hum Psychopharmacol 2003 Mar;18[2]:113-119
Patkar, A. A., Berrettini, W. H., Lundy, A., Murray, H. W., Hill, K. P., Vergare, M. J., and Weinstein, S. P., Seasonal variations in the binding of [3H]paroxetine to the platelet serotonin transporter sites in African-American cocaine-dependent patients and healthy volunteers. Hum Psychopharmacol 2003 Mar;18[2]:103-111
Lass-Florl, C., Ledochowski, M., Fuchs, D., Speth, C., Kacani, L., Dierich, M. P., Fuchs, A., and Wurzner, R., Interaction of sertraline with Candida species selectively attenuates fungal virulence in vitro. FEMS Immunol Med Microbiol 2003 Jan21;35[1]:11-15
Patkar, A. A., Gopalakrishnan, R., Berrettini, W. H., Weinstein, S. P., Vergare, M. J., and Leone, F. T., Differences in platelet serotonin transporter sites between African-American tobacco smokers and non-smokers. Psychopharmacology (Berl) 2003 Mar;166[3]:221-227
Kugaya, A., Seneca, N. M., Snyder, P. J., Williams, S. A., Malison, R. T., Baldwin, R. M., Seibyl, J. P., and Innis, R. B., Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration. Neuropsychopharmacology 2003 Feb;28[2]:413-420
Murck, H., Nickel, T., Kunzel, H., Antonijevic, I. A., Schill, J., Zobel, A., Steiger, A., Sonntag, A., and Holsboer, F., State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine. Neuropsychopharmacology 2003 Feb;28[2]:348-358
Carpenter, L. L., Anderson, G. M., Siniscalchi, J. M., Chappell, P. B., and Price, L. H., Acute changes in Cerebrospinal Fluid 5-HIAA following Oral Paroxetine Challenge in Healthy Humans. Neuropsychopharmacology 2003 Feb;28[2]:339-347
Shimodozono, M., Kawahira, K., Kamishita, T., Ogata, A., Tohgo, S., and Tanaka, N., Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neurosci 2002 Oct;112[10]:1173-1181
Guiraud-Chaumeil, B., Pariente, J., Albucher, J. F., Loubinoux, I., and Chollet, F., [In Process Citation]. Bull Acad Natl Med 2002;186[6]:1015-1023
Ng, C. H., Tam, M. M., and Hook, S. J., Acne, isotretinoin treatment and acute depression. World J Biol Psychiatry 2001 Jul;2[3]:159-161
Lima, L. and Urbina, M., Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cell Mol Neurobiol 2002 Dec;22[5-6]:797-804
Singareddy, R. K. and Balon, R., Sleep in posttraumatic stress disorder. Ann Clin Psychiatry 2002 Sep;14[3]:183-190
Masand, P. S. and Gupta, S., Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002 Sep;14[3]:175-182
Chaudhry, H. R., Qureshi, Z., Tareen, I. A., and Yazdani, I., Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety. J Pak Med Assoc 2002 Nov;52[11]:518-525
Sullivan, M. D., Katon, W. J., Russo, J. E., Frank, E., Barrett, J. E., Oxman, T. E., and Williams, J. W., Jr., Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J Am Board Fam Pract 2003 Jan;16[1]:22-31
Guo, X., Fukushima, T., Li, F., and Imai, K., Determination of fluoxetine and norfluoxetine in rat plasma by HPLC with pre-column derivatization and fluorescence detection. Biomed Chromatogr 2003 Jan;17[1]:1-5
Fernandez, F., Sarre, S., Launay, J. M., Aguerre, S., Guyonnet-Duperat, V., Moisan, M. P., Ebinger, G., Michotte, Y., Mormede, P., and Chaouloff, F., Rat strain differences in peripheral and central serotonin transporter protein expression and function. Eur J Neurosci 2003 Feb;17[3]:494-506
Atmaca, M., Kuloglu, M., Tezcan, E., Ustundag, B., and Semercioz, A., Serum leptin levels in patients with premature ejaculation before and after citalopram treatment. BJU Int 2003 Feb;91[3]:252-254
Varty, G. B., Cohen-Williams, M. E., and Hunter, J. C., The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 2003 Feb;14[1]:87-95
Anderer, P., Saletu, B., Semlitsch, H. V., and Pascual-Marqui, R. D., Perceptual and cognitive event-related potentials in neuropsychopharmacology: methodological aspects and clinical applications (pharmaco-ERP topography and tomography). Methods Find Exp Clin Pharmacol 2002;24 Suppl C:121-137
Saletu, B., Anderer, P., Saletu-Zyhlarz, G. M., Arnold, O., and Pascual-Marqui, R. D., Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA). Methods Find Exp Clin Pharmacol 2002;24 Suppl C:97-120
Anderer, P., Saletu, B., Semlitsch, H. V., and Pascual-Marqui, R. D., Structural and energetic processes related to P300: LORETA findings in depression and effects of antidepressant drugs. Methods Find Exp Clin Pharmacol 2002;24 Suppl D:85-91
Melke, J., Westberg, L., Landen, M., Sundblad, C., Eriksson, O., Baghei, F., Rosmond, R., Eriksson, E., and Ekman, A., Serotonin transporter gene polymorphisms and platelet [(3)H] paroxetine binding in premenstrual dysphoria. Psychoneuroendocrinology 2003 Apr;28[3]:446-458
Devanand, D. P., Pelton, G. H., Marston, K., Camacho, Y., Roose, S. P., Stern, Y., and Sackeim, H. A., Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 2003 Feb;18[2]:123-130
Eichhammer, P., Langguth, B., Wiegand, R., Kharraz, A., Frick, U., and Hajak, G., Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI). Psychopharmacology (Berl) 2003 Mar;166[3]:294-297
Fantegrossi, W. E., Godlewski, T., Karabenick, R. L., Stephens, J. M., Ullrich, T., Rice, K. C., and Woods, J. H., Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 2003 Mar;166[3]:202-211
Mendes-Da-Silva, C., Souza, S. L., Barreto-Medeiros, J. M., Freitas-Silva, S. R., Antunes, D. E., Cunha, A. D., Ribas, V. R., Fran a MF, Nogueira, M. I., and Manh es-De-Castro, R., Neonatal treatment with fluoxetine reduces depressive behavior induced by forced swim in adult rats. Arq Neuropsiquiatr 2002 Dec;60[4]:928-931
Horiuchi, H., Ogata, T., Morino, T., Takeba, J., and Yamamoto, H., Serotonergic signaling inhibits hyperalgesia induced by spinal cord damage. Brain Res 2003 Feb14;963[1-2]:312-320
Chen, J., Mabjeesh, N. J., Matzkin, H., and Greenstein, A., Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 2003 Jan;61[1]:197-200
Shukla, R., Husain, M., Tandon, R., Khanna, V. K., Nag, D., Dikshit, M., Srimal, R. C., and Seth, P. K., Platelet 3H Ketanserin Binding in Tension-type Headache. Headache 2003 Feb;43[2]:103-108
Wegener, G., Bandpey, Z., Heiberg, I. L., Mork, A., and Rosenberg, R., Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium: neurochemical and behavioural studies in the rat. Psychopharmacology (Berl) 2003 Mar;166[2]:188-194
Liang, J. H., Wang, X. H., Liu, R. K., Sun, H. L., Ye, X. F., and Zheng, J. W., Buspirone-induced antinociception is mediated by l-type calcium channels and calcium/caffeine-sensitive pools in mice. Psychopharmacology (Berl) 2003 Mar;166[3]:276-283
Thompson, D. S., Kirshner, M. A., Klug, T. L., Kastango, K. B., and Pollock, B. G., A Preliminary Study of the Effect of Fluoxetine Treatment on the 2:16-alpha-Hydroxyestrone Ratio in Young Women. Ther Drug Monit 2003 Feb;25[1]:125-128
Gex-Fabry, M., Balant-Gorgia, A. E., and Balant, L. P., Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003 Feb;25[1]:46-53
Robbins, A. and Waldinger, M. D., Comments on "A Double-Blind, Randomized Fixed-Dose Study With Paroxetine and Citalopram" by waldinger and associates. J Clin Psychopharmacol 2003 Feb;23[1]:108-109
Bell, C., Wilson, S., Rich, A., Bailey, J., and Nutt, D., Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology (Berl) 2003 Mar;166[2]:102-110
Dias, Soares D., Fernandez, F., Aguerre, S., Foury, A., Mormede, P., and Chaouloff, F., Fox odour affects corticosterone release but not hippocampal serotonin reuptake and open field behaviour in rats. Brain Res 2003Jan24;961[1]:166-170
Sperry, T. S., Thompson, C. K., and Wingfield, J. C., Effects of Acute Treatment with 8-OH-DPAT and Fluoxetine on Aggressive Behaviour in Male Song Sparrows (Melospiza melodia morphna). J Neuroendocrinol 2003 Feb;15[2]:150-160
Stephen, L. J., Drug treatment of epilepsy in elderly people: focus on valproic Acid. Drugs Aging 2003;20[2]:141-152
Burmeister, J. J., Lungren, E. M., and Neisewander, J. L., Effects of fluoxetine and d-fenfluramine on cocaine-seeking behavior in rats. Psychopharmacology (Berl) 2003Jan16
Hirani, K., Khisti, R. T., and Chopde, C. T., Behavioral action of ethanol in Porsolt’s forced swim test: modulation by 3alpha-hydroxy-5alpha-pregnan-20-one. Neuropharmacology 2002 Dec;43[8]:1339-1350
Dwivedi, Y., Agrawal, A. K., Rizavi, H. S., and Pandey, G. N., Antidepressants reduce phosphoinositide-specific phospholipase C (PI-PLC) activity and the mRNA and protein expression of selective PLC beta(1) isozyme in rat brain. Neuropharmacology 2002 Dec;43[8]:1269-1279
Miralles, A., Asensio, V. J., and Garcia-Sevilla, J. A., Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein-coupled receptor kinases 2/3 in rat brain. Neuropharmacology 2002 Dec;43[8]:1249-1257
Joyce, P. R., Mulder, R. T., Luty, S. E., McKenzie, J. M., Sullivan, P. F., and Cloninger, R. C., Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response, and 6-month outcome. Compr Psychiatry 2003 Jan;44[1]:35-43
Holmes, A. and Rodgers, R. J., Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine. Eur J Pharmacol 2003Jan17;459[2-3]:221-230
Ossowska, G., Zebrowska-Lupina, I., Danilczuk, Z., and Klenk-Majewska, B., Repeated treatment with selective serotonin reuptake inhibitors but not anxiolytics prevents the stress-induced deficit of fighting behavior. Pol J Pharmacol 2002 Jul;54[4]:373-380
Miller, M., Depression after cardiac transplant treated with interpersonal psychotherapy and paroxetine. Am J Psychother 2002;56[4]:555-561
Sobczak, S., Honig, A., van Duinen, M. A., and Riedel, W. J., Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disord 2002 Dec;4[6]:347-356
Henry, M. E., Kaufman, M. J., Hennen, J., Michelson, D., Schmidt, M. E., Stoddard, E., Vukovic, A. J., Barreira, P. J., Cohen, B. M., and Renshaw, P. F., Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment. Biol Psychiatry 2003Jan1;53[1]:100-105
Meijer, W. E., Heerdink, E. R., van Eijk, J. T., and Leufkens, H. G., Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Pharmacoepidemiol Drug Saf 2002 Dec;11[8]:655-662
Castaneda, R., Sussman, N., Levy, R., and Trujillo, M., A Treatment Algorithm for Attention Deficit Hyperactivity Disorder in Cocaine-Dependent Adults: A One-Year Private Practice Study with Long-Acting Stimulants, Fluoxetine, and Bupropion.. Subst Abus 1999 Mar;20[1]:59-71
Hernandez-Avila, C. A., Burleson, J. A., and Kranzler, H. R., Stage of Change as a Predictor of Abstinence Among Alcohol-Dependent Subjects in Pharmacotherapy Trials. Subst Abus 1998 Jun;19[2]:81-91
Liu, H. C., Wang, N., Yu, Y., and Hou, Y. N., Stereoselectivity in trans-tramadol metabolism and trans-O-demethyltramadol formation in rat liver microsomes. Acta Pharmacol Sin 2003 Jan;24[1]:85-90
Wang, W., Danielsson, A., Svanberg, E., and Lundholm, K., Lack of effects by tricyclic antidepressant and serotonin inhibitors on anorexia in MCG 101 tumor-bearing mice with eicosanoid-related cachexia. Nutrition 2003 Jan;19[1]:47-53
Senechal, A., Landry, P., Deschamps, R., and Lessard, M., [Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs]. Encephale 2002 Nov;28[6]:567-569
Miro, X., Perez-Torres, S., Artigas, F., Puigdomenech, P., Palacios, J. M., and Mengod, G., Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 2002 Dec;43[7]:1148-1157
Finberg, J. P. and Youdim, M. B., Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002 Dec;43[7]:1110-1118
Wilson, S. J., Bailey, J. E., Alford, C., Weinstein, A., and Nutt, D. J., Effects of 5 weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood. J Psychopharmacol 2002 Dec;16[4]:321-331
Beyer, C. E., Boikess, S., Luo, B., and Dawson, L. A., Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 2002 Dec;16[4]:297-304
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., and Bava, A., Depression and Alzheimer’s disease: symptom or comorbidity?. Am J Alzheimers Dis Other Demen 2002 Nov;17[6]:338-344
Bayes, M., Rabasseda, X., and Prous, J. R., Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2002 Oct;24[8]:525-551
Daniel, W. A., Haduch, A., and Wojcikowski, J., Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. J Pharm Pharmacol 2002 Nov;54[11]:1545-1552
Atmaca, M., Kuloglu, M., Tezcan, E., and Semercioz, A., The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res 2002 Dec;14[6]:502-505
Keller, M. B., Long-term treatment strategies in affective disorders. Psychopharmacol Bull 2002;36 Suppl 2:36-48
Tenney, N. H., Denys, D. A., Van Megen, H. J., Glas, G., and Westenberg, H. G., Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder. Int Clin Psychopharmacol 2003 Jan;18[1]:29-33
Pini, S., Amador, X. F., Dell’Osso, L., Rossi, N. B., Cassano, P., Savino, M., and Cassano, G. B., Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide. Int Clin Psychopharmacol 2003 Jan;18[1]:15-21
Ferguson, J. M., Wesnes, K. A., and Schwartz, G. E., Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003 Jan;18[1]:9-14
Koch, J. M., Kell, S., and Aldenhoff, J. B., Differential effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell-viability. J Psychiatr Res 2003 Jan;37[1]:53-59
Karpa, K. D., Cavanaugh, J. E., and Lakoski, J. M., Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 2002;8[4]:361-376
Kenis, G., Steinbusch, H., De Baets, M., and Maes, M., Influence of antidepressants on intracellular levels of cyclic adenosine monophosphate in human peripheral blood mononuclear cells. Eur Neuropsychopharmacol 2003 Jan;13[1]:53-56
Berggard, C., Damberg, M., and Oreland, L., Chronic citalopram treatment induces time-dependent changes in the expression and DNA-binding activity of transcription factor AP-2 in rat brain. Eur Neuropsychopharmacol 2003 Jan;13[1]:11-17
Yu, Y. W., Tsai, S. J., Chen, T. J., Lin, C. H., and Hong, C. J., Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002;7[10]:1115-1119
Prince, J. B., Bostic, J. Q., Monuteaux, M., Brown, K., and Place, S., Citalopram for the treatment of adolescent anxiety disorders: a pilot study. Psychopharmacol Bull 2002;36[3]:100-107
Piasecki, M. P., Antonuccio, D. O., Steinagel, G. M., Kohlenberg, B. S., and Kapadar, K., Penetrating the blind in a study of an SSRI. J Behav Ther Exp Psychiatry 2002 Jun;33[2]:67-71
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., and Bava, A., Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms. a randomized, controlled, open 14-month study. Eur Neurol 2003;49[1]:13-19
Hanania, T., McCreary, A. C., Haughey, H. M., Salaz, D. O., and Zahniser, N. R., MK-801- and ethanol-induced activity in inbred long-sleep and short-sleep mice: dopamine and serotonin systems. Eur J Pharmacol 2002Dec20;457[2-3]:125-135
D’Souza, D. N., Zhang, Y., Garcia, F., Battaglia, G., and Van De Kar, L. D., Destruction of serotonergic nerve terminals prevents fluoxetine-induced desensitization of hypothalamic 5-HT(1A) receptors. Psychopharmacology (Berl) 2002 Dec;164[4]:392-400
Kent, J. M., Coplan, J. D., Lombardo, I., Hwang, D. R., Huang, Y., Mawlawi, O., Van Heertum, R. L., Slifstein, M., Abi-Dargham, A., Gorman, J. M., and Laruelle, M., Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [(11)C]McN 5652. Psychopharmacology (Berl) 2002 Dec;164[4]:341-348
Wilens, T. E., Cohen, L., Biederman, J., Abrams, A., Neft, D., Faird, N., and Sinha, V., Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 2002 Dec;22[6]:568-575
Rocc, P., De Leo, C., Eva, C., Marchiaro, L., Milani, A. M., Musso, R., Ravizza, L., Zanalda, E., and Bogetto, F., Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2002 Oct;26[6]:1155-1160
Matsumoto, M., Kojima, T., Togashi, H., Mori, K., Ohashi, S., Ueno, K., and Yoshioka, M., Differential characteristics of endogenous serotonin-mediated synaptic transmission in the hippocampal CA1 and CA3 fields of anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 2002 Dec;366[6]:570-577
Freeman, E. W., Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder. Curr Psychiatry Rep 2002 Dec;4[6]:435-440
Gotjen, D., Szabo, Z., Lee, And S., and Wand, G., Hormone responses to citalopram in abstinent alcohol dependent subjects. Alcohol Clin Exp Res 2002 Nov;26[11]:1625-1631
Diaz, A., Fouilloux, C., and Ortiz, S., Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients. Proc West Pharmacol Soc 2002;45:154-155
Tran, T. H., Von Moltke, L. L., Venkatakrishnan, K., Granda, B. W., Gibbs, M. A., Obach, R. S., Harmatz, J. S., and Greenblatt, D. J., Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 2002 Dec;30[12]:1441-1445
Mirghani, R. A., Yasar, U., Zheng, T., Cook, J. M., Gustafsson, L. L., Tybring, G., and Ericsson, O., Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. Drug Metab Dispos 2002 Dec;30[12]:1368-1371
Kelly, P. A., Ritchie, I. M., Quate, L., McBean, D. E., and Olverman, H. J., Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 2002 Dec;137[7]:963-970
Rocca, P., Marchiaro, L., Rasetti, R., Rivoira, E., and Bogetto, F., A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res 2002Oct10;112[2]:145-152
Bayes, M., Rabasseda, X., and Prous, J. R., Gateways to Clinical Trials.. Methods Find Exp Clin Pharmacol 2002 Sep;24[7]:431-455
Smith, G. S., Kramer, E., Hermann, C. R., Goldberg, S., Ma, Y., Dhawan, V., Barnes, A., Chaly, T., Belakhleff, A., Laghrissi-Thode, F., Greenwald, B., Eidelberg, D., and Pollock, B. G., Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression. Am J Geriatr Psychiatry 2002 Nov;10[6]:715-723
Johnson, D. A., Gartside, S. E., and Ingram, C. D., 5-HT(1A) receptor-mediated autoinhibition does not function at physiological firing rates: evidence from in vitro electrophysiological studies in the rat dorsal raphe nucleus. Neuropharmacology 2002 Nov;43[6]:959-965
Thase, M. E., Ferguson, J. M., Lydiard, R. B., and Wilcox, C. S., Citalopram treatment of paroxetine-intolerant depressed patients. Depress Anxiety 2002;16[3]:128-133
Rush, A. J., Bose, A., and Heydorn, W. E., Naturalistic study of the early psychiatric use of citalopram in the United States. Depress Anxiety 2002;16[3]:121-127
Yu, Z. F., Kong, L. D., and Chen, Y., Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 2002 Nov;83[1-2]:161-165
Yalcin, A. U., Kudaiberdieva, G., Sahin, G., Gorenek, B., Akcar, N., Kuskus, S., Bayrak, F., and Timuralp, B., Effect of sertraline hydrochloride on cardiac autonomic dysfunction in patients with hemodialysis-induced hypotension. Nephron 2003 Jan;93[1]:21-28
Habek, D., Habek, J. C., and Barbir, A., Using acupuncture to treat premenstrual syndrome. Arch Gynecol Obstet 2002 Nov;267[1]:23-26
Jones, N., King, S. M., and Duxon, M. S., Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: Differential effects of fluoxetine and chlordiazepoxide. Behav Pharmacol 2002 Nov;13[7]:525-535
Eap, C. B., Buclin, T., and Baumann, P., Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41[14]:1153-1193
Novotny, V. and Faltus, F., Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study. Hum Psychopharmacol 2002 Aug;17[6]:299-303
Stephenson, D. A., Harris, B., Davies, R. H., Mullin, J. M., Richardson, E., Boardman, H., Meanley, D., and Banerjee, A., The impact of antidepressants on sleep and anxiety: a comparative study of fluoxetine and dothiepin using the Leeds Sleep Evaluation Questionnaire. Hum Psychopharmacol 2000 Oct;15[7]:529-534
Artigas, F., Limitations to enhancing the speed of onset of antidepressants - are rapid action antidepressants possible?. Hum Psychopharmacol 2001 Jan;16[1]:29-36
Biswas, A. B., Bhaumik, S., and Branford, D., Treatment-emergent behavioural side effects with selective serotonin re-uptake inhibitors in adults with learning disabilities. Hum Psychopharmacol 2001 Mar;16[2]:133-137
Lepine, J. P., Altamura, C., Ansseau, M., Gutierrez, J. L., Bitter, I., Lader, M., and Waintraub, L., Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6-week double-blind study dagger. Hum Psychopharmacol 2001 Apr;16[3]:219-227
Toren, P., Eldar, S., Laor, N., Wolmer, L., Samuel, E., and Weizman, R., Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: an open-label pilot study. Hum Psychopharmacol 2001 Jun;16[4]:327-332
Mundo, E., Rouillon, F., Figuera, M. L., and Stigler, M., Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001 Aug;16[6]:461-468
Ruwe, F. J., Smulders, R. A., Kleijn, H. J., Hartmans, H. L., and Sitsen, J. M., Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2001 Aug;16[6]:449-459
Liechti, M. E. and Vollenweider, F. X., Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 2001 Dec;16[8]:589-598
Loo, H., Saiz-Ruiz, J., Costa E Silva JA, Ansseau, M., Herrington, R., Vaz-Serra, A., Dilling, H., and de Risio, S., Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine*. Hum Psychopharmacol 2001 Jan;16[S1]:S31-S38
Nathan, P. J., Stough, C., and Siteram, G., Serotonin and information processing: a pharmacodynamic study on the effects of citalopram on cognitive and psychomotor function. Hum Psychopharmacol 2000 Jun;15[4]:306-307
Dodd, S., Stocky, A., Buist, A., Burrows, G. D., Maguire, K., and Norman, T. R., Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 2000 Jun;15[4]:161-264
Cooney, J. M. and Dinan, T. G., Hypothalamic-pituitary-adrenal axis early-feedback responses are preserved in melancholic depression: a study of sertraline treatment. Hum Psychopharmacol 2000 Jul;15[5]:351-356
Deas, D., Randall, C. L., Roberts, J. S., and Anton, R. F., A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: a pilot study. Hum Psychopharmacol 2000 Aug;15[6]:461-469
Charlier, C., Pinto, E., Ansseau, M., and Plomteux, G., Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 2000 Aug;15[6]:453-459
Conca, A., Swoboda, E., Konig, P., Koppi, S., Beraus, W., Kunz, A., Fritzsche, H., and Weiss, P., Clinical impacts of single transcranial magnetic stimulation (sTMS) as an add-on therapy in severely depressed patients under SSRI treatment. Hum Psychopharmacol 2000 Aug;15[6]:429-438
Dehpour, A. R., Sadeghipour, H. R., Nowroozi, A., and Akbarloo, N., The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum Psychopharmacol 2000 Aug;15[6]:423-428
Zhu, Z. and Neirinck, L., High-performance liquid chromatography-mass spectrometry method for the determination of paroxetine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2002 Nov25;780[2]:295-300
Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Gulati, M., Thornton, A. J., Schultz, R. L., Valentine, A. D., Meyers, C. A., and Howell, C. D., A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7[9]:942-947
Bian, J. T., Yeh, J. Z., Aistrup, G. L., Narahashi, T., and Moore, E. J., Inhibition of K+ currents of outer hair cells in guinea pig cochlea by fluoxetine. Eur J Pharmacol 2002 Oct25;453[2-3]:159-166
Koetsier, G. C., Volkers, A. C., Tulen, J. H., Passchier, J., van den Broek, W. W., and Bruijn, J. A., CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine. J Psychiatr Res 2002 Nov;36[6]:391
Yau, J. L., Hibberd, C., Noble, J., and Seckl, J. R., The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Brain Res Mol Brain Res 2002Oct15;106[1-2]:117
Martinez, Perez B., Gonzalez, Goizueta E., and Mauri, J. A., [Depression and epilepsy]. Rev Neurol 2002Sep16;35[6]:580-586
Muijsers, R. B., Plosker, G. L., and Noble, S., Spotlight on sertraline in the management of major depressive disorder in elderly patients. CNS Drugs 2002;16[11]:789-794
Huang, Y., Hwang, D. R., Zhu, Z., Bae, S. A., Guo, N., Sudo, Y., Kegeles, L. S., and Laruelle, M., Synthesis and pharmacological characterization of a new PET ligand for the serotonin transporter: [11C]5-bromo-2-[2-(dimethylaminomethylphenylsulfanyl)]phenylamine ([11C]DAPA). Nucl Med Biol 2002 Oct;29[7]:741-751
Misri, S. and Kostaras, X., Benefits and risks to mother and infant of drug treatment for postnatal depression. Drug Saf 2002;25[13]:903-911
Ito, K., Yoshida, K., Sato, K., Takahashi, H., Kamata, M., Higuchi, H., Shimizu, T., Itoh, K., Inoue, K., Tezuka, T., Suzuki, T., Ohkubo, T., Sugawara, K., and Otani, K., A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 2002Aug30;111[2-3]:235-239
Rosel, P., Arranz, B., Urretavizcaya, M., Oros, M., San, L., Vallejo, J., and Navarro, M. A., Different distributions of the 5-HT reuptake complex and the postsynaptic 5-HT(2A) receptors in Brodmann areas and brain hemispheres. Psychiatry Res 2002Aug30;111[2-3]:105-115
Ohia, S. E., Opere, C. A., LeDay, A. M., Bagchi, M., Bagchi, D., and Stohs, S. J., Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). Mol Cell Biochem 2002 Sep;238[1-2]:89-103
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., and Khan, Z. M., Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002 Oct;36[10]:1577-1589
Barbui, C., Hotopf, M., and Garattini, S., Fluoxetine dose and outcome in antidepressant drug trials. Eur J Clin Pharmacol 2002 Sep;58[6]:379-386
Franke, H., Grosche, J., Illes, P., and Allgaier, C., 5,7-Dihydroxytryptamine--a selective marker of dopaminergic or serotonergic neurons?. Naunyn Schmiedebergs Arch Pharmacol 2002 Oct;366[4]:315-318
Jezova, D. and Duncko, R., Enhancement of stress-induced pituitary hormone release and cardiovascular activation by antidepressant treatment in healthy men. J Psychopharmacol 2002 Sep;16[3]:235-240
Sonawalla, S. B., Farabaugh, A., Johnson, M. W., Morray, M., Delgado, M. L., Pingol, M. G., Rosenbaum, J. F., and Fava, M., Fluoxetine treatment of depressed patients with comorbid anxiety disorders. J Psychopharmacol 2002 Sep;16[3]:215-219
Schmitt, J. A., Ramaekers, J. G., Kruizinga, M. J., van Boxtel, M. P., Vuurman, E. F., and Riedel, W. J., Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 2002 Sep;16[3]:207-214
De Nayer, A., Geerts, S., Ruelens, L., Schittecatte, M., De Bleeker, E., Van, Eeckhoutte, I, Evrard, J. L., Linkowski, P., Fossion, P., Leyman, S., and Mignon, A., Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002 Jun;5[2]:115-120
Dekeyne, A., Gobert, A., Auclair, A., Girardon, S., and Millan, M. J., Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors. Psychopharmacology (Berl) 2002 Jul;162[2]:156-167
Sach, J. A. and Chang, L., Irritable Bowel Syndrome. Curr Treat Options Gastroenterol 2002 Aug;5[4]:267-278
Karramkam, M., Dolle, F., Valette, H., Besret, L., Bramoulle, Y., Hinnen, F., Vaufrey, F., Franklin, C., Bourg, S., Coulon, C., Ottaviani, M., Delaforge, M., Loc’h, C., Bottlaender, M., and Crouzel, C., Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the in vivo serotonin transporter imaging with PET. Bioorg Med Chem 2002 Aug;10[8]:2611-2623
Cusin, C., Serretti, A., Zanardi, R., Lattuada, E., Rossini, D., Lilli, R., Lorenzi, C., and Smeraldi, E., Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 2002 Mar;5[1]:27-35
Hansen, E. S., Hasselbalch, S., Law, I., and Bolwig, T. G., The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol 2002 Mar;5[1]:1-10
Gleiter, C. H., Wozniak, K. M., and DeJong, J., Modification by Chronic Antidepressant Treatment of the Effect of Electroconvulsive Shock on Body Temperature in Mice. Convuls Ther 1990;6[2]:146-152
Papp, M., Nalepa, I., Antkiewicz-Michaluk, L., and Sanchez, C., Behavioural and biochemical studies of citalopram and WAY 100635 in rat chronic mild stress model. Pharmacol Biochem Behav 2002 May;72[1-2]:465-474
Smith, R. L., Gresch, P. J., Barrett, R. J., and Sanders-Bush, E., Stimulus generalization by fenfluramine in a quipazine-ketanserin drug discrimination is not dependent on indirect serotonin release. Pharmacol Biochem Behav 2002 May;72[1-2]:77-85
Yalcin, A. U., Sahin, G., Erol, M., and Bal, C., Sertraline hydrochloride treatment for patients with hemodialysis hypotension. Blood Purif 2002;20[2]:150-153
Januzzi, J. L. and Pasternak, R. C., Depression, Hostility, and Social Isolation in Patients with Coronary Artery Disease. 2002 Feb;4[1]:77-85
Luo, L. and Tan, R. X., Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing nitric oxide synthase expression in rat depression model. Acta Pharmacol Sin 2001 Oct;22[10]:865-870
Liu, Z. Q., Shu, Y., Huang, S. L., Wang, L. S., He, N., and Zhou, H. H., Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin 2001 Jan;22[1]:85-90
Jolkkonen, J., Puurunen, K., Rantakomi, S., Sirvio, J., Haapalinna, A., and Sivenius, J., Effects-of fluoxetine on sensorimotor and spatial learning deficits following focal cerebral ischemia in rats. Restor Neurol Neurosci 2000;17[4]:211-216
Post, R. M., Nolen, W. A., Kupka, R. W., Denicoff, K. D., Leverich, G. S., Keck, P. E., Jr., McElroy, S. L., Rush, A. J., Suppes, T., Altshuler, L. L., Frye, M. A., Grunze, H., and Walden, J., The Stanley Foundation Bipolar Network: 1. Rationale and methods. Br J Psychiatry 2001 Jun;178[41]:S169-S176
Montgomery, S. A., A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001 May;16[3]:169-178
Schweizer, E., Rynn, M., Mandos, L. A., Demartinis, N., Garcia-Espana, F., and Rickels, K., The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001 May;16[3]:137-143
Javors, M. A., Houston, J. P., Tekell, J. L., Brannan, S. K., and Frazer, A., Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000 Sep;3[3]:229-235
Seedat, S., Stein, D. J., and Emsley, R. A., Open trial of citalopram in adults with post-traumatic stress disorder. Int J Neuropsychopharmacol 2000 Jun;3[2]:135-140
Bondolfi, G., Lissner, C., Kosel, M., Eap, C. B., and Baumann, P., Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol 2000 Mar;3[1]:55-60
Kakiuchi, T., Tsukada, H., Fukumoto, D., and Nishiyama, S., Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with. Synapse 2001 Jun;40[3]:170-179
Rodrigues-Filho, R. and Takahashi, R. N., Antinociceptive effects induced by desipramine and fluoxetine are dissociated from their antidepressant or anxiolytic action in mice. Int J Neuropsychopharmcol 1999 Dec;2[4]:263-269
Winter, J. C., Fiorella, D. J., Helsley, S. E., and Rabin, R. A., Partial generalization of (-)DOM to fluvoxamine in the rat: implications for SSRI-induced mania and psychosis. Int J Neuropsychopharmcol 1999 Sep;2[3]:165-172
Palvimaki, E. P., Kuoppamaki, M., Syvalahti, E., and Hietala, J., Differential effects of fluoxetine and citalopram treatments on serotonin 5-HT(2C) receptor occupancy in rat brain. Int J Neuropsychopharmcol 1999 Jun;2[2]:95-99
Rossby, S. P., Manier, D. H., Liang, S., Nalepa, I., and Sulser, F., Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. Int J Neuropsychopharmcol 1999 Mar;2[1]:1-8
Mori, S., Garbini, S., Caivano, M., Perez, J., and Racagni, G., Time-course changes in rat cerebral cortex subcellular distribution of the cyclic-AMP binding after treatment with selective serotonin reuptake inhibitors. Int J Neuropsychopharmcol 1998 Jul;1[1]:3-10
De Montis, M. G., Gambarana, C., Ghiglieri, O., and Tagliamonte, A., Reversal of stable behavioural modifications through NMDA receptor inhibition in rats. Behav Pharmacol 1995 Aug;6[5 And 6]:562-567
Ybema, C. E., Slangen, J. L., Olivier, B., and Mos, J., Dose-dependent discriminative stimulus properties of 8-OH-DPAT. Behav Pharmacol 1993 Dec;4[6]:610-624
Richard, I. H., Depression in Parkinson’s Disease. Curr Treat Options Neurol 2000 May;2[3]:263-274
van Bemmel, A. L., Beersma, D. G., and van den Hoofdakker, R. H., Changes in EEG power density of NREM sleep in depressed patients during treatment with citalopram. J Sleep Res 1993 Sep;2[3]:156-162
Bendtsen, L. and Mellerup, E. T., The platelet serotonin transporter in primary headaches. Eur J Neurol 1998 May;5[3]:277-282
Mortola, J. F., From GnRH to SSRIs and Beyond: Weighing the Options for Drug Therapy in Premenstrual Syndrome. Medscape Womens Health 1997 Oct;2[10]:3